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Summary 
 
Most westernized countries have experienced a major increase in the prevalence of obesity during 
the last decades. Obesity is one of the major underlying risk factors for the development of the 
metabolic syndrome, type-2 diabetes and cardiovascular disease. Much evidence suggests that 
common obesity is caused by several factors, including environmental and behavioural factors, as 
well as by a genetic susceptibility to an increasingly more obesogenic environment. Obviously, there 
is a need to provide further evidence about the contributing genetic factors to better formulate 
preventive and treatment strategies. There is also an acute need to identify safe inexpensive treatment 
options.  
 
It is likely that the pathogenesis of obesity-associated diseases involves an abnormal fat distribution, 
usually identified and described as enlarged waist circumference and/or excessive visceral fat. 
Furthermore, several lines of evidence suggest that a more precise pathogenetic explanation is found 
in so-called ectopic fat deposition, i.e. that fat is deposited in non-fat body tissues, such as liver, 
skeletal muscle, heart and pancreas, which are not adapted to handle excessive amounts of fat. When 
chronically exposed to excessive amounts of fat, these organs become dysfunctional. Hence, there is 
evidence that obesity – at least when characterized as body mass index, is not per se the real 
underlying disease-causing factor. Thus, optimally, any treatment strategy should target the abnormal 
fat distribution, rather than obesity per se.  
The transcription factor PPARγ is known to hold a central role in fat cell differentiation, and there 
are indications that modulation of PPARγ activity may inhibit ectopic fat deposition. It has been 
shown that agonistic activation of this transcription factor improves insulin sensitivity and regulation 
of blood glucose and possibly also the risk of cardiovascular disease. However, the effects of a more 
subtle modulation of PPARγ activity, either via variation in the gene encoding the protein or via 
partial activation or deactivation using specific agonists (also including various fatty acids) that can 
be taken as part of the diet, are not yet clear. In paper 3 and 4 and in the present thesis, aspects of the 
current understanding of the role of PPARγ in fat cell differentiation, as well as the potential of 
treating obesity with conjugated linoleic acids (CLA) are discussed. 
 
Several studies in humans have documented that rare mutations in the PPARγ gene have devastating 
effects and causes lipodystrophy as well as an increased risk of type-2 diabetes and atherosclerosis. 
Also common variants have been identified in the PPARγ gene. Some studies have found these 
associated with an increased risk of obesity and type-2 diabetes, but the literature is inconsistent.  
In paper 1, we studied whether these inconsistent findings could be explained by hitherto un-
identified variants within the PPARγ2 promoter region. Screening for variants within the promoter 
region, spanning from base pair -3371 to +43 in a group of 83 either severely obese or type-2 
diabetic patients identified a total of 8 variants, of which the 7 (-792, -816C>T, -882, -1505G>A, -
1881C>T, -1884T>A and -2604T>C) had not been reported before. We identified different degrees 
of linkage disequilibrium between these and the previously identified variants 
-1953A>G, Pro12Ala and 1431C>T. However, using data from clinical investigations performed on 
a subgroup of men recruited from the ADIGEN cohort we were unable to document any major 
association between these variants and adult BMI, early-onset obesity or change in BMI during 
adulthood neither by associations with adult waist, fat mass, lean tissue mass or body fat percentage. 
This suggests that none of these variants contribute substantially to the pathogenesis of common 
obesity in this population.  
Although we cannot clearly refute that common variants within the PPARγ locus may contribute to 
obesity and/or type-2 diabetes, our data suggest that such effects are relatively small or that they may 
depend on interaction with other – yet unidentified – genetic or environmental factors. The success 
of future association studies of common PPARγ variants will most likely depend on the availability 
of appropriate data, i.e. an optimal study design, which preferably should include large sample sizes 
with thorough and detailed phenotypic characterization (preferably including fat distribution using 
Magnetic Resonance or CT-scanning techniques) and descriptions of several environmental and 
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behavioural factors. Also, taking possible effects of various haplotypes, gene-gene and gene-
environment effects into account would probably further increase success rate. 
 
An accumulating number of studies have found that that specific conjugated linoleic acids (CLA), 
particularly the trans10, cis12-isomer have unique PPARγ receptor down-regulating properties, that 
are associated with inhibition of adipocyte differentiation and inhibition of fat tissue gain when 
studied in vivo in animals and possibly also in humans. In the paper 4, we set out to evaluate if a 
commercially available CLA dietary supplement would affect 1-year regain of body weight or body 
composition after a major initial weight loss, and whether treatment with CLA induced any adverse 
effects. Overall, we found no evidence that CLA did induce any changes impact on in body weight, 
body composition or fasting levels of blood glucose or insulin. However, we did find a marginally 
increased blood leukocyte count, which may indicate enhancement of inflammatory processes by 
CLA treatment. CLA-isomers are likely the most well-studied single fatty acid isomers, and the 
pertinent literature suggests that at least some of the specific CLA-isomers may have biological 
characteristics resembling other trans fatty acids, with which they are structurally related. Some of 
these characteristics suggest that, although they may possess anti-obesity properties, they do also 
seem to have modest adverse effects, some of which may increase insulin resistance and risk of 
cardiovascular disease.  
In conclusion, CLA does not seem to be a promising agent for treatment of obesity, and the safety 
profile is not yet defined. However, the biological system with PPARγ as a central regulator of lipid 
metabolism and obesity may be a promising target for other novel drugs and bio-active food 
ingredients.
 5
Dansk sammendrag 
 
De fleste vestlige lande har oplevet en voldsom stigning i prævalensen af fedme i løbet af de seneste 
årtier. Fedme er en af de væsentligste underliggende risikofaktorer for udvikling af det metaboliske 
syndrom, type 2 diabetes og hjerte-kar sygdom. Det er veldokumenteret, at såkaldt simpel fedme 
opstår som et samspil mellem forskellige miljø- og adfærdsmæssige faktorer og en arvelig 
disposition som øger følsomheden overfor et stærkt fedmedisponerende miljø. Der er et åbenlyst 
behov for at få en bedre forståelse for de genetisk prædisponerende faktorer for dermed bedre at 
kunne tilrettelægge forebyggelses- og behandlingsmuligheder. Desuden er der også et akut behov for 
at finde nye effektive, sikre og billige behandlingsmetoder af fedme. 
 
Patogenesen bag fedme-associerede sygdomme involverer en abnormal fedtfordeling, normalt 
identificeret og karakteriseret som en forøget talje-omkreds, og især øget visceral fedme. Ydermere 
er der dokumentation for at en mere præcis patogenetisk forklaring skal søges i den såkaldte 
ektopiske fedtaflejring, dvs. en fedt-ophobning som sker i væv og organer udenfor de almindelige 
fedtdepoter. Disse væv er typisk lever, muskler, hjerte og bugspytkirtel – væv som normalt ikke er 
udviklet til at deponere fedt. Når disse væv kronisk udsættes for denne overflod af fedt tager de 
skade. Således anses fedme i sig selv ikke for at være den egentlige sygdomsfremkaldende faktor. 
Optimalt set, så bør derfor enhver behandlingsstrategi målrettes mod denne abnormale fedtfordeling i 
stedet for mod kroppens totale fedtmasse  
 
Transkriptionsfaktoren PPARγ har en central rolle i fedtcelle differentieringen, og en modulering af 
PPARγ aktiviteten kan hæmme den ektopiske fedtaflejring. Således er det vist at agonistisk 
aktivering af denne transkriptionsfaktor kan øge insulin følsomheden, således at blodglukose falder 
og muligvis også sænker risikoen for hjerte-kar sygdom. Effekten af en moderat modulering af 
PPARγ aktiviteten er til gengæld uklar, dette gælder hvad enten det drejer sig om betydningen af 
genetisk variation i PPARγ genet, eller om det induceres via en partiel aktivering eller hæmning ved 
hjælp af specifikke agonister eller antagonister (herunder også specifikke fedtsyrer som kan indtages 
som en del af kosten).  
I artikel 3 og 4 og i denne phd-afhandling gennemgås og diskuteres den nuværende forståelse af 
PPARγ´s rolle i fedtcelle udviklingen samt de potentielle muligheder der er for at behandle fedme 
ved hjælp af konjugerede fedtsyrer (CLA) som sandsynligvis virker på PPARγ.  
 
Flere humane studier har fundet at sjældne mutationer i PPARγ kan medføre udvikling af lipodystrofi 
samt give øget risiko for udvikling af type 2 diabetes og aterosklerose. Også mere hyppigt 
optrædende varianter er identificeret i PPARγ. Nogle studier har fundet, at disse almindelige 
varianter også kan give en øget risiko for udvikling af fedme og type 2 diabetes, men litteraturen er 
modstridende. I artikel nummer 1 har vi undersøgt om disse modstridende fund kunne forklares af 
effekten af hidtil ukendte varianter i PPARγ2 promotor regionen. Denne screening for varianter i 
promotor regionen, spændende fra basepar nummer -3371 til +43 i en gruppe af 83 enten svært fede 
eller type 2 diabetes patienter identificerede 8 varianter, af hvilke de 7 (-792, -816C>T, -882, -
1505G>A, -1881C>T, -1884T>A og -2604T>C) ikke var rapporteret tidligere. Vi fandt forskellig 
grad af genetisk kobling mellem disse og de tidligere identificerede varianter -1953A>G, Pro12Ala 
and 1431C>T.  
Ud fra kliniske undersøgelser af en gruppe af mænd rekrutteret fra ADIGEN kohorten fandt vi dog 
ingen sammenhæng mellem de fundne genetiske varianter og BMI i voksenalderen, tidlig opstået 
fedme eller på ændring i BMI i voksenalderen. Vi fandt heller ingen sammenhæng i forhold til talje 
omkreds, fedtmasse, mager legemsmasse eller kropsfedtprocent i denne gruppe af mænd. Dette peger 
således på at ingen af disse varianter bidrager væsentligt til patogenesen bag almindelig fedme i 
denne population. Selvom vi ikke helt kan afvise at hyppige varianter i PPARγ regionen kan influere 
på risikoen for fedme og/eller type 2 diabetes, så viser disse undersøgelser at sådanne effekter under 
alle omstændigheder er ret begrænsede, eller at effekten afhænger af en interaktion med andre – 
endnu uidentificerede – genetiske eller miljømæssige faktorer. Succesen af fremtidige genetiske 
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associationsstudier af hyppige PPARγ varianter afhænger i høj grad af kvaliteten af de tilgængelige 
data, dvs. at et optimalt studiedesign helst skal inkludere et stort populationsmateriale med en 
grundig og detaljeret fænotypisk karakteristik (optimalt set også en bestemmelse af 
kropsfedtfordeling vurderet ved hjælp af magnetisk resonans eller CT-scanning) samt en beskrivelse 
af en vifte af miljø- og adfærdsmæssige faktorer. Yderligere inddragelse af haplotype-analyser, samt 
af gen-gen og gen-miljø effekter kan formodentlig øge succesraten yderligere. 
 
Studier i en række dyremodeller og enkelte humane studier har fundet at specifikke konjugerede 
fedtsyrer (CLA), især trans10,cis12-isomeren, har unikke PPARγ receptor nedregulerende effekter, 
som er påvist at hæmme udviklingen af fedtceller og fedtvæv. I artikel 4 har vi undersøgt om et 
kommercielt tilgængeligt CLA kosttilskud kan påvirke kropsvægten eller fedtmassen hvis det gives i 
op til 1 år efter et diætinduceret større vægttab. Vi har desuden undersøgt eventuelle bivirkninger af 
CLA. 
Overordnet fandt vi at CLA ikke gav ændringer i kropsvægt, kropssammensætning eller påvirkede 
fasteniveauet af glukose eller insulin i blodet, sammenlignet med placebo. Dog fandt vi at CLA 
medfører en lille øgning af leukocytter i blodet, et fund som indikerer en øget inflammation. CLA-
isomerer er sandsynligvis de mest velstuderede enkelt-fedtsyre-isomerer, og den tilgængelige 
litteratur godtgør at i hvert fald nogle af disse specifikke CLA-isomerer har biologiske egenskaber 
som minder om andre transfedtsyrer, med hvilke de også er strukturelt relateret til. Selvom det tyder 
på at CLA-isomerer kan besidde anti-fedme egenskaber, så ser de også ud til at inducerede negative 
effekter, herunder en øgning af insulin resistens og en mulig forøgelse af risikoen for hjerte-kar 
sygdom. 
 
Samlet set, så ser CLA ikke ud til at være en lovende behandling af fedme, og sikkerhedsaspektet er 
tillige endnu ikke fuldt ud undersøgt. Det er til gengæld klart at det biologiske system hvori PPARγ 
indgår, er en nøglefaktor i reguleringen af fedtstofskiftet og fedmeudviklingen og at det derfor kan 
være et lovende angrebspunkt for nye typer af medicin og bioaktive fødevareingredienser. 
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supportive. Also a warm thank to Søren Toubro for your always open door and welcoming attitude, 
your willingness to help and discuss pending issues, and for your always good (but sometimes black) 
humour. I would like to thank Benjamin Buemann, with whom I shared office during approx. 2 
years. Thank you for always having the time and interest to discuss scientific issues and for being an 
excellent travelling partner at our trips to various scientific meetings.  
I gratefully acknowledge the expert help from the technical and administrative staff at the 
Department of Human Nutrition and Hvidovre Hospital, without which these studies would not have 
been possible. Therefore, for excellent laboratory and technical help, I thank Kirsten Bryde 
Rasmussen, Inge Timmermann, Helle Reinikka Christensen and Martin Kreutzer; for excellent 
dietetic help I thank Ulla Pedersen, Annette Vedelspang, Kit Henningsen and Pia Gronemann. 
Finally, for secretarial or administrative help, I thank Heidi Jensen, Trine Stougaard Stasiak, Maj-
britt Petersen and Maybritt Rydahl. 
As it is no secret that other studies, particularly the MUFObes study have also taken some of my 
working time during the period from summer 2003 until now, and because this work is not described 
in this thesis, I would also like to thank the substantial number of people (not mentioned, not 
forgotten!) who have helped me – and us - during the substantial collaborative work carried out 
within the MUFObes study. This help I hope to be able to acknowledge further in the future. 
In general, I would also like to thank the staff at the Department of Human Nutrition; i.e. Kitchen 
Staff, Laboratory and other Technical staff, Dietician Staff and the very long list of academic 
personal with whom I have shared time and fellowship. In particular I will thank my close colleague 
and current room mate Anette Due for all her help, for fruitful discussions and for being very patient 
and tolerant with me. Also, I sincerely thank the help of Camilla Verdich for her constructive critique 
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what it meant to me. Fortunately, I have found substantial meaning of studying the implications of 
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1 Introduction 
The aim of the present thesis is to make a thorough evaluation and perspectivation of the results 
presented in the two original papers (Larsen TM et al., 2005a;Larsen TM et al., 2005b). In particular 
to discuss the key findings in these papers in the context of the data currently available in the 
relevant literature, covering issues as diverse as fat cell differentiation, molecular-genetic studies, 
animal models, human epidemiological studies and human intervention studies. In order to 
appropriately cover these diverse areas, the discussion and interpretation of the 2 papers are put into 
the perspective of the two review papers (Larsen et al., 2003a;Larsen et al., 2003b) and include 
whatever pertinent data that have been published before and after these reviews. Hence, the findings 
already described in these reviews will not be referenced in all details, and instead the emphasis is 
put on other or more recent literature. It is emphasized that this thesis has obesity, the metabolic 
syndrome (MS), including risk of type 2 diabetes (T2D) and cardiovascular disease (CVD) as its 
primary areas, although variation within the PPARγ gene and supplementation of CLA may have 
significant biological effects on other diseases not particularly related to the pathogenesis of obesity, 
MS, T2D or CVD. The physiology of the PPARγ system and the metabolic effects of CLA-
supplementation may at first sight appear to be two very different research areas. However, as it will 
hopefully appear in this thesis, and as illustrated in figure 1, an emerging amount of data supports the 
notion that the PPARγ system and dietary fatty acids, including CLA, do actually interact in multiple 
ways, affecting human metabolism and potentially also human disease. I hope that further 
exploration of these complex interactions, along with other interacting factors, may provide further 
evidence, which can be used to pave the way for more effective and more individualized prevention 
and treatment of obesity and to prevent obesity-related diseases. 
 
Figure 1: The complex interaction between genetic variation and dietary fatty acids on PPARγ 
activity and the development of obesity and associated diseases.  
BODY FAT CONTENT 
AND  DISTRIBUTION
FAT CELL 
DIFFERENTIATION
T2D CVD
DIETARY FATTY ACIDS 
INCLUDING CLA
ENVIRONMENTGENETIC VARIATION
PPARγ ACTIVITY
METABOLIC 
SYNDROME
PPARγ GENE 
VARIANTS
OTHER GENE 
VARIANTS
 
Genetic variation within the PPARγ gene together with environmental effects which also includes dietary fatty acids (i.e. 
also CLA) may regulate PPARγ activity, particularly in fat cells. The effects on fat cells may influence the distribution of 
subcutaneous and visceral fat in the body, ultimately affecting the risk of developing the metabolic syndrome, type 2 
diabetes and cardiovascular disease. 
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1.1 Obesity and associated diseases 
Body weight relative to body height has been shown to increase the risk of various diseases, such as 
the MS,CVD and T2D, which are in focus in this thesis, but also certain forms of cancer (WHO, 
2000). The WHO (WHO, 2000) has made classifications of BMI (kg/m2) to categorize people 
according to increased risk of developing diseases (Figure 2). 
 
Figure 2: Classification of overweight in adults according to BMI 
 
Adapted from (WHO, 2000) 
 
The pathophysiology of obesity is complex and so is also the exact calculation of relative risk of 
developing obesity-related co-morbidities. It can be argued that the BMI index is a rather inaccurate 
measure of obesity degree, and that it is too inaccurate to use it to assess effects on risk of disease. 
Though this may be true for the individual (as it will be discussed thoroughly in the sections below), 
epidemiological studies strongly suggest that being overweight (assessed via BMI) is an important 
predictor of all-cause mortality. This risk is independent but additive from the risk of being 
physically inactive (Hu et al., 2004). Unfortunately, the prevalence of obesity is reaching epidemic 
proportions (International Obesity TaskForce & European Association for the Study of Obesity, 
2002;Hedley et al., 2004) and thus concerns for future increased medical costs and a potential 
decline in life expectancy have arisen (Olshansky et al., 2005)  
1.1.1 The metabolic syndrome 
The excessive risk of disease associated with the obese state per se is controversial. Accumulating 
evidence suggest that obesity is merely the underlying cause of emerging risk factors. It has been 
known for decades that obesity is often associated with several risk factors for the development of 
T2D and CVD. Suggestions of a state of insulin resistance as a common associate to the development 
of diabetes was published as early as 1939, and the concept of syndrome X, a constellation of risk 
factors associated to the development of CVD was described by Gerald M Reaven in 1988 (Reaven 
GM, 2005). Subsequently this pattern of risk factors associated with the development of T2D and 
CVD has also been designated the insulin resistance syndrome or MS, and the American Heart 
Association, The US National Heart, Lund and Blood Institute and the American Diabetes 
Association now recommend using the wording “Metabolic Syndrome” (Expert Panel, 2001;Grundy 
et al., 2004). Today, there are several – and slightly different – definitions of MS that are adapted by 
different organizations such as the American Diabetes Association (Expert Panel, 2001), WHO 
 11
(Alberti and Zimmet, 1998), and the International Diabetes Federation (www.idf.org, 2005). In 
addition, the American Association of Clinical Endocrinologists and the European Group for the 
study of Insulin Resistance 2002 (EGIR) have proposed alternative but similar clinical criteria for 
their description of the insulin resistance syndrome (Balkau et al., 2002;Einhorn et al., 2003).  
According to the National Health and Nutrition Examination Survey (NHANES) 1999-2000, the 
prevalence of MS, as defined by the National Cholesterol Education Program/Adult Treatment Panel 
III (NCEP/ATPIII) among US adult is approximately 27 % (Ford et al., 2004). For comparison, in 
Denmark the prevalence of MS in women is around 15 % in 1999 as defined by the NCEP/ATPIII 
criteria (Lauenborg et al., 2005). Unfortunately, these numbers are most likely on the rise in most 
westernized countries.  
1.1.2 Type-2 diabetes 
Similar to the metabolic syndrome, the use of diagnose and classifications of T2D are also different; 
WHO (Alberti and Zimmet, 1998) and ADA (American Diabetes Association, 2005) although they 
are nearly identical. In 2001, the prevalence of T2D in US adults was 7.9 % (Mokdad et al., 2003), 
whereas it is estimated that 100.000-150.000 people in Denmark have diagnosed T2D, corresponding 
to 2-2,5 % of the adult (>20 years) population (Sundhedsstyrelsen, 2003). In addition, it is 
anticipated that a quite substantial number of persons have undiagnosed T2D. Obesity, and 
particularly indices of abdominal obesity, is one of the major underlying risk factors for the 
development of T2D, and the waist circumference seems the best predictor of T2D (or at least as 
good a predictor) compared to other anthropometric indexes of central obesity (Guerrero-Romero 
and Rodriguez-Moran, 2003;Mamtani and Kulkarni, 2005). A recent study in 909 korean women 
with a history of gestational diabetes found an odds ratio of 5.8 to develop T2D between patients 
within the upper and lower quartile of waist circumference (Cho et al., 2005). Also, a study in 
swedish men found an 16.6 times higher risk of developing T2D in the group within the upper 5% 
distribution of waist/hip ratio when compared to the group within the lowest quintile (Ohlson et al., 
1985), the association being stronger than for BMI only. For a general description of important risk 
factors (including family history and diet) for development of T2D, the reader is advised to one of 
the several reviews and statements on this topic (Sheard et al., 2004;Mann et al., 2004;Klein et al., 
2004b). Finally, and of major importance, a study suggest that having a diagnosis of T2D reduces life 
expectancy with 7 years in men and 7.5 years in women, primarily as a result of increased risk of 
CVD (Morgan et al., 2000). 
1.1.3 Cardiovascular disease 
It is difficult to obtain a precise definition of atherosclerotic CVD. In this thesis, the description will 
include peripheral atherosclerosis, coronary ischemic disease and stroke although it is quite obvious 
that the underlying pathophysiological mechanisms may be somewhat different for these different 
conditions. The prevalence of peripheral arterial disease in the US adults aged >40 y, estimated by an 
ankle-brachial index >0.90 in the leg (an important marker of sub-clinical coronary heart disease) is 
approx. 4.3 % in the 1999-2000 National Health and Nutrition Examination Survey (Selvin and 
Erlinger, 2004). As discussed above, the risk factors known to cluster within MS are highly 
associated to the development of ischemic CVD, and particularly the diagnosis of T2D is a major 
risk factor for future CVD. It is generally agreed, that obesity per se does not affect the risk of CVD 
as much as for T2D, but obesity still increases the risk by a factor of approx. 2 (Kenchaiah et al., 
2002) (Nanchahal et al., 2005) (Expert Panel, 2001). 
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1.2 Abnormal fat distribution – implications for adverse effects of fatness 
Epidemiological studies support the notion that central adiposity (e.g. measurement of waist 
circumference) is a better predictor than BMI of the development of T2D in humans (Ohlson et al., 
1985) and also a better predictor of all-cause mortality (Bigaard et al., 2004). 
A recent study also suggest that body weight history, i.e. the time point for weight gain, may have 
substantial influence on subsequent risk of T2D, as late-onset obesity has been shown to be a better 
predictor of development of T2D than early onset obesity (Black et al., 2005). This finding could be 
explained by an increased ratio of abdominal weight gain/total weight gain after the age of ~30 y 
compared to age <30 years. Upper-body obesity has been shown to be a significant risk factor of 
impaired glucose tolerance, whereas lower-body fat (adjusted for total body fat) seems to protect 
against impaired glucose tolerance (Buemann et al., 2005) and against risk factors associated with 
CVD (Buemann B et al., 2005). 
 
Following the substantial evidence, that fat distribution (lower- or upper-body obesity) is a better 
predictor of disease than just obesity as assessed by BMI, total body fat, or body fat percentage 
(which do usually not give any information about the fat distribution). A substantial number of 
studies have indicated that particularly the upper-body obesity phenotype is associated with fat 
deposition in a variety of tissues not designed for storage of fat, such as liver, skeletal muscle, heart 
and pancreas. Several expressions have been proposed for the description of this condition, such as 
‘failure of adipocyte differentiation’ (Danforth E Jr, 2000), ‘ectopic lipids’ (Unger, 2003), ‘ectopic 
fat distribution’ (Ravussin and Smith, 2002), ‘disordered fat storage’ (Lewis et al., 2002) 
‘lipotoxicity’ (Schaffer, 2003), and ‘adipocyte insensitivity syndrome’ (Erol, 2005). 
 
Figure 3: Development of lipotoxicity when positive energy balance exceeds the buffering capacity of 
adipose tissue.  
 
An increased calorie intake and a reduced energy expenditure, whether being a result of environmental and/or genetic 
effects, leads to a positive energy balance. The energy surplus will usually be deposited in adipose tissue. However, in 
situations of chronic positive energy balance, the adipose tissue cannot sufficiently adapt to the surplus of fat. This leads 
to triglyceride accumulation in non-adipose tissues such as the liver, muscle and pancreas, ultimately leading to 
malfunctioning of these organs. Adapted from (Lewis et al., 2002) 
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As illustrated in figure 3, the belief is that in situations of continuous energy surplus, the adipose 
tissues cannot store the increased amount of energy as triglycerides (TG) in the fat cells. The result is 
that the fatty acid “spill-over” from the subcutaneous adipose depots (or perhaps also fats derived 
directly from the blood during the postprandial state) will eventually end up as fat in other tissues 
including visceral fat, liver, muscle, pancreas, heart etc. This so-called ectopic fat deposition in turn 
has detrimental effects on the metabolism in these tissues, and there is evidence that hepatic steatosis, 
intra-skeletal myocellular lipid accumulation, lipotoxicity in pancreas, deposition of fat in cardiac 
myocytes, and accumulation of fatty acids in the kidney are all results of this condition (Schaffer, 
2003). 
 
1.2.1 Lipodystrophy and its role in MS, T2D and CVD 
The insight into the possible causal relationship between upper-body obesity and the development of 
insulin resistance, hyperglycaemia, dyslipidaemia, and hepatic steatosis gained support from the 
characterization of lipodystrophy syndromes. Lipodystrophies are clinically heterogeneous aquired 
or inherited disorders characterized by the selective loss of adipose tissue. Although patients 
suffering from these syndromes are often of normal body weight, they may suffer from a variety of 
different metabolic disorders, eventually leading to clinical disease. The clinical phenotype is often a 
selective lack of subcutaneous fat from face, arms and legs, whereas the intra-abdominal fat is 
maintained to some extent. The associated complications often include accumulation of triglycerides 
in the lever and skeletal muscle and lowered plasma adiponectin levels, all contributing to insulin 
resistance and increased risk of T2D and CVD (Garg, 2004). Patients suffering from lipodystrophy 
may actually have substantially increased metabolic rate (energy expenditure pr. day), and although 
they have a relatively normal BMI and are insulin sensitive at a younger age, they may eventually 
become insulin resistant in later life, despite still being of normal body weight (Johansen et al., 
1995). 
Hence, this pathophysiological picture is overall in agreement with the development of lipotoxicity 
and the MS as illustrated in figure 3. Inherited lipodystrophies are caused by genetic defects in a 
number of different genes; in many cases genes involved in fat cell differentiation, e.g. PPARγ 
(Hegele, 2005). However, lipodystrophies can also be acquired: Treatment of Human 
Immunodeficiency Virus (HIV) using antiretroviral therapy is an example of a clinical disorder  
associated with the development of lipodystrophy (~40% of patients), making HIV-infected patients 
the most prevalent patient group with lipodystrophy (Garg, 2004). These patients have disturbed 
postprandial free fatty acid (FFA) metabolism, most likely due to inadequate incorporation of FFA 
into TG in subcutaneous adipose tissue (van Wijk et al., 2005). 
As obesity increases the risk of disease, it could be hypothesized that partial ablation of fat (e.g. 
liposuction) could improve or eliminate several of the risk factors associated with obesity. Klein et 
al. evaluated the effects of large-volume tumescent liposuction in obese subjects with or without 
T2D. The fat removed was primarily superficial and deep subcutaneous abdominal fat. Although the 
subjects experienced a loss of approx. 10 kg of subcutaneous abdominal body fat (keeping the 
amount of visceral fat unchanged) and a significant decrease in waist circumference, they had a 
tendency for a lower circulating adiponectin level. Also, they did not show any improvement in the 
insulin sensitivity of liver or skeletal muscle as assessed by the euglycemic-hyperinsulinaemic clamp 
technique (Klein et al., 2004a). However, others have found improvements in insulin sensitivity after 
selective removal of less than 1 kg of visceral fat in human patients in connection with bariatric 
surgery procedures (Arner, 2004).  
Supportive evidence has also been obtained from the use of transgenic animal models: 
Reitman and colleagues reviewed the metabolic complications in mice with different degrees of fat 
ablation, and found that the degree of fat loss correlated with the frequency with which the mice 
were affected by mortality before weaning. Also the degree of fatty liver, level of 
hypertriglyceridaemia, and age of onset of hyperglycaemia were associated with the degree of fat-
depletion (Reitman et al., 1999). 
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1.2.2 Metabolic characteristics of different fat depots – influence on hepatic and whole-body 
insulin sensitivity 
It is a long-standing hypothesis that hepatic insulin resistance is mediated – at least in part – by an 
increased flux of FFA from visceral fat to the liver by the portal circulation (Bjorntorp, 1991), and 
several confirmatory studies now exist. In anaesthetised dogs, the mean effective dose of insulin for 
suppression of lipolysis was almost fourfold higher in visceral adipose tissue than for whole-body 
suppression of lipolysis, suggesting that only at extremely high insulin concentrations is lipolysis 
suppressed in visceral fat (Mittelman et al., 2002). Hence, an increased free fatty acid flux to the 
liver may account for hepatic insulin resistance often found in the obese state. Likewise, in 
moderately obese rats, surgical removal of visceral fat significantly improved hepatic insulin 
sensitivity compared to rats having subcutaneous fat removed, and improved insulin sensitivity was 
observed despite the (whole-body) plasma FFA level was unchanged (Barzilai et al., 1999;Gabriely 
et al., 2002).  
 
In humans, the systemic levels of fasting serum TG and FFA have in some studies been identified as 
risk factors for the development of T2D, but other studies suggest that the abundance of visceral fat 
versus the same amount of subcutaneous fat does not necessarily translate into higher levels of FFA 
(Couillard et al., 1998). However, the postprandial levels of TG and FFA are much higher in men 
with higher levels of visceral fat (Couillard et al., 1998), or in women with a android fat distribution 
versus a gynoid distribution after a high fat load (Mekki et al., 1999). Like in dogs, visceral obesity 
in humans is also associated with a decrease in the anti-lipolytic effect of insulin, as assessed via 
FFA turnover (Albu et al., 1999). With the use of very sophisticated isotope dilution/hepatic vein 
catherization techniques, a recent study also concluded that the contribution of visceral adipose tissue 
lipolysis to the total delivery of FFA to the liver increases with increasing levels of visceral fat in 
humans (Nielsen et al., 2004). 
 
In humans, further support of a causal relationship between FFA and T2D comes from evidence that 
the drug acipimox both affects FFA and insulin sensitivity. In obese T2D and non-diabetic patients 
this long-acting anti-lipolytic agent lowered fasting levels of plasma FFA and plasma insulin and 
increased insulin-stimulated glucose uptake. It also improved the outcome of oral glucose tolerance 
tests (Santomauro et al., 1999;Bajaj et al., 2004). In T2D patients, treatment with acipimox for 12 
weeks did not decrease the fasting serum levels of FFA, but decreased serum cholesterol and TG 
levels and improved glycaemic regulation as assessed by fructosamine and HbA1c measures 
(Davoren et al., 1998). The long term efficacy of this drug on glucose regulation is disappointing 
however (Saloranta et al., 1993). 
 
1.2.3 Intrahepatic fat 
Intrahepatic fat accumulation may also be involved in the development of MS, T2D, and CVD, and 
several clinical and experimental studies have suggested that non-alcoholic fatty liver diseases 
(NAFLD), in its whole spectrum ranging from pure fatty liver to non-alcoholic steatohepatitis 
(NASH) and cryptogenic cirrhosis, may simply be the hepatic manifestation of the metabolic 
syndrome (Marchesini et al., 2003;Marchesini et al., 2005). The causal relationship between obesity, 
whole-body insulin resistance and hepatic fat accumulation has however presumably been very 
difficult to establish, because prospective studies of hepatic fat accumulation involving even small 
numbers of human subjects are very difficult to carry out.  
Studies in animal models do support that intrahepatic TG accumulation is indeed involved as a causal 
factor in the development of MS (Qi et al., 2005), Also, a recent study in glucose tolerant patients 
compared subjects with or without hepatic steatosis assessed via ultrasound scanning of the liver. As 
expected, based on the inclusion criteria (only glucose tolerant patients were allowed), there was no 
significant differences in either circulating glucose or insulin levels two hours after glucose loading, 
but the homeostasis model (HOMA) insulin resistance index was significantly higher in patients with 
signs of steatosis and this was also independent of BMI (Venturi et al., 2004). 
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1.2.4 Intramuscular fat 
The role of intra-myocellular lipid (IMCL) accumulation for the development of MS is still not 
clarified. Although associations between IMCL content and insulin resistance have been reported 
(Pan et al., 1997), others have found higher levels of IMCL in physically trained persons compared 
with sedentary individuals (Goodpaster et al., 2001), thus questioning the pathogenic role of IMCL. 
It is therefore likely that increased IMCL content does not represent the direct cause of the 
development of insulin resistance per se, but is rather a marker of the presence of other lipid 
intermediates linked directly to defects in insulin signalling (Perseghin, 2005). 
 
1.2.5 Animal models of the “unhealthy lean phenotype” and “the healthy obese phenotype” 
One would assume that lean individuals are in general metabolically more healthy and thus without 
the diseases associated with obesity, such as T2D and MS. Although this may be the case in some 
animal models, there are also several studies of mice, which via transgenic modelling are turned lean, 
but still have a metabolically unhealthy phenotype. Hence, a lean phenotype is not always 
synonymous with a healthy phenotype, and the models described below support the hypothesis that 
fatty acid spill-over from fat depots, whether it occurs in lean or obese models, leads to lipotoxic 
effects on non-fat tissues. 
 
The high mobility group protein HMGI-C is localized in the cell nucleus, where it functions as a 
transcription factor predominantly expressed during embryogenesis. Hmgic knockout mice gain 
substantially less weight without any apparent differences in food intake, compared to wild type 
mice. The knock-out (KO) mice have decreased fat cell proliferation and hence ~87% less fat 
(Anand and Chada, 2000). Unfortunately, the authors of the paper did not report any clinically 
relevant measures regarding nutrient metabolism, such as insulin sensitivity and hepatic lipid 
content. Thus, as indicated by Danforth in the associated commentary to that study: “Although 
manipulation with the expression of this gene, whether by genetic or medical methods may seem as a 
reasonable strategy, such changes in fat cell differentiation and loss of body fat may not necessarily 
turn into beneficial changes in whole body energy metabolism” (Danforth E Jr, 2000).  
The Preadipocyte factor-1 protein (Pref-1) is a transmembrane protein highly expressed in 
preadipocytes. Transgenic mice with selective overexpression of Pref-1 in adipose tissue did not 
exhibit changes in food intake compared to wild type mice. They had however, a substantial loss of 
adipose tissue, and the mice exhibited hypertriglyceridaemia, impaired glucose tolerance, and 
decreased insulin sensitivity, thus demonstrating that inhibition of adipogenesis by pref-1 
(presumably by inducing an “arrest” in adipocyte maturation) in vivo resulted in an impairment of 
adipocyte function and lead to the development of metabolic abnormalities (Lee et al., 2003). 
The perilipin protein is associated to the surface of lipid droplets, where it protects the droplet from 
being broken down by hormone-sensitive lipase (HSL). The peripilin-/- mouse has a constitutively 
activated lipolysis (via uncoupling of the HSL regulation) and increased energy expenditure. This 
mouse, although being very lean despite increased food intake, eventually develops insulin resistance 
and impaired glucose tolerance (Martinez-Botas et al., 2000;Saha et al., 2004). 
Lipoprotein lipase is positioned at the luminal surface of the vascular endothelium where its function 
is to hydrolyze triglycerides from circulating chylomicrons and very low density lipoproteins 
(VLDL). Transgenic non-obese mice with selective overexpression of lipoprotein lipase in liver and 
muscle, developed insulin resistance in liver and muscle, likely due to accumulation of intracellular 
fatty acid-derived metabolites in the insulin resistant tissues (Kim et al., 2001). These studies of lean, 
but metabolically adversely affected mice models underscore the importance of abnormal lipid 
deposition in the development of insulin resistance. 
 
On the contrary, one would assume that animal models with an obese phenotype would have 
increased risk of metabolic abnormalities. However, there are models that are actually obese, but 
have a risk profile that is equal, or even better than the one for wild type animals.  
The adipocyte lipid-binding protein (AFABP) is localized in the cytoplasma where it binds both long 
chain fatty acids and retinoic acid thus controlling lipid transport in adipocytes. The AFABP-/- mouse 
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exhibits reduced fatty acid efflux from adipose tissue, possibly via downregulation of the activity of 
hormone sensitive lipase. Despite increased adiposity, the KO mouse has lower fasting blood sugar 
levels and increased insulin sensitivity and improved glucose tolerance compared to wild type 
animals (Uysal et al., 2000;Baar et al., 2005). 
Lipin-1 (Fatty liver dystrophy protein), encoded by the Lipin1 gene is a nuclear protein, known to be 
involved in adipocyte differentiation. Specific overexpression of lipin-1 in adipose tissue increased 
the amount of body fat tissue, but the insulin sensitivity was improved compared to wild type 
animals. This was likely induced by an increased triglyceride synthesis and storage in adipose tissue, 
preventing fatty acid overflow and ectopic fat storage in muscle, liver or pancreas. Conversely, 
specific overexpression of lipin-1 in skeletal muscle induced insulin resistance (Phan K and reue k, 
2005).  
The Diacylglycerol O-acyltransferase 1 protein (DGAT) encoded by the Dgat1 gene is an integral 
membrane bound protein residing within the endoplasmic reticulum. The protein catalyzes the 
terminal and only committed step in TG synthesis by using diacylglycerol and fatty acyl CoA as 
substrates. Transgenic mice overexpressing DGAT1 were more obese (had ~20% more body weight) 
but had normal glucose and insulin tolerance tests, and normal triglyceride deposition in skeletal 
muscle and liver (Chen et al., 2002).  
The phosphoenolpyruvate carboxykinase protein (PEPCK) encoded by the Pepck gene is a rate-
limiting gluconeogenic enzyme. Transgenic mice with selective overexpression of PEPCK in adipose 
tissue developed obesity, but did not develop insulin resistance (Franckhauser et al., 2002). 
The adiponectin protein is encoded by the Acrp30 gene, and it is synthesized exclusively by 
adipocytes and known to be secreted into plasma. Mice with transgenically induced higher levels of 
adiponectin had increased fat mass but had also improved lipid clearance and improved suppression 
of insulin-mediated endogenous glucose production (Combs et al., 2004). 
 
Although the ectopic fat hypothesis may seem relatively straightforward, there are reports of 
transgenic animals with - what seems to be – a selective decrease in white adipose tissue via 
manipulation of either insulin receptor in fat tissue (Bluher et al., 2002), heterozygotic Crebbp mice 
(a nuclear enzyme involved in histone acetylation during transcriptional activation) (Yamauchi et al., 
2002) and increased expression of the transcription factor FOXC2 expression (Cederberg et al., 
2001), and which also have improved insulin sensitivity. However, these studies lack a thorough 
description of food intake, so the (if any?) effects on the central appetite regulation cannot be ruled 
out. 
 
Overall, the above discussed animal models support the accumulating evidence that peripheral 
subcutaneous fat functions as fat depots, effectively absorbing fat from the blood and maintaining 
this fat in depots. Also, without these fat depots, the clearance of fats and nutrients from the blood is 
attenuated, potentially increasing the load of these nutrients toward other tissues such as muscle, 
liver and pancreas, eventually leading to malfunction of these tissues. 
 
1.2.6 Definition of a healthy lean phenotype with optimal metabolic regulation for the 
interpretation of future risk of MS, T2D and CVD. 
The human body is genetically able to adequately regulate blood pressure, body temperature, salt 
balance etc. in order to maintain its homeostasis. Hence, the body is usually also perfectly adapted to 
regulate the level of glucose, lipids and amino acids in the blood in order to supply the tissues and 
organs with the nutrients necessary for the provision of energy and for cell maintenance or cell 
growth. Under normal circumstances the body adjusts this regulation under a wide variety of 
conditions such as during sleep, starvation and high intensity exercise. Also overfeeding is regulated 
in the sense that excess energy is efficiently stored as triglycerides in fat depots, where the lower-
body, subcutaneous fat depots seem metabolically best adapted for this purpose. Chronic 
perturbations of energy balance are less likely to be optimally regulated however, as these fat depots 
cannot expand infinitely. Thus, chronic oversupply of energy may lead to a state where the nutrients 
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are not properly taken up by the tissues, and there is risk of so-called “leak” or “spill-over” of energy 
from these tissues. In such situations, the level of nutrients in the blood is not adequately regulated. 
To avoid such situations, the body engages counter-regulatory mechanisms. In humans, there are 
suggestions that hormones such as leptin and/or possibly adiponectin may be counter-regulatory 
hormones, leptin acting as both a satiety signal in the brain, and as a fat-burning signalling directed 
to peripheral tissues such as liver and muscle tissues (Unger, 2005). However, as is unfortunately 
often seen, innate counter-regulatory signalling may not be sufficiently powerful to regulate such 
chronically imbalanced states.  
Many such imbalances are reversible by behavioural means, e.g. lowering of energy intake and 
concomitant weight loss may help the body to better regulate the metabolism of nutrients.  
Also, at least theoretically, drug-induced changes in nutrient flux – whether regulated on the 
transcriptional or on the protein level – may be used as a mean for re-establishing nutrient regulation. 
As previously illustrated and as it will be discussed in the case of CLA supplementation, the method 
by which such energy imbalance is regulated may not be equally effective in terms of overall health 
effects. Thus, although one can make suggestions of plausible useful treatment based on biological 
grounds, in any case, real experiments need to be performed, and it seems highly important to 
evaluate if metabolic changes are beneficial not only in terms of the study efficacy endpoint (e.g. fat 
loss), but also in terms of other risk factors related to the medical condition (e.g. hepatic steatosis or 
insulin sensitivity), and preferably also to other conditions.  
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1.3 Molecular genetic aspects in the pathogenesis of obesity 
Traits like eye or hair colours are substantially influenced by genetic inheritance. Likewise, almost 
every human trait is to some extent genetically determined, but where some traits may be determined 
by a single causative gene (monogenic), others may be under the influence of a variety of different 
and interacting susceptibility genes (polygenic) as well as epigenetic and environmental factors. 
The basic premise of the studies of obesity genetics is the assumption that the inherited component of 
obesity is real and that is has a relatively large impact on the development of obesity, also compared 
to non-genetic factors such as environmental factors (physical activity, socioeconomic status, diet 
etc.) and epigenetic factors (non-mendelian, paternally or maternally inherited traits, that is not 
ascribed to changes in the nucleotide sequence, but to subtle modifications of the genes, which in 
turn may affect their expression). Thus a low genetic heritability will decrease the power of the 
study, and the likeliness of finding a genetic influence will diminish. Heritability can be estimated 
using either twin studies (looking for greater concordance between monozygotic twin pairs than 
between dizygotic twin pairs), by studying families (examining the degree of similarity within 
families versus between families) or by adoption studies (looking for greater concordance between 
biological relatives than for the adoption parents-adoptive child relationship). A complementary 
statistic is λs, which is the degree of elevated risk of disease for a sibling of an affected individual 
compared with a member of the general population (see box below).  
 
 
 
 
 
λs does not exclusively reflect pure genetic influence, but it also reflects the impact of familial 
environmental factors. However, before embarking on a costly study, one should have prior evidence 
that genetic variation plays some role in determining the phenotype, and it is also relevant to have an 
estimate of heritability or λs. 
For T2D, for which genetic influence have been quite intensively studied, several estimates of 
heritability have been suggested. Florez et al. describe, that in T2D, the absolute risk to siblings is 
30-40% as compared to a population prevalence of 7%, providing a releative risk to siblings of four 
to sixfold (Florez et al., 2003). Other investigators argue that the relative risk (λs) is about 3 (Parikh 
and Groop, 2004), while yet others suggest that heritability estimates of T2D are unrealistic to 
derive, as many genetic and environmental effects are intimately related and interact throughout life 
(McCarthy, 2004). 
For obesity, different measures may be defined e.g. BMI, body fat percentage, waist circumference, 
visceral fat etc. The correlation between each of these measures is in general very variable. Hence, 
strictly speaking, one should actually talk about several obesity phenotypes. Therefore, it can also be 
argued that any individual can be susceptible to develop a higher BMI, but not necessarily a higher 
visceral fat content. Most genetic studies have looked at BMI as the “obese phenotype”.  
The results from the studies of the heritability of common (common = polygenic) obesity (e.g. BMI) 
have generally been quite heterogeneous, the heritability level being the highest with twin studies 
and the lowest in adoption studies. When several types of relatives are used jointly in the same 
design, the heritability estimates typically cluster around 25-40% of the age- and gender-adjusted 
phenotypic variance (Claude Bouchard et al., 2004).  
If considering which obesity phenotype would be most important for metabolic complications, one  
would most likely study the amount of visceral fat content. But measurement of visceral fat content 
is limited by a very laborious and costly procedure, and therefore only very few studies have looked 
at genetic susceptibility for visceral fat accumulation. Reliable estimates of the genetic contribution 
of visceral fat content can consequently not yet be made. 
 
The study of the genetics of human obesity has focused on both monogenic (including syndromic) 
and polygenic obesity, and a variety of different study designs, including Quantitative Trait Loci 
Risk of disease for sibling
Risk of disease for 
background population
λs =
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(QTL), linkage studies and association studies as well as the use of a lot of different transgenic and 
knockout animal models have been used, recently reviewed by Bell et al. (Bell et al., 2005). 
 
1.3.1 Monogenic and syndromic obesity 
From the beginning of the 1990s, the development of genome-wide genetic maps (including the 
sequencing of the human genome) permitted the widespread application of genome-wide linkage 
analysis to disease status. When applied to complex traits, this method has proved to be largely 
unsuccessful, although some genes contributing to complex diseases have been identified.  
On the contrary, for analysis of single-gene disorders, linkage analyses have been tremendously 
successful, leading to many new insights into molecular disease pathogenesis, including obesity. 
In general, a distinction is made between monogenic obesity and syndromic obesity, the latter being 
phenotypically characterized by several distinct clinical abnormalities of which mental retardation is 
a common one. Within the syndromic phenotypes, the most well-known are Prader-Willi, Cohen, 
Alström and Bardet-Biedl syndromes. The monogenic obesity phenotypes are usually related to 
disturbances of the central regulation of appetite regulation (Clement, 2005). Thus, within 
monogenic phenotypes, the most studied variants have been identified in the genes encoding leptin, 
leptin receptor, pro-opiomelanocortin (POMC), proconvertase 1 and melanocortin-4 receptor 
(MC4R), all genes which are related to the central regulation of appetite (Clement, 2005). The 
importance of these genes for the development of obesity has in most cases been confirmed by 
knock-out or transgenic animal models. In humans these mutations are rare. However, there are 
suggestions that mutations in the gene encoding MC4R may be the most common form of known 
monogenic obesity accounting for 2-3 % of juvenile-onset obesity among Danes (Larsen et al., 
2005a). 
 
1.3.2 Polygenic obesity 
It is generally agreed that common obesity (both defined as a discrete and as a quantitative trait) has 
a complex pathogenesis, with multiple genetic and environmental factors contributing to the 
observed phenotype (e.g. BMI, waist circumference etc.). Because of its multi-factorial nature, each 
individual genetic variant generally has only a modest effect, and the interaction of genetic variants 
with each other or with environmental factors can potentially be quite important in determining the 
observed degree of obesity. Yet it remains largely unknown which genetic variants explain the 
inherited variation of obesity. Genetic association studies, in which the allele or genotype frequencies 
of markers are determined in affected individuals and compared with those of control subjects (either 
population- or family-based), may be an effective approach to detect the impact of common variants 
with modest effects (Newton-Cheh and Hirschhorn, 2005). With the recent increase in single 
nucleotide polymorphism (SNP) discovery and genotyping technologies, large-scale association 
studies have become feasible, and small-scale association studies have become plentiful. According 
to the yearly update on the overview of studies of obesity genetics, association studies between gene 
variation and obesity phenotypes now represent positive associations with more than 358 findings in 
113 different genes (Perusse et al., 2005). However, despite the accumulating number of “positive 
studies”, there have been very few gene variants, where several independent studies have been 
supportive, thus questioning the validity of the majority of these small positive association studies, 
most of which are statistically underpowered. 
 
The polygenic inheritance of obesity has been described by different hypotheses: 
1) The Common Disease/Common Variant (CD/CV) hypothesis predicts that the genetic risk for 
common disease (or obesity) will often be due to disease-predisposing alleles with relatively high 
frequencies – that is, there will be one or a few predominating disease alleles at each of the major 
underlying disease loci (Lander, 1996;Reich and Lander, 2001).  
 
2) A hypothesis, in which a large number of loci, each with multiple disease-predisposing alleles of 
low frequency (high allelic heterogeneity) is involved in the increased risk of obesity (Pritchard, 
2001;Pritchard and Cox, 2002). 
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3) The common variants/multiple disease hypothesis. The hypothesis states that the common alleles 
which contribute to a given disease under a certain combination of interacting genes and 
environmental conditions, may act in other genetic backgrounds influenced by other environmental 
factors, resulting in different but possibly related clinical outcomes. For example, physical inactivity 
is a common risk factor to both T2D and obesity. Both disorders are influenced by different diets, 
both may share loci determining carbohydrate and lipid metabolism, ultimately contributing to 
disease (Becker, 2004). Formally this hypothesis does not refute any of the other 2 hypotheses. 
 
Also, none of the three hypotheses exclude that each of several genetic variants may only have a 
small or moderate effect on obesity, and that the cumulative contribution of each or all of these 
variants may only become important when there is an interaction with environmental factors 
predisposing to their phenotypic expression, such as overeating and reduction in physical activity.  
 
Currently it is assumed that approximately 90 % of the sequence variation among human individuals 
is due to common variants (with allele frequency ≥ 1%), and the remaining 10% is due to a vast array 
of variants that are each rare in the population (HapMap Consortium, 2003). A haplotype is defined 
as a specific set of alleles observed on a single chromosome.  
An example of a haplotype is the coexistence of the three nucleotides -1505A, -1881T and -2604C at 
the three positions: -1505, -1881 and -2604 in the PPARγ2. 
The goal of the ongoing International HapMap project is to determine the common patterns of DNA 
sequence variation in the human genome. The project will develop a map of these patterns across the 
genome by determining the genotypes of one million or more sequence variants, their frequencies 
and the degree of association between them. The map will be based on DNA samples from 
populations with ancestry from Africa, Asia and Europe. One of the project aims is to allow the 
discovery of sequence variants that affect common disease to improve diagnostics and therapeutic 
intervention (HapMap Consortium, 2003). However, the success of the HapMap project to identify 
disease variants highly depends on the assumption that the “common variant/common disease” 
hypothesis is true, because many rare variants will not be detected. Unfortunately there are several 
arguments against this hypothesis. Generally, gene variants which only have marginal effects on the 
phenotype are more likely to be maintained and therefore have a higher frequency. Gene variants 
with moderate effects are more likely to be sorted out due to evolutionary selection pressure, and 
gene variants with fatal effects will in most cases not be passed on to the next generation. Therefore, 
the more common the variant is, the less likely it is to have any impact on common diseases. In 
contrast, rare variants are more likely to have large effects on disease. Rare variants will of course 
per definition not give rise to common disease. It can be argued that the genetic evolution in western 
countries is characterized by an absence of strong natural selection. Hence, there is likely to be a 
broad spectrum in frequency of gene variants, many of which are likely to be common in the 
population. Each common variant does not significantly increase the risk of being obese, and it does 
not have any impact on obesity in the population. However, there may be a subset of individuals who 
possess several variants that together increase their risk of obesity. Also, the totality of such people 
may affect obesity in the whole population. Conversely, the number of people with many such 
common variants will be small (illustrated in figure 4 below). 
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Figure 4: Illustration of the effects imposed by rare and by common genetic variants on obesity in  
individuals and in the population. 
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Black columns indicate proportion of obesity in individuals that are explained by different types of genetic variants. 
Hatched columns indicate proportion of obesity in the population that are explained by different types of genetic variants. 
 
The candidate gene approach used for association studies can be based on various evidence; the 
knowledge of the function of the gene under consideration and the anticipation that changes in the 
gene sequence, either changing the function or the amount of the gene product, may influence the 
phenotype under study. Thus, the choice can be based on the physiological role of its encoded 
protein product in the mechanism of obesity, the consequences of its genetic deletion (knock-out) or 
its overexpression (transgenesis) in the rodent and even the in vitro functional characteristics of 
mutations or variations of the DNA studied (biological candidate).  
Other evidence can be the chromosomal location, i.e. if positioned in a region previously shown to be 
genetically linked to obesity in man or animals (positional candidate). 
 
In common diseases (and common obesity) with a polygenic inheritance, common genetic variants 
(or polymorphisms defined as those for which two or more alleles each exist in 1% or more of the 
population at large), are individually or together not expected to be necessary nor sufficient to cause 
the disease. That is, some individuals will have the variant but not the disease, and others will have 
disease without harbouring a causal variant of that gene. Because of this imperfect correlation, 
association studies must compare frequencies of a putative causal variant in individuals with disease 
and in appropriate control subjects. If the genetic variant is found at a statistically significant higher 
frequency in affected individuals, this implies that the variant is associated to disease. 
Proof of causality of a gene variant-phenotype association typically depends on several lines of 
evidence. First, for polygenic diseases, the putative causal genomic changes should be found more 
often in affected individuals. Second, one hopes for a “smoking gun”, – i.e. that the disease-
associated variants are obviously deleterious to protein function (due to truncation or deletion of a 
coding region or alteration of a highly conserved residue) or expression (due to changes in important 
regulatory regions). Success is typically declared when the following criteria are all satisfied: The 
putative disease gene (or genes) 1) is located in a chromosomal region that co-segregates with 
disease in affected families, 2) contains multiple independent variants that are perfectly (or almost) 
associated with disease status in the families, 3) obviously alter protein function or expression 
(Hirschhorn and Altshuler, 2002). Confirmation of the satisfaction of these criteria in independent 
studies will further strengthen the association. 
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Although various association studies have suggested that individual genetic variants have important 
effects on BMI, and although genome-wide studies have also suggested that various loci do show 
some associations to obesity, there are yet no convincing evidence (i.e. independent replicated 
studies) that any individual gene variant or any individual locus has a significant effect on common 
obesity (Bell et al., 2005;Perusse et al., 2005). Actually, the PPARγ Pro12Ala variant is very likely 
to be the variant most often associated to obesity, but even this association is not yet definitive as it 
will be discussed further in section 1.4.3.  
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1.4 PPARγ – is it a central player in obesity and related diseases?  
The peroxisome proliferator-activated receptors (PPARs) comprise a subfamily of the nuclear 
hormone receptor (NHR) superfamily. The family of PPARs includes the PPARγ, PPARα and 
PPARβ. All PPAR family members serve as transcription factors via heterodimer binding with the 
retinoic acid receptors (RXRα, RXRβ og RXRγ). The PPARs are all activated by a variety of fatty 
acids, but the specificity for fatty acids differs between the PPARs. They also differ in their tissue 
expression, PPARα being primarily expressed in the liver, PPARβ being expressed in virtually all 
tissues and PPARγ being mostly expressed in adipose tissue.  
The PPARα is known to play an important role for plasma TG regulation and the fibrate drugs, 
which are used in clinic care of dyslipidaemia are known to decrease TG levels via their action on 
PPARα in the liver. The exact role PPARβ has not yet been firmly established, but there is evidence 
that it is involved in cholesterol metabolism in the liver (Larsen et al., 2003b). 
It is well established that the PPARγ protein has a very important role in adipocyte differentiation, 
but it has also been reported to be expressed in a variety of different tissues. It is expressed as the two 
different transcripts PPARγ1 and PPARγ2, giving rise to identical proteins except that the PPARγ2 
proteins carry an extra 28 amino acid long n-terminus. Maybe the existence of tissue-specific 
expression and different transcripts may have important consequences for its biological importance.    
To address the importance of variation within the PPARγ and the associated effects on obesity and 
related diseases, it is therefore important to evaluate its role in various human organs like fat tissue, 
liver, muscle and pancreas - all organs that have a major influence in the pathogenesis of obesity and 
related diseases. The following sections will address the biological function of PPARγ and of each of 
the transcripts PPARγ1 and PPARγ2 in relation to cellular functions, and it will present evidence 
from animal and human studies, including the possible role of gene variants in the promoter region as 
well as the coding on human obesity, carbohydrate and lipid metabolism, and the development T2D 
and CVD. It will be discussed whether there is consistency between the current biological knowledge 
and the findings from genetic studies. 
 
1.4.1 The importance of the PPARγ receptor for fat cell differentiation and metabolic 
regulation. 
As described in the review, paper 3 (Larsen et al., 2003b), our understanding of the PPARγ and its 
involvement in adipocyte development has increased substantially over the recent years. The interest 
is – at least in part – explained by the accumulating evidence that PPARγ agonistic activation using 
the Thiazolidinedione drug class or similar drugs, can be used as a treatment modality to attenuate 
the insulin resistance which seems to underlie the development of T2D in the majority of patients. It 
is generally agreed that prevention of insulin resistance would be a better solution to tackle the 
disease, rather than treating the disease with other means when the disease is more manifest and 
often followed by complications. Hence, as the insulin resistance is thought to underlie the 
development of T2D, the underlying mechanisms behind these insulin-sensitizing effects of PPARγ 
activation is of major interest for the medical industry as well as for the scientific community as it 
may give further insight into the pathophysiological mechanisms behind the development of the 
disease. Also, this insight can be useful for the development of other treatment options, including 
medical drugs but potentially also novel herbal compounds and dietary supplements or maybe a 
better optimization of the diet. 
 
The importance of PPARγ has been investigated by using a variety of approaches, including 
transgenic mice. As discussed in the review paper, several independent research groups have 
generated and investigated mice heterozygous for Pparg (Larsen et al., 2003b). However, possibly 
due to different genetic background of the mice strains used, and due to different study designs, such 
as length of study (i.e. also the age of mice), the results of the characterization of these mice are not 
always congruent.  
Initial studies suggested that these mice exhibited greater insulin sensitivity and were protected from 
the development of insulin resistance mediated by a high fat diet (Kubota et al., 1999;Miles et al., 
2000). A subsequent study confirmed that when fed a high fat diet, these mice are less obese, less 
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insulin resistant, but that they have only a normal glucose tolerance, probably mediated by a less than 
expected insulin release because of an increased TG content in the beta cells (Matsui et al., 2004).  
Of further contrast, another group found that Pparγ +/- KO mice also develop insulin resistance 
when fed a high fat diet (Miles et al., 2003). 
 
Transgenic mice with a dominant negative pparγ hL466A mutation leads to impaired adipocyte 
differentiation and lipodystrophy. They do not develop severe insulin resistance when fed normal 
diet, but overt insulin resistance is induced by long term high fat feeding (Freedman et al., 2005). 
As is often the case, the identification of these phenotypes were a result of genotype-environment 
interactions. Hence, genetic manipulations or natural genetic variations may in many cases only 
result in a different phenotype, when studied under certain conditions, such as high fat feeding. 
The understanding of the biological function of PPARγ has also been quite intensively studied using 
transgenic mice with selective tissue Pparg inactivation. Hence there is now quite a few different 
Pparg transgenic mice, i.e. fat tissue specific deletion of Pparg (both g1 & g2) (He et al., 2003;Imai 
et al., 2004;Jones et al., 2005), specific deletion of Pparg2 (Koutnikova et al., 2003;Zhang et al., 
2004;Medina-Gomez et al., 2005), liver specific deletion of Pparg (both g1 & g2) (Gavrilova et al., 
2003;Matsusue et al., 2003) and muscle specific deletion of Pparg (both g1 & g2) (Hevener et al., 
2003;Norris et al., 2003). 
A recent comprehensive review (Argmann et al., 2005) (and to which I agree!) of the main Pparg 
tissue specific KO mice models that have been described in the recent years, suggested that in the 
models with selective absence of WAT, the liver PPARγ participates in both fat regulation and 
glucose homeostasis, but in the models with presence of WAT, the impact of PPARγ in the liver on 
glucose homeostasis is rather minimal. The role of PPARγ in the muscle is however, not yet obvious, 
as two independent reports of muscle-specific Pparg KO mouse models were essentially opposite, 
one study suggesting that mice lacking muscle PPARγ develop severe muscle insulin-stimulated 
insulin resistance and as result are hyperinsulanemic, glucose intolerant and hypertriglyceridaemic 
(Hevener et al., 2003), whereas the other study suggested that muscle-specific PPARγ KO mice have 
normal glucose homeostasis and insulin levels, but have reduced hepatic insulin sensitivity, 
suggested to be a consequence of the increased WAT mass (Norris et al., 2003). Further, although 
some studies suggest that muscle PPARγ is a direct target of TZDs, most studies suggest that PPARγ 
in muscle is more responsible for coordinating the use of energy rather than directly controlling 
glucose homeostasis or responses to insulin, validating the concept that WAT is predominantly 
responsible for the insulin-sensitizing effect of PPARγ (Argmann et al., 2005). 
 
As the amount and activity of visceral fat seems to be one of the key factors in the regulation of 
hepatic, and probably whole-body glucose regulation, one of the key questions is therefore the actual 
role of PPARγ in the differentiation of (lower-body) subcutaneous fat versus (upper body) visceral 
fat. Our current understanding of PPARγ´s interaction in fat cell differentiation is, however, still 
quite complex. Studies in mice give evidence that PPARγ activation of the lipogenic programme 
does not depend on the presence of glucocorticoids, and inasmuch as rodent inguinal and 
retroperitoneal fat can be taken as representatives of “human” subcutaneous and visceral fat, PPARγ 
activation seems to promote differentiation of subcutaneous fat to a higher degree than of visceral fat 
(Berthiaume et al., 2004). Others have concluded that the adipose-depot specific effects of PPARγ 
agonist cannot be explained by differences in the mRNA expression of total PPARγ between adipose 
tissue from human subcutaneous and omental adipose depots as the transcription levels were equal 
(Montague, 2002). In obese women, in both subcutaneous and visceral fat, the expression of PPARγ2 
was substantially more expressed (>20 fold) than that of PPARγ1. However, only PPARγ1 was 
differently expressed, its levels in subcutaneous adipose tissue being approximately 2 fold those in 
visceral adipose tissue (Giusti et al., 2003). In obese rats, treatment with a PPARγ agonist for 3 
weeks significantly increased subcutaneous fat, but decreased visceral fat (Laplante et al., 2003), and 
similar findings have been reported in human studies (Larsen et al., 2003b). On the other hand, 
excessive – and thus toxicological - doses of PPARγ agonists in rats and monkeys induce massive 
lipid accumulation, oedema and anaemia (Aleo et al., 2003) 
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In mice, selective disruption of Pparg2 is not lethal (whereas combined Pparg1 and Pparg 2 KO is). 
Pparg2 KO mice are of normal body weight, but have reduced WAT, less lipid accumulation and 
decreased adipogenesis in adipose tissue, though with no severe metabolic perturbations on 12-15 
weeks on a regular chow diet. Yet, the increase in body fat is more severely compromised when put 
on a high fat diet (Zhang et al., 2004). These findings were corroborated by another research group, 
although the amount of WAT was less affected by Pparg2 disruption (Medina-Gomez et al., 2005). 
Transfection of Pparg  -/- mice embryonic fibroblasts shows that PPARg2 is a more powerful 
inducer of adipogenesis of WAT than PPARg1 (Zhang et al., 2004).  
 
Although some studies have suggested that PPARγ antagonists could be used in the treatment of 
obesity and MS and selective PPARγ antagonists have now been available for more than 5 years, 
only one in vivo study in mice has been carried out (and reported) using these drugs. Treatment with 
the PPARγ antagonist SR-202 reduced body mass, fat mass and seemed to improve insulin 
sensitivity in growing diabetic ob/ob mice (Rieusset et al., 2002). In this study, however, there was 
no data on concurrent changes in energy expenditure, energy intake and levels of triglycerides in 
plasma and ectopic fat deposition in the liver, findings which may have occurred. Also, no similar 
studies are available in adult and weight stable mice, nor are there any studies in larger models such 
as pigs, dogs or monkeys, thus questioning whether these findings are reproducible. 
 
Activation of PPARγ with drugs are used clinically to treat type-2 diabetes, and post-approval studies 
have added further evidence that the drugs currently available, pioglitazone and rosiglitazone really 
are (equally) effective at blood sugar regulation and insulin sensitization, although they may differ 
somewhat in their effects on circulating triglycerides, HDL- and LDL-cholesterol, all effects being in 
favour of pioglitazone (Goldberg et al., 2005). 
Our understanding of the mechanism of action has also improved substantially. In T2D patients, 12 
weeks of treatment with the PPARγ agonist pioglitazone increased the expression of several, though 
not all, lipogenic enzymes in abdominal subcutaneous fat (Bogacka et al., 2004). The same study 
found that a 24 week treatment period induced a weight gain of ~3.5 kg, of which fat tissue 
accounted for almost all of the weight gain. The amount of visceral fat tissue did however not 
change. A prior study with 24 weeks treatment of 400 mg/day of troglitazone showed decreased ratio 
of visceral fat/subcutaneous fat, together with preserved fasting insulin secretion and decrease of 
liver fat (Katoh et al., 2001). Overall, these effects on body fat redistribution by activation of PPARγ 
activation is illustrated in figure 5.  
 
Figure 5: Effect of PPARγ agonists on fat distribution 
 
Abdominally obese patients often suffer from increased intramuscular and intrahepatic fat and have elevated levels of 
circulating triglycerides and free fatty acids. Treatment with PPARgamma agonists thiazolidinediones (TZD) decreases 
triglycerides and free fatty acids and induces a relative redistribution of fat – i.e. the amount of subcutaneous fat is 
increased, whereas the amount of visceral fat is decreased. Adapted from Bays H et al.(Bays et al., 2004) 
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A study in T2D patients, with 16 weeks of 8 mg/day of rosiglitazone resulted in decreased liver fat 
content, lowering of hepatic insulin resistance, and increased expression of lipoprotein lipase (LPL) 
and adiponectin in subcutaneous abdominal adipose (Tiikkainen et al., 2004). In addition to 
decreased liver fat content, a lowering of triglycerides in skeletal muscle has been reported after 12 
week treatment (Mayerson et al., 2002). 
Also, long-term treatment (2 year) with pioglitazone compared with the insulin-secretagogue 
gliclazide, showed that pioglitazone was significantly more effective in long-term blood sugar 
regulation and on indices of insulin resistance and beta-cell function (Tan et al., 2005).  
Whether treatment using PPARγ agonists also can lead to improvement of CVD risk profile – in 
addition to the effects on insulin sensitization and glucose regulation – is now one of the major 
questions that are being clinically evaluated in ongoing studies, though preliminary evidence is 
available; in a 24 week study with non-diabetic men with coronary heart disease, treatment with 8 
mg/day rosiglitazone reduced insulin resistance, and also the levels of C-Reactive Protein (CRP) and 
von Willebrand factor (markers of inflammation and endothelial activation): However, the treatment 
actually increased circulating LDL and triglyceride levels, and did not seem to translate into positive 
improvements in endothelial function (Sidhu et al., 2004). Another study found that pioglitazone, 
when given as 45 mg/day to diabetic patients, improved plasma glucose and insulin levels, and in 
addition improved some (serum concentrations of LDL, hsCRP, MMP-9, MCP-1, HDL, 
adiponectin), but not all markers of CVD risk (no effects on e.g. serum concentrations of ICAM, 
VCAM, fibrinogen, von Willebrand, PAI-1). Interestingly though, there was an improvement in 
carotid intima media thickness (IMT) (Pfutzner et al., 2005). Thus, as preliminary evidence on the 
long-term effects of PPARγ activation for the treatment of CVD is contradictory, we await further 
clarification from ongoing studies. 
 
1.4.2 Genetic variation in the PPARγ locus 
As discussed in the previous section, there is accumulating evidence that PPARγ is strongly involved 
in fat cell differentiation. Also animal studies and human clinical studies suggest that PPARγ activity 
regulates whole-body fat content, fat distribution, glucose and lipid metabolism and affects the risk 
of metabolic diseases. Hence, there is biologically plausible evidence that also variation in the gene 
encoding the PPARγ transcription factor may have important implications for obesity and related 
diseases. As illustrated in figures 6 and 7, quite a few different variants have been identified in 
PPARγ. But most previous studies have focused on variation within the coding region of the gene. 
Several of the variants identified in the coding region are missense mutations with effects on in vitro 
transcriptional activity. Some of them have been suggested to underlie clinical cases of lipodystrophy 
syndromes, suggesting a severe attenuation of PPARγ activity and of development of fat tissue. 
However, the genetic variants underlying the development of lipodystrophy are very rare (Hegele, 
2005).  
 
The 2 common variants; the silent 1431C>T (His477His) variant positioned within the ligand 
binding domain, and the Pro12Ala variant positioned in the proximal part of the ligand independent 
activation domain of the PPARγ2 protein are (i.e. this polymorphism does not exist in the PPARγ1 
transcript), possibly due to their high allele frequency, the most intensively studied variants in  
PPARγ. Thus the effects of these variants have been the focus in many association studies in a wide 
variety of human populations. 
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Figure 6: Schematic of PPARγ secondary structure and identified human polymorphisms. 
 
Schematic of PPARγ secondary structure and human polymorphisms. The three principal domains of PPARγ, the N-
terminal domain (gray), DNA-binding domain (white), and C-terminal ligand-binding domain (black), are highlighted. 
PPARγ1 is widely expressed, whereas PPARγ2 is restricted to adipocytes. PPARγ2 contains an additional 30 residues at 
its N terminus in humans (28 in mice). The common Pro12Ala polymorphism is within these extra residues of PPARγ2. 
All other mutations affect both isoforms. The constitutively active Pro113Gln mutation is located near serine 112 and 
interferes with phosphorylation. All the dominant-negative mutations are found in the ligand-binding domain 
and may interfere with ligand binding and/or heterodimerization with RXRα. No mutations have yet been found in the 
DNA-binding domain. Adapted from (Knouff and Auwerx, 2004) 
 
Figure 7: Variants in the PPARγ2 region including novel variants in the PPARγ2 promotor. 
Novel and previous identified variants in the PPARγ2 gene
(Novel variants are given under the line)
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The arrow indicate the translation initiation site. Black bars indicate exon regions within the PPARγ2 gene. 
Adapted from paper 1 (Larsen et al., 2005b) 
 
1.4.3 Heterogeneous findings in studies of PPARγ polymorphisms.  
As with genetic studies of other common diseases with a complex inheritance where results are often 
inconsistent and therefore the subject for much dispute (Editor, 1999;Ioannidis et al., 2001;Dahlman 
et al., 2002;Terwilliger et al., 2002), the available studies on the genetic influence on common 
obesity are often inconsistent or even contradictory (Hirschhorn et al., 2002;Lohmueller et al., 
2003;Perusse et al., 2005). For a given polymorphism the effects reported are sometimes uncertain, 
even conflicting, and illustrate the complexity of obesity as well as the statistical difficulties often 
associated with the lack of power of the analyses (Clement, 2005). 
This is also the case regarding variants in PPARγ and its effects on T2D and obesity (Meirhaeghe and 
Amouyel, 2004). Still, some argue that the overall evidence actually suggests that the PPARγ 
Pro12Ala variant actually causes a modest but real effect on the risk of T2D, the Ala allele being 
protective compared to the Pro variant (Lohmueller et al., 2003).  
Recently Meirhaeghe and Amouyel reviewed the literature on common PPARγ variants (Pro12Ala & 
C1431T variants) and their association to different phenotypes, including T2D and obesity. Overall, 
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the data for the effect of the Pro12Ala variant remains controversial (Meirhaeghe and Amouyel, 
2004) (Table 1). The review considered only studies of BMI, and to my knowledge, there are no 
studies available on the association between the Pro12Ala variant and visceral fat content. The in 
vitro studies of the Pro12Ala variant were quite consistent, all 3 available studies suggesting that the 
Ala variant had a reduced PPARγ transcriptional activity. But when studied in vivo, three 
independent research groups found that the insulin sensitivity was higher in Ala carriers (Meirhaeghe 
and Amouyel, 2004). One study evaluated the expression of PPARγ target genes in various fat depots 
of massively obese humans being either Pro12 or Pro12Ala carriers, and concluded that the 
polymorphism had only minor influence on the expression of these genes (PPARγ2, PPARγ1, LPL 
and others) (Kolehmainen et al., 2003). 
 
Table 1: Influence of the Ala12 allele on type-2 diabetes risk, insulin sensitivity and BMI 
Phenotype Number of studies 
with protective effect 
Number of studies 
with deleterious effect 
Number of studies 
with no effect 
Type 2 diabetes 7 3 8 
Insulin sensitivity 15 0 8 
BMI 6 10 25 
Modified from (Meirhaeghe and Amouyel, 2004) 
 
The inconsistencies in the association studies can be ascribed to several factors, all essentially 
ascribed to three causes:  
1) A false-positive association is correctly not replicated; 2) A correct report of a true association 
fails to be replicated in an underpowered study (false negative); 3) A true association in one 
population is not true in a second population because of heterogeneity in genetic or environmental 
background.  
In brief, false positives can arise due to inappropriate use of the p-value of <0.05 as a criterion for 
declaring success, particularly if not taking into account the number of tested hypotheses. Another 
probable cause of false positives may be population stratification and admixture (where populations 
with different rates of disease and possibly also with other genetic or non-genetic differences are 
unintentionally commingled in the same study).  
Given the often modest effect sizes of common variants contributing to complex diseases, false 
negative findings may occur if the sample size is not sufficiently powered in the statistical sense to 
achieve even nominal significance (p<0.05). Of course, findings going in the opposite directions 
cannot account for false negative findings, but false negative findings can occur as a result of 
population admixture.  
Finally, true heterogeneity between the populations of two different studies may exist. If a genetic 
variant’s influence on disease susceptibility is only manifest on a certain genetic background (e.g. a 
particular susceptible gene variant on which the effect of the studied gene variant is affected by, is 
only occurring in one population) or environmental background (e.g. access to cheap palatable food), 
then genetic and environmental differences could account for a failure to replicate an initial reported 
association (Newton-Cheh and Hirschhorn, 2005). 
Thus, as the inconsistencies may be due to false positive studies, false negative studies or true 
heterogeneity in association among different populations, meta-analyses can be used to assess small 
but real effects on common disease risk (Lohmueller et al., 2003). However, it should be mentioned 
that publication bias (i.e. significant results, including the false positive studies, are more likely to be 
published than those studies finding no difference) does not per se affect the outcome of individual 
studies but may affect the outcome of meta-analyses of published studies (Easterbrook et al., 1991). 
 
1.4.4 Studies of variation in the PPARγ2 promotor 
As the studies of variation in PPARγ in general have shown quite inconsistent results, we (in paper 1) 
set out to evaluate whether other – and hitherto unidentified - variants in the PPARγ2 promotor could 
be identified, and whether these variants, if existing, could explain the discrepancies in the results 
reported in previous studies (Larsen et al., 2005b). 
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For the identification of novel variants, mutation analysis was performed on 61 obese T2D patients 
recruited from the outpatient clinic at Steno Diabetes Center. In addition, screening was also 
performed on 22 severely obese (mean BMI ~48 kg/m2) subjects recruited from the ADIGEN cohort 
(Morberg et al., 2003). Thus, we believe that we had a reasonable chance to detect genetic variants 
that could be observed at a higher frequency in patients with T2D or in severely obese patients 
compared to lean persons. As previous studies have identified the PPARγ2 transcript as important in 
adipocyte differentiation (Tontonoz et al., 1994;Saladin et al., 1999;Zhang et al., 2004), we chose to 
screen for variants in the promoter regulating the expression of PPARγ2. The examined region 
spanned a total of ~ 3400 base pairs, defined as nucleotide -3371 to +43 relative to the ATG 
translation initiation site. This region was split up in 7 segments, each ~600 bp in length. These 
segments were amplified using PCR, and via the denaturing high-performance liquid 
chromatography technique (dHPLC) (denaturation/renaturation of DNA double-helix allows for the 
detection of heterozygote carriers from homozygotic carriers of the particular allele with more than 
95 % sensitivity) we identified a total of 8 gene variants, of which 7 had not been reported before. 
The subsequent identification of each of the nucleotide changes was done via direct sequencing of 
each of the 7 segments for those individuals that were initially identified as representatives of wild 
type or variant carriers via the dHPLC technique. The -1884T>A variant was only identified in one 
person and was not studied further. 
Four of the identified variants (-816C>T, -1505G>A, -1881C>T and -2604T>C) were in complete 
linkage disequilibrium. The study indicates that the PPARγ2 promoter region is highly polymorphic 
containing polymorphisms that are quite common (the allele frequencies of -792A>G, -882T>C, -
2604T>C, -1953A>G were ~27, ~1, ~14 and ~11%, respectively), somewhat similar to the 
frequencies of the common well-studied Pro12Ala (~15%) and 1431C>T (~14%) variants.  
For the association studies, a total of 6 variants, i.e. the -792A>G, -882T>C, -2604T>C, -1953A>G, 
Pro12Ala and 1431C>T (for Pro12Ala and 1431C>T some genotyping data was available from 
previous studies) which were only partially linked, were studied.  
The study cohort included a sample of 234 obese and 323 non-obese subjects from the ADIGEN 
cohort. We examined the potential association between each of these variants with adult (age ~49 
years) obesity, early-onset obesity (BMI>31 kg/m2 at age ~20 years) or change in BMI during 
adulthood (from age 20 to 49) as well as their association with adult waist circumference, fat mass, 
lean tissue mass or body fat percentage. We did however not find any significant association to any 
of these measures. 
 
1.4.4.1 Discussion of results 
We studied a quite large proportion of what we considered to be the most important part of the 
PPARγ2 promoter and found the region to be highly polymorphic.But if any of the identified variants 
has a large effect on the transcription rate of the PPARγ2 gene, we would expect that this would have 
influenced the degree of adiposity in the subjects studied.  
Therefore, as no association to any of the measures of adiposity was identified, we believe that in this 
population it is unlikely that any of these common promoter variants substantially affects the 
transcription of the gene – at least when each variant is considered on each own, i.e. without 
interaction with other gene variants or certain environments.  
However, as we did only screen for variants in the PPARγ2 promotor, we cannot state if variants in 
the coding region of PPARγ2 (except for the Pro12Ala and 1431C>T variants) could have played a 
role in the development of obesity and T2D in the studied population. Also, this study does not rule 
out, that any of the identified gene variants could have an impact on the risk of T2D, if this increased 
risk is independent from the effects on obesity. Although our study population was well-
characterized, as we had measures of BMI, waist circumference and body fat percentage measured 
by DXA-scanning, we are aware that our study also has its limitations. Most importantly, the sample 
size may not be large enough to detect more subtle effects on these measures. Considering only the 
Pro12 and Pro12Ala carriers, the sample size needed to attain a power of more than 0.80 to detect a 
difference in BMI of 1.0 kg/m2, would be more than 2000 subjects (table 2a). However, in our 
dataset, the difference in BMI between these groups was actually much less (~0.2 kg/m2 for the total 
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dataset of lean and obese subjects). Also, to detect a difference of 1% in body fat %, more than 3500 
subjects are needed (table 2b). In our pooled sample of lean and obese subjects, the numerical 
difference in body fat % between the Pro12 and Pro12Ala group was ~0.5 % (Not significant, data 
not shown), and if this difference should have reached statistical significance, probably more than 
15000 subjects would have been required (table 2c). 
 
Table 2: Statistical power calculations 
2a) N N N N N   
Pro12 383 766 1149 1532 1915   
Pro12Ala 141 282 423 564 705   
Power 0.30 0.54 0.71 0.83 0.90   
Calculation of power for BMI, assuming difference of 1.0 kg/m2 and SD/group = 7.0 (1 BMI unit ~ 3.19 kg BW) 
 
2b) N N N N N N N 
Pro12 374 748 1122 1496 1870 2244 2618 
Pro12Ala 139 278 417 556 695 834 973 
Power 0.20 0.35 0.49 0.61 0.71 0.78 0.84 
Calculation of power for fat mass %, assuming difference of 1.0 % and SD/group = 9.0  (1 fat mass% ~ 0.96 kg) 
 
2c) N N N N    
Pro12 2690 5380 8070 10760    
Pro12Ala 1000 2000 3000 4000    
Power 0.32 0.56 0.74 0.85    
Calculation of power for fat mass %, assuming difference of 0.5 % and SD/group = 9.0 (0.5 fat mass% ~0.48 kg) 
N indicates number of subjects. Power calculations performed using the website: 
http://www.stat.uiowa.edu/~rlenth/Power/index.html / and the procedure: two-sample t-test (pooled or satterthwaite) 
 
Thus, estimating the sample size needed is difficult and fully depends on the biological impact of 
each of these variants. Also, study population heterogeneity is a source of potential bias. In this study 
we selected the obese and control subjects based on their BMI (below or above 31 kg/m2) at the 
mandatory draft board examinations which were carried out in the period between 1943 and 1977. 
This case-cohort sampling design may likely have introduced substantial genetic heterogeneity 
between the obese and the control subjects. In other words, there may be a significant accumulation 
of obesity-predisposing alleles in the obese cohort, and variants within the PPARγ2 may actually 
only contribute very little to the overall sum of such predisposing alleles. However, although that we 
per design had created population heterogeneity, we do not believe that it invalidates neither the 
results nor the conclusions drawn from the study. 
 
Although we failed to show any associations between any of the variants and the phenotypes studied, 
we cannot rule out that combinations of gene-variants could actually influence the transcription of 
PPARγ2, and thus the risk of obesity. Such effects could be evaluated using haplotype analyses. 
However, due to the relative small sample size and the relatively many gene variants identified, we 
believe that we cannot perform meaningful haplotype analyses in this study. If such analyses were to 
be performed, there would be a large risk that some of the haplotypes would be represented by very 
few study subjects, making the interpretation very uncertain. Also, the risk of false positive findings 
would increase due to multiple testing, and although corrections could be made, such additional 
testing should preferably be based on a priori established hypotheses (e.g. based on in vitro 
experiments) that the specific gene-variant combinations would have additional deleterious effects, 
as compared to single variants only.  
 
Findings by Cole et al. have suggested that the PPARγ2 Pro12Ala polymorphism only accounts for 
approximately 1% of the variation in e.g. BMI and waist circumference (Cole et al., 2000). If this is 
the case, significant effects on these measures may be quite unlikely to identify in small studies like 
ours, or in studies that are even minimally biased by heterogeneity – i.e. variations in other genes or 
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environmental factors contributing to these traits. These considerations were also pointed out by 
Altschuler et al. Having only a small sample size, one may fail to observe a small magnitude of 
effect. A meta-analysis of the association between the PPARγ Pro12Ala variant and T2D, including 
all reported association studies (including all published studies up to year 1999) identified a modest 
(approx. 1.25 fold) but significant increased risk of T2D in carriers of the Pro allele (Altshuler et al., 
2000;Lohmueller et al., 2003). Thus, that study pointed out that not all studies found a significant 
association toT2D, but when all studies were analysed together, there was a small, but significant 
association.  
But, as pointed out previously, meta-analyses also have their limitations, and also very large studies 
published after this meta-analysis have been quite inconsistent (Meirhaeghe and Amouyel, 2004). 
Moreover, no such similar meta-analyses have yet been reported for the association between the 
polymorphism Pro12Ala and obesity. 
As it is our basic study premise that genetic variation will significantly affect gene transcription, 
splicing, mRNA stability, translation, or protein function, any variation with only marginal effects 
may not be identified. Therefore, the effect of the variants we identified could also be studied in 
functional in vitro studies. There are several drawbacks to in vitro studies, e.g. they cannot reveal the 
effects of heterozygous carriers and they cannot take into account any feed-back regulatory 
mechanisms that often operate in vivo. Therefore, although such data cannot be translated directly 
into effects observed in vivo, they can suggest which in vivo findings that may be expected. 
 
Of course the phenotypes under study should be carefully chosen. As discussed in previous sections, 
variation of PPARγ activity may not necessarily influence obesity as assessed by BMI, but the effects 
may be more pronounced on the distribution of fat within the whole body. In the clinical cases of 
lipodystrophy where mutations in PPARγ have been identified as the underlying cause, most in vitro 
studies have suggested that the variants induces a severely compromised PPARγ activity. Despite 
these findings, the body mass index has been reported to be normal in most cases of lipodystrophy, 
whereas only the fat distribution was abnormal (Hegele, 2005). Hence, one could argue that studying 
the effects on BMI of the Pro12Ala polymorphism or variants within the promoter region will not be 
useful if the real effects are changes in body composition, rather than just BMI. 
Clinical evidence suggests that patients with T2D who are either Pro12 allele or Ala12 allele carriers, 
do not differ in their response rate to therapy with the PPARγ agonist pioglitazone, suggesting that 
the polymorphism does not have major effects on PPARγ activity (Bluher et al., 2003). 
It is very likely that most genetic variants will only have significant effects under certain 
environmental circumstances. In the heterozygous dominant negative PPARg hL466A knock-in 
mouse (PPARKI), which shows characteristics of hypoadiponectinemia, increased circulating levels 
of free fatty acids and hepatic steatosis (Freedman et al., 2005), these effects were more pronounced 
when the mice were fed a high fat diet. Similarly, in humans the Pro12Ala variant and other variants 
that are expected to have only small effects on PPARγ expression or activity, such effects may only 
become apparent when influenced by an unhealthy diet and/or low physical activity. So far, only few 
studies of relative small sample sizes have been performed where also the interaction with non-
genetic factors has been investigated. 
 
1.4.4.2 PPARγ gene - environment interaction 
As suggested by Becker, the impact of common disease-influencing alleles should be examined 
when they occur in different genetic backgrounds, in other genetic combinations, or influenced by 
different epigenetic or environmental factors (Becker, 2004). Such interactions have already been 
studied on the common Pro12Ala variant in PPARγ (discussed below).  
 
Nutrient-gene interaction deals with the differential functional and eventual phenotypic effects of 
different doses of total energy intake or specific nutrients, in combination with various gene variants. 
Thus, nutrient-gene interaction can address inter-individual differences for the biological basis for 
development of obesity in some but not in other individuals eating the same diet. 
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Similarly, the environment-gene interaction addresses inter-individual differences for development 
of obesity when influenced by a particular environment. 
Animal studies can be designed to model the effect of a specific genetic modification on 
susceptibility to the obesity-promoting effect of a high-fat diet and/or obesogenic environment, and 
the effect of these variables on gene expression in various tissues and organs. Nonetheless, only 
human studies will reveal the complex interaction between genetic, diet and environmental factors 
responsible for human obesity and hence for the current epidemic of obesity.  
 
In a large sample involving more than 2141 subjects that served as a control group in the Nurses 
Health Study, there was no direct association between Pro12Ala genotype and BMI, but an 
association between total fat intake and BMI (higher fat intake associated with higher BMI) was 
found in Pro/Pro carriers, whereas no such association was found for the combined group of Pro/Ala 
and Ala/Ala carriers (Memisoglu et al., 2003). A somewhat similar finding was reported from 
analyses of the Québec Family Study comprising a total of 720 adults. In Pro12Ala carriers, there 
was no association between total fat (and saturated fat) and components of MS, including BMI and 
waist circumference, whereas in the Pro12Pro carriers these associations were obvious. Overall 
though, the Ala carriers had a higher BMI and waist circumference (Robitaille et al., 2003). 
 
In the prospective Isle of Ely study, including about 600 non-diabetic subjects, Luan and colleagues 
found that among the Ala carriers there was an association between the ratio of polyunsaturated fat to 
saturated fat (P:S ratio) and BMI and fasting serum insulin level (higher P:S ratio associated with 
lower BMI and fasting insulin), whereas such an association was absent in the Pro/Pro carriers. Also, 
with a low P:S ratio the Ala carriers had a higher BMI than Pro/Pro carriers, whereas the opposite 
was seen in subjects with a high P:S ratio (Luan et al., 2001). Overall, they did not find any 
association between Pro12Ala genotype and BMI or fasting serum insulin level. 
 
Another study in the German Epic cohort comprising 154 subjects with BMI > 35 kg/m2 and 154 
age- and sex-matched controls demonstrated that Ala carriers had a higher odds ratio for obesity 
when having a high intake of arachidonic acid compared with subjects homozygous for the Pro allele 
(Nieters et al., 2002).  
Although not directly related to the development of obesity, in a small study of 56 Uruguayan 
Caucasians, Ala carriers seemed more susceptible to develop T2D, but there was evidence that this 
was caused by an excessive intake of trans-fatty acids, suggesting that the ala allele is more 
susceptible to the adverse effects of high intake of trans fats (Pisabarro et al., 2004). Also, in 150 
subjects participating in the KANWU study, Lindi and colleagues found that carriers of the Ala allele 
have a greater reduction in serum TG in response to 3 month fish oil supplementation as compared to 
subjects with the Pro12Pro genotype(Lindi et al., 2003). 
 
The possible interaction with physical activity has been investigated in 3 studies. In a group of 123 
Japanese healthy men undergoing a physical activity program for 3 months, the improvements in 
fasting serum insulin and insulin sensitivity (HOMA-IR) were more pronounced in Ala carriers 
(Kahara et al., 2003). In a cohort of 506 Caucasian men and women within the Ely Study, the 
findings were somewhat more complex; in Pro/Pro carriers the beneficial effect of an habitual high 
P:S ratio and a high physical activity (measured via heart rate monitoring for 4 days), the benefial 
effects of such habits correlated independently with fasting serum insulin levels (high P:S ratio and 
high physical activity were both associated with low insulin). Ala carriers did however, only have 
lowered fasting serum insulin levels, when both physical activity and P:S ratio was high, suggesting 
a multiplicative interaction (Franks et al., 2004). In a Danish cohort of 29 healthy offspring of type-2 
diabetic subjects, who underwent a training program for ten weeks, Ala carriers had a larger loss of 
body weight than Pro/Pro carriers, however they did not benefit further in terms of changes in 
VO2max or insulin sensitivity (Ostergard et al., 2005). 
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These studies emphasize the possible importance of interaction of this gene variant with inter-
individual differences in nutritional and exercise habits, but the studies may also provide 
explanations of the discrepancies found in other association studies that neglect the role of the 
individual’s everyday practices. On the other hand, the methodological issues pertaining to the search 
for obesity candidate genes are even more problematic in the study of e.g. nutrient-gene interaction. 
In the above-mentioned studies, estimates of habitual dietary intake and physical activity are often 
based on measurement methods with a considerable uncertainty compared to the more simple 
measurement of BMI. 
 
1.4.4.3 Future association studies of PPARγ variants: 
Due to the lack of convincing evidence of major important genes underlying the development of 
common obesity, there is still a need for large-scale and phenotypically well characterized cohorts 
(preferably using prospective designs). 
It has been estimated that up to 75% of the publications on the association between risk of disease 
and particular gene variants are likely to be false positive ones. It has therefore been suggested that 
more stringent criteria are needed for improving the quality of future genetic studies to be able to 
better interpret such studies (Editor, 1999;Lohmueller et al., 2003).  
Such criteria seem also reasonable for the studies of the molecular genetics of obesity: 
1) A single, nominally significant association should be viewed as tentative until it has been 
independently replicated at least once and preferably twice. A review of 25 association studies 
suggested that two studies with P<0.01 or a single study (other than the first positive) with P<0.001 
is strongly predictive of future replication (Lohmueller et al., 2003) 
2) Large-scale studies should be encouraged, with collaborative efforts probably required to achieve 
the sample size of many thousands of case-control pairs,which is necessary for definitive studies of 
common variants with modest genetic effects. Even larger samples will be required to detect gene-
gene or gene-environment interactions or associations specific to defined subgroups or to correct for 
testing association to multiple phenotypes.  
3) To help increase the effective sample size, reports of association would ideally include a meta-
analysis of all available published data to give a more robust estimate of the genetic effect. To 
facilitate such meta-analyses and minimize publication bias, all disease association studies that meet 
minimal quality standards should be published. Such standards could include explicit phenotype 
definitions, complete listing of all phenotypes analyzed, precise localization of the polymorphism(s), 
low genotyping error rate, analysis that avoids overlap with previous studies and availability of 
genotype counts for cases and control subjects (or equivalent data for family-based studies).  
4) As many studies will not be able to fulfil such high standards and because of risk of publication 
bias, such studies could be published (positive as well as negative findings) in widely accepted and 
curated web sites and/or in brief “negative or suggestive results” sections of specialty journals with 
sufficient credit to provide incentives for publication (Hirschhorn et al., 2002). Also, as these 
common variants often only have modest effects, the impact of each variant should be considered 
(e.g. also reported) together with other risk factors associated with obesity development (i.e. 
environmental factors including physical activity, diet patterns, behavioural and socio-economic 
factors) (Ardlie et al., 2002). Although such a further thorough characterization of the study 
population is difficult and often not possible, there is increased understanding that further insight into 
gene-gene and gene-environment interaction is needed, and such studies are indeed on the rise. 
Preferably large-scale prospective intervention studies with randomised designs should be employed, 
as such studies will be able to include thorough characterizations of the study population including 
also the registration and controlled manipulation of several environmental variables, while 
eliminating the risk of population stratification.  
 
For the study of PPARγ variants, there may be some more specific study designs that could be 
considered, taking into account the knowledge about its possible role in lipid and carbohydrate 
regulation:  
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In addition to the phenotypes considered in paper 1 (Larsen et al., 2005b), other and more novel 
phenotypes could be studied, such as abdominal fat for given body fat percentage (preferably 
assessed by MR or CT-scan), ectopic fat depots and waist/BMI ratio. As gene effects may only 
become visible when the subjects are studied under particular conditions or challenges, glucose 
tolerance test or meal tolerance test (e.g. FFA suppression) could be considered. In addition, gene 
expression of PPARγ2 and expression of genes regulated by PPARγ in adipocytes isolated from fat 
biopsies from various body compartments would be of major interest.  
Finally, as previously mentioned, haplotype analyses within the PPARγ locus could be considered if 
the sample size is large enough. As illustrated in appendix A + B, the PPARγ locus possess several 
SNPs, with linkage disequilibrium values (R2) up to 1 within the nearest 20 kb, documenting the 
large genetic variability and variation in linkage within this region in this population of European 
American descent. 
 
1.4.5. In summary: The role of polymorphisms in PPARγ2 in the pathogenesis of obesity, T2D 
and CVD 
There is both theoretical and clinical evidence that PPARγ is a plausible candidate gene involved in 
the molecular pathogenesis of obesity. The evidence that genetic variation within the PPARγ locus is 
implicated in common obesity is however still limited. Clearly the evidence for involvement of 
common polymorphisms (e.g. the Pro12Ala) in common obesity is highly controversial, and the 
evidence from in vitro studies, as well as from transgenic animal models and in vivo measures in 
humans does not always fit with the findings from genetic association studies, questioning the 
validity of the studies available. Nonetheless as discussed, there may be several explanations for the 
observed discrepancies, and more – and preferably more optimally designed - studies are needed to 
clarify these inconsistencies.  
Ideally, to study such effects of each of the identified variants within PPARγ would require a study 
design that would mimic “life-long” situations, taking into account also the influence of different 
environmental factors. Such a study is unfortunately quite unfeasible in humans. Probably the best 
study that one could imagine to establish proof of concept would be to study transgenic e.g. 
Pro12Ala mice in life-long studies while also controlling the amount of physical activity and the diet 
composition. In conclusion, we undertook a thorough analysis of the variation in the PPARγ2 
promoter, in order to assess whether hitherto unknown genetic variants could explain the inconsistent 
findings between PPARγ variants and obesity. It was, however, not possible to offer such 
explanations.  
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1.5 Conjugated Linoleic Acid – a natural and novel approach in the treatment of obesity? 
We have recently conducted a review addressing the effect of Conjugated Linoleic Acid (CLA) on 
body weight, body fat content and various health outcomes in the literature of human and animal 
studies (Larsen et al., 2003a). Subsequently we have performed an intervention trial studying the 
effects of supplying obese humans with CLA in addition to their usual diet after an initial weight loss 
(Larsen TM et al., 2005).  
In the following I have addressed the biological effects of different types of fatty acids, and in 
particular the effects of CLA, with regard to their effect on body weight and body fat.  
The effect of CLA on fat cells as well as the data from cellular, animal, and human clinical studies is 
reviewed to further understand if and how long-term CLA treatment in humans may affect obesity 
and risk of T2D and CVD. Also, any potential safety issues associated with CLA supplementation 
are discussed. 
  
1.5.1 The definition of CLA 
As described in paper 4 (Larsen et al., 2003a), CLA is a collective term used to describe the mixture 
of positional and geometric isomers of linoleic acid (c9,c12-C18:2)  with conjugated double bonds 
(i.e., the two double bonds are separated by one single bond). These double bonds, each of which 
may be in the cis or trans configuration, can be in any position on the carbon chain. They are, 
however, most frequently found in positions 8 and 10, 9 and 11, 10 and 12 or 11 and 13, 
respectively. CLA is sold commercially as diet supplements. The CLA in commercial supplements is 
obtained by alkaline isomerization of vegetable oil enriched with linoleic acid (e.g. from safflower 
oil or sunflower oil). The fatty acid composition in the most sold CLA-preparations is dominated by 
2 main isomers, e.g. the 9c,11t-isomer and 10t,12c-isomer (see Figure 7), including in some 
preparations, a minor content of other isomers of conjugated linoleic acid (Figure 8). The 9c,11t-
isomer is the main CLA occurring naturally in foodstuffs (up to ~80% of total isomers). Since most 
of the CLA intake and therefore the 9c,11t-isomer arise from ruminant products (dairy and meat), 
this isomer is called rumenic acid. It is a byproduct of microbial biohydrogenation that takes place in 
the rumen from linoleic acid (and α-linolenic acid) occurring from plants and ingested by ruminants 
(Appendix D). When dealing with the bioactivity of CLA, it is likely that their structural peculiarities 
underlie some of their radically different actions when compared to linoleic acid. Nevertheless, only 
few studies have addressed the discrete potency of each of these isomers, or the particular synergistic 
or competitive effect of having several isomers present together in the same mixture (Larsen et al., 
2003a). In comparison, the most common industrially produced trans fatty acids (TFA) (which are 
usually trans isomers of oleic acid c9-C18:1) is elaidic acid, t9-C18:1, vaccenic acid t11-C18:1 and 
other (yet un-named) fatty acids with different positions of the trans binding, illustrated in Appendix 
F (Steen Stender and Jørn Dyerberg, 2003). For a list of common fatty acids, please see Appendix C 
adapted from Shields et al.(Shields et al., 1999).  
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Figure 7: Structure of linoleic acid and the most common CLA-isomers c9,t11 (9Z11E) and t10,c12 
(10E12Z) 
 
 
Figure 8: Labelling of the commercial CLA product “TONALIN®” 
 
Adapted from www.cognis.com, August 2003 
 
1.5.2 The molecular effects of CLA 
As discussed in paper 4 (Larsen et al., 2003a), there is substantial evidence that CLA attenuates 
adipocyte differentiation in various cell systems. Besides, most studies find that this effect can be 
ascribed solely to the t10,c12 isomer, as it has been shown that the t10,c12 isomer lowers TG 
accumulation in preadipocytes, whereas the c9,t11 isomer tends to increase TG content. In addition, 
there is evidence, that this effect is caused, at least in part, by a downregulation of the expression 
(and possibly inactivation) of the transcription factor PPARγ, which is known to be a strong inducer 
of adipogenesis. Recent studies in both mouse 3T3-L1 adipocyte cells and human SGBS cells have 
found that the t10,c12-induced attenuation of adipocyte differentiation is dependent on both time 
point and duration of treatment, i.e. that early and prolonged treatment substantially decreases the 
expression of lipogenic marker genes (PPARγ, C/EBPα, LXRα, aP2 and CD36) and severely down-
regulates the lipid accumulation in mature adipocytes (Angeles ZM et al., 2004;Granlund et al., 
2005b). In addition, a recent study suggests that small structural changes (i.e. changing to trans/trans 
binding or introducing an α-methyl group in the molecules tested; c9,t11, t10,c12, TTA, EPA or 
DHA) totally abolished their “native” effects, i.e. for the t10,c12-isomer, its down-regulation of 
adipogenic markers, including PPARγ, returned to levels of control treatment if it had an α-methyl 
group added. Thus, the “native” isomer t10,c12 is highly specific in preventing lipid accumulation in 
adipocytes (Granlund et al., 2005a). 
 
To assess the binding affinity of different fatty acids on the PPARγ transcription factor, competitive 
assays against the radioactively labelled highly selective PPARγ ligand, thiazoledinedione 
BRL49653 (Avandia, rosiglitazone) have been performed. There it was shown that saturated fatty 
acids in general had a lower affinity than polyunsaturated and monounsaturated fatty acids (Xu et al., 
1999;Desvergne and Wahli, 1999). The degree of affinity can however, not necessarily be translated 
into degree of agonist activity. Still, using a co-activator-dependent receptor ligand assay (CARLA) 
(i.e. also taking into account the important interaction with the associated transcription complexes 
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controlling transcription), similar results were obtained (Krey et al., 1997). But in co-transfection 
studies, the potency of saturated fats were not always lower than for polyunsaturated and 
monounsaturated fatty acids (Kliewer et al., 1997). Overall though, the PPARγ receptor is considered 
a low-affinity receptor, using a very broad range of different fatty acids or fatty acid derivatives as 
low-affinity ligands. Some data indicate that some fatty acids do have a higher PPARγ activating 
capacity than others. Thus, 15-deoxy-Δ12,14-Prostaglandin J2 has a higher affinity than other fatty 
acids(Forman et al., 1995). Also, nitrolinoleic acid (LNO2) which is commonly found in human 
blood at concentrations of ~500 nM has been shown to activate PPARγ as much as the highly 
specific TZD drugs (Schopfer et al., 2005). 
Although the in vivo effects of each particular fatty acid isomer can be predicted from in vitro 
studies, the actual concentrations of the fatty acids may in some situations not be linearly related to 
the dosing regimens if there is a high metabolism and turn-over of the fatty acids, decreasing the 
concentration of the particular isomers in the blood and in various types of body tissues.  
 
1.5.3 Effects of CLA in animal studies 
As discussed in paper 4 (Larsen et al., 2003a), numerous studies have investigated the effect of CLA 
on different animal models, and under a variety of different feeding conditions. In animals, it is 
widely recognized that feeding CLA (various mixtures of isomers) to different animal species results 
in changes in body composition, i.e. lowering of body weight in some cases, and a relative decrease 
in body fat mass together with relative gain of lean body tissue in most studies. The effects in 
animals are highly variable, possibly depending on a variety of factors including, but not limited to, 
species, age, gender, dosage, concomitant feeding regimen (e.g. total fat content of diet), and 
duration of CLA feeding, and certainly also the CLA isomer tested. Furthermore, adult animals may 
not be as susceptible to these effects – at least in rats, as it has been shown that adult rats (aged >13 
weeks old) were not affected by 6 weeks of 1% CLA supplement (Mirand et al., 2004). Although not 
yet definite, most studies have identified the t10,c12 isomer, rather than the c9,t11 isomer, as being 
responsible for the attenuation of body weight and body fat gain. Most studies in animals have 
evaluated the effects on body weight and body composition, but some of the studies may also give 
hints on the effect of CLA-supplementation and its effects on risk for T2D and CVD, although one 
has to be very cautious to extrapolate results from animal studies into potential use in humans. 
Unfortunately most evidence supports the notion that feeding CLA may adversely affect liver 
metabolism and have negative effects on glucose homeostasis in mice. Also it is likely that the major 
part of these adverse effects can be ascribed to the t10,c12 isomer. Moreover, the t10,c12 isomer 
seems to be responsible for the so-called “milk fat depression syndrome” (i.e. a reduced fat content 
in the milk) observed in cows (Larsen et al., 2003a). 
 
Recent data support the findings from the studies in cell systems. In mice fed a mixture of 1% CLA 
for 28 days, the expression of PPARγ, aP2 and adiponectin in adipose tissue decreased as early as 2 
days after dosing initiation. Subsequently, the amount of adipose tissue mass was attenuated, and the 
fasting serum insulin levels increased dramatically, which was explained by pancreatic beta cell 
hyperplasia. In the liver, the expression of PPARγ and aP2 increased dramatically, likely explaining 
the observed increase in hepatic lipid content (Poirier et al., 2005a;Poirier et al., 2005b). Subsequent 
studies have observed that these effects are reversible, when the CLA is removed from the diet 
(Martin J-C et al., 2004). Similar findings were reported by another research group. In this case, mice 
had decreased fat mass and developed hepatomegaly when fed CLA. Furthermore, addition of 
increasing amounts of fish oils to the diet, substantially reversed these effects of CLA, increasing 
body fat and lowering hepatic TG content (Ide, 2005). Apolipoprotein E knockout mice are sensitive 
to the development of artherosclerosis due to a deficiency of LDL-cholesterol clearance in the liver. 
Also in these mice, t10,c12 has been shown to increase insulin resistance and to increase lesion area 
in the heart, suggesting a progression of inflammation and atherosclerosis (de Roos et al., 2005a;de 
Roos et al., 2005b). 
Moreover, in contrast to CLA, apart from being negative regulators of hepatic lipogenesis and 
activators of hepatic PPARα, long-chain n-3 polyunsaturated fatty acids may also attenuate 
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hyperinsulinaemia and hyperglycemia (Sekiya et al., 2003). Somewhat in contrast, and therefore 
slightly surprising, another study in mice supplied with (only) 0.2 % t10,c12 CLA for 4 weeks did 
not find any down-regulation of the expression of either PPARγ or aP2 in adipose tissue, although 
body fat gain was reduced (Kang et al., 2004). 
 
There are indeed suggestions that CLA may have biological similarities to other dietary trans fats. 
From a structural viewpoint, the CLA isomers should be considered trans fats. Overall there is 
substantial evidence that CLA or other trans fats are likely to compete with the metabolism of 
essential fatty acids in a variety of different biochemical pathways, which could give deficiencies 
related to the lack of important cellular lipid components that should be produced from dietary intake 
of essential fatty acids (Kinsella et al., 1981;Hill et al., 1982). Appendix E shows the current 
evidence of – at least part of - the metabolic fate of the 2 isomers c9,t11 and t10,c12 CLA (Martin 
and Valeille, 2002). 
Such effects on lipid metabolism does not necessarily decrease fat gain. But, if CLA does attenuate 
fat gain in animals, so could other trans fatty acids also do, and vice versa. 
Thus, studies of trans fats in animal models and their impact on body weight change etc. might give 
some hints about the general effects of CLA also. Unfortunately, there are only few such studies 
available. As early as in 1979, Hwang and Kinsella studied the effects of trans fat on growth rate in 
rats and found that trans C18:2 (n-9,12) severely attenuated growth rate compared to either c9,c12-
C18:2, to a 50% mixture of each of the cis,cis and trans,trans isomers or to hydrogenated coconut oil 
(Hwang and Kinsella, 1979). More recently, Colandré and colleagues studied the effect of 30 days 
feeding with trans C18:1 (n-9) fats in rats, and did not find any effects on body weight gain 
compared to c9,c12-C18:2 or 18:0 fats, although the trans fats seemed to increase hepatic TG content 
(Colandre et al., 2003). Partially hydrogenated fish oils have also been shown to increase LDL-
cholesterol and LDL/HDL ratio in rats (Morgado et al., 1999). 
Also, trans fat has been shown to decrease insulin sensitivity to a greater extent than saturated fats, 
possibly via a downregulation of PPARγ and LPL in epididymal fat tissue (Saravanan et al., 2005). 
Studies of isolated mouse islets have also shown that the trans isomers, trans vaccenic acid and 
elaidic acid elicit a higher maximal insulin output that the respective cis isomers (Alstrup et al., 
1999). 
 
1.5.4 Effects of CLA in human studies  
 
How to assess effects on body weight and body composition 
As discussed in paper 2 (Larsen TM et al., 2005) and paper 4 (Larsen et al., 2003a), quite a few 
studies on CLA have now been carried out in humans. Although the studies identified in paper 4 may 
have looked for a variety of different outcomes, we will focus on the effects reported for changes in 
body weight and body composition and on changes in risk factors of T2D and CVD. 
  
To study such effects it is necessary to use reliable measurement methods. Regarding the effects on 
body composition, the effect variables most often studied are changes in body weight, waist and hip 
circumference, whereas body composition is less often studied, possibly because measures such as 
fat percentage, fat mass or fat free mass can only be assessed in a precisely fashion if appropriate 
equipment (e.g. DXA-scanning) is available. Similarly, the assessment of changes in abdominal 
and/or visceral fat depots requires access to CT or MRI-scanning methods. Overall, as discussed in 
the review paper (Larsen et al., 2003a) we did not find any convincing data supporting that CLA has 
effects on body weight, and there was no unequivocal evidence of an effect on body fat percentage, 
although not all studies had used optimal methods to measure such changes in body composition. 
Also, we concluded that most studies actually suggest that CLA may actually induce adverse effects, 
including insulin resistance in pre-diabetic patients. 
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How to predict risk of T2D and CVD 
As described in the section about the definitions of the metabolic syndrome, there are quite a few 
different variables that are often used to assess changes in risk of T2D or CVD. In relation to T2D, 
fasting blood levels of glucose and HbA1c are often used. Also indices of insulin sensitivity or 
glucose tolerance can be evaluated using fasting serum specific insulin, HOMA-IR, clamp-
techniques and oral glucose tolerance test. There are quite a lot of different blood component that by 
them selves or in combination are associated with future risk of cardiovascular disease. For clinical 
practice, the most used are blood levels of total cholesterol, LDL, HDL and TG, whereas assessment 
of artery intima-media thickness (IMT) is more labour-intensive and therefore less used. 
Newer markers of increased risk of CVD include measures such as blood content of hsCRP, 
adiponectin, fibrinogen, coagulation factor VII or PAI-1. In addition, a list of emerging markers 
includes, but are not limited to; von Willebrand factor, MCP-1, MMP-9, sCD40CL, ICAM, VCAM, 
VEGF, endothelin, E-selectin, BNP, ApoB, Lp(a), TNFα and IL-6. 
Most of these measures have by themselves or in combination been associated with future risk of 
development of cardiovascular disease. But there may be a substantial degree of complexity in the 
use of these novel markers. Thus, although changes in behaviour or medical treatment known to 
decrease future risk of cardiovascular events (e.g. increased physical activity, weight loss or statin 
treatment), would be expected to be associated with beneficial changes in these risk factors, this is 
not always the case. Often, some risk markers may be improved, whereas others are unaffected or 
may even be adversely affected. Such apparent discrepancies may be caused by measurement error 
or measurement variability, but such effects may also be real. 
 
1.5.4.1 Does CLA resemble trans fats? – evidence from effects on risk of T2D and CVD. 
As it has been shown many years ago (Mensink and Katan, 1992) and recently reviewed by Ronald 
P. Mensink (Mensink, 2005), different fatty acids (e.g. n-3 fats versus saturated fats) do have 
different effects on serum lipoproteins, and also isomeric fatty acids, either different in the direction 
of the double bond (e.g. c11-C18:1 vaccenic acid versus t11-C18:1 vaccenic acid) or in the position 
(e.g. c9-C18:1, oleic acid versus c7-C18:1 un-named) do exhibit different effects.  
Concurrently there is quite clear evidence that trans monounsaturated fatty acids (e.g. t9-C18:1, 
elaidic acid) have adverse effects on the serum lipoprotein profile, as it increases serum LDL 
cholesterol and lowers serum HDL cholesterol levels when compared to e.g. oleic acid (c9-
C18:1)(Mensink et al., 2003). Trans fatty acids are also found to increase serum levels of 
apolipoprotein(a)(Mensink et al., 1992;Nestel et al., 1992;Mensink et al., 2003;Gatto et al., 2003) 
These changes in serum lipoproteins induced by TFA would be expected to increase the risk of 
coronary heart disease. A meta-analysis of randomised studies estimated that the effect on a 2 E% 
increase in TFA would influence lipoproteins to an extent, corresponding to an increased risk of 5% 
for developing coronary heart disease (Ascherio et al., 1999). In comparison, the average intake of 
TFA in Europe in the years 1995-1996 was 0.87 and 0.95 E% in men and women respectively, an 
amount similar to the intake in Denmark (van Poppel, 1998;van de Vijver et al., 2000). Also, several 
of the largest epidemiological prospective studies, i.e. Nurses Healthy Study, Health Professionals 
Follow-up study, The Alpha-Tocopherol Beta-Carotene Cancer Prevention Study and the Zupthen 
Elderly Study have demonstrated that trans fat intake is associated with increased risk of coronary 
heart disease: The increased risk of coronary heart disease for an increase of 2% of energy in TFA 
was estimated to be approx 25% in a pooled analysis of these 4 studies (Oomen et al., 2001). 
The discrepancy for these estimates (5% based on lipoprotein profiles vs. 25% based on 
epidemiological studies) is yet unclear, but may be ascribed to the use of different study designs or it 
may be caused by adverse effects of the TFA on CVD risk that are mediated by other factors that act 
independently of changes in lipoproteins. In this context, studies have also shown that TFA impairs 
endothelial function (de Roos et al., 2001), increases the level of pro-inflammatory risk markers such 
as hsCRP and E-selectin(Baer et al., 2004). Further, there are suggestive evidence of an increased 
heart rate after a high TFA intake (Dyerberg et al., 2004).   
The molecular mechanisms by which TFA may infer increased risk of CHD is more or less 
unknown. There are suggestions that TFA via its incorporation into cardiac cell membranes may 
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modulate membrane ion channel function and thereby have arrhythmogenic effects (Katz, 2002); 
however the relative importance of TFA´s possible adverse effects on artherosclerosis progression, 
function of the arterial wall and cardiac rhythm is largely unknown. Hence, TFA may give increased 
risk of peripheral atherosclerosis, heart disease and possibly stroke, but the molecular pathogenic 
mechanism may be different for each of these diseases. 
Similarly, TFA may increase the risk of T2D via several mechanisms which could include, but are 
not limited to, increased insulin resistance in either muscle, liver or via effects on adipose tissue. 
In humans, studies of relative short duration have been performed. A 4 week cross-over study of 14 
healthy women found an increase in serum levels of total cholesterol/HDL, triglycerides and apoB, 
but no effect on insulin sensitivity during intake of 5.1 E% TFA (Louheranta et al., 1999), whereas a 
6 week cross-over study in 16 obese type-2 diabetic patients found no effects on fasting lipids, 
glucose and insulin, but TFA increased postprandial insulinemia, similar to a diet high in saturated 
fats (Christiansen et al., 1997).  
 
Thus, it is of major interest to study whether conjugated linoleic acid that are currently available in 
the diet (primarily c9,t11 linoleic acid) or as dietary supplements (usually c9,t11 and t10,c12) have 
effects on lipoproteins, plasma markers of low-grade chronic inflammation or on IMT.  
A meta-analysis of more than 11.000 subjects involved in 37 intervention studies (Yu-Poth et al., 
1999) has reported that certain beneficial changes in plasma lipids (i.e. LDL- and HDL-cholesterol 
and TG) can be expected for every 1-kg decrease in body weight. Therefore, if CLA introduces 
weight or fat loss, it is of interest to show if these effects are followed by improvements in the 
lipoprotein profile, or if CLA has some other – yet unidentified – adverse effect on lipoprotein 
profile, that offsets the expected changes seen with weight loss.  
 
1.5.4.2 Human studies of CLA – effects on body weight and risk of T2D and CVD. 
As discussed in paper 4 (Larsen et al., 2003a), the CLA-isomers commercially available in dietary 
supplements are usually a 50:50 ratio of c9,t11 and t10,c12. However, as also described, the actual 
amount and composition of the CLA supplements used in the various studies may differ significantly 
and therefore the results are not always directly comparable. In general, although there are quite a 
few studies of CLA, also in humans, most are of quite short duration (<6 months) and many of the 
studies are of a poor quality (lack of placebo-group, unreliable measurement methods etc.).  
Most animal studies have examined the effect of CLA during growth. This is a state where the 
adipocytes are actively differentiating and therefore the anti-adipogenic effect of CLA may in such 
circumstances be more pronounced compared to situations of weight stabilisation. Indeed, a study in 
rats have suggested that the anti-adipogenic effect of CLA may not be very effective in adult rats. 
Also, in humans, most studies of CLA have been performed in weight stabile lean subjects. 
In the CLA005 (Paper 2) (Larsen TM et al., 2005), we tested the hypothesis that in obese subjects, 
after an initial large weight loss, CLA would help to maintain this initial loss of body weight and 
body fat to a larger extent than placebo. 
 
In the CLA005 study (Paper 2) (Larsen TM et al., 2005) we assessed the effect of a mixture of c9,t11 
and t10,c12 CLA isomers on 1-year body weight regain in obese subjects. Data on body weight and 
body composition were available for a total of 83 participants (40 in CLA group and 43 in placebo 
group) who completed 25 and 52 weeks of treatment (Intention-To-Treat data which were defined as 
those who completed 25 weeks of treatment were carried forward to week 52 for 6 subjects). We 
assessed changes in total body weight, body composition (using DXA-scanning), and we obtained 
measures of waist and hip circumference, analyses of fasting circulating levels of glucose, insulin, 
growth hormone, IGF-1, total testosterone, TSH and various safety analyses including leucocyte 
count, as well as energy-intake via 3 day self-recorded diet registrations at baseline and after 25 and 
52 weeks treatment, respectively. 
Overall, we found no evidence that CLA effected changes in body composition, blood glucose or 
insulin, but we did not assess changes in lipoproteins. Taken together, this finding is in agreement 
with most of the previous studies with a duration of ≤ 6 month, including a recent 6 month study of 
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approx. 50 subjects (Tricon et al., 2004). However, our findings stand in contrast to the only other 
studies with a duration of >6 month (Gaullier et al., 2004;Gaullier et al., 2005). As pointed out in 
paper 2, the reason for these differences may be due to the different study design, e.g. in our study 
supplementation was given during a period of weight regain.  
 
Regarding the effects on cardiovascular risk factors, Tricon et al. have recently reviewed the effect of 
CLA on plasma lipoproteins, and although there is a substantial degree of variation in the results 
obtained in different studies, the overall findings suggest, that if CLA has any effect – it seems to 
decrease the serum HDL-cholesterol level and to increase the ratio of LDL/HDL cholesterol (Tricon 
et al., 2005). A recent cross-over study assessed the effect of butter containing naturally occurring 
CLA (i.e. c9,t11-isomer) in 16 overweight or obese men and found a slight increase in total 
cholesterol/HDL-cholesterol compared to butter without CLA (Desroches et al., 2005). Therefore, it 
may be premature to provide a solid answer. With respect to other risk factors of T2D and CVD, 
such as hsCRP, adiponectin or Lp(a), so far only few studies of limited duration are available. 
 
In our study we found no clear evidence of changes in insulin sensitivity as measured by the HOMA-
IR index, nor did we identify effects on the various blood hormones assessed. However, we found 
that CLA increased blood leucocyte count. This has also been found in several previous studies 
(Gaullier et al., 2004;Gaullier et al., 2005), indicating that this is a robust finding.  
This finding may be of some concern, since there is accumulating evidence that low- to moderate 
grade inflammation is associated with, and possibly also involved in the pathogenesis of 
atherosclerosis (Hansson, 2005). Hence, this finding may indicate that CLA could increase the risk of 
atherosclerosis via increased inflammation, an effect that may be independent of any effects on 
changes in body composition, insulin sensitivity or lipid profile. 
Though, as discussed in paper 2, the clinical relevance of this finding is unclear, it adds further 
evidence that these fatty acids possess unique characteristics that should be investigated further.  
 
There are several shortcomings in the study presented in paper 2 (Larsen TM et al., 2005). We did 
only assess compliance to the treatment via counting of non-consumed capsules returned to the study 
personnel. Clearly, a more objective measure of drug compliance could have been assessed via 
analyses of e.g. fatty acid analyses of blood platelets. Also, we did not evaluate treatment effects 
related to risk of cardiovascular disease. Changes in blood lipids could have been analyzed to assess 
the changes in risk of CVD, plasma adiponectin could have been analyzed to assess changes in 
insulin sensitivity, and the inflammatory risk marker hsCRP could also have been a useful indicator 
of cardiovascular health. However, the primary aim of the study was to assess the effect on changes 
in body composition and several safety factors. This aim was satisfactorily answered. 
 
1.5.5 In summary: Is CLA a trans fat or a healthy fat? 
The totality of evidence suggests that CLA, or more specifically the t10,c12-isomer, has various 
effects on lipid metabolism, including effects on adipocytes and hepatocytes. However, even though 
its possible effects on body fat accumulation seems a tempting modality to treat obesity, there is now 
a substantial amount of data indicating that it is followed by metabolic effects on adipocytes and 
hepatocytes, which seem to lead to a modest increase in the development of insulin resistance, T2D 
and possibly CVD. Although data is still sparse, it seems that at least some of the effects of CLA (or 
perhaps specifically the t10,c12 isomer) are similar to the biological effects obtained from studies of 
trans fatty acids, including effects on transcriptional regulation in adipocytes, effects on blood 
cholesterol levels and animal growth. Thus, although CLA currently may be one of the best studied 
dietary supplements, both in terms of efficacy and safety, it is unfortunately far from certain that 
CLA has a potential benefit to human health. If CLA is compared to the current medications Xenical 
(orlistat) and Meridia (sibutramine), (or Rimonabant coming up), that are approved and used for 
weight loss, there may be some studies suggesting that CLA on a long-term basis has some effects on 
fat loss, however it does still not seem as effective as Xenical and Meridia to decrease body fat loss. 
Also, our own study (Larsen TM et al., 2005) does not support that CLA is effective, at least not 
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during weight gain in obese persons. Also, in terms of changes in risk factors of development of MS, 
T2D or CVD such as levels of glucose, insulin, blood pressure, cholesterol, hsCRP or others, it is of 
concern that CLA has not shown any significant improvements in these traditional risk factors.  
Therefore, based on the current evidence, the (if any) potential use of CLA seems to be restricted to a 
cosmetic purpose only (i.e. to obtain a slight decrease in body fat) - and not for health benefits. For 
many health professionals, the missing link between the loss of fat mass (which is observed in some 
studies) and changes in these disease risk factors is actually a major concern, and it also gives some 
scepticism about the overall health effects of CLA which therefore needs further research. 
Also, the get a regulatory approval as a weight control drug, the US Federal Drug Administration 
specifically states that “Measurement of obesity-associated cardiovascular risk factors (lipids, blood 
pressure and glucose tolerance) during drug administration is encouraged, as they may have a place 
in determining the balance of benefit vs. risk for the drug. If one or more of these factors deteriorates 
or is not improved, the risk associated with this deviation must be considered in making a benefit-to-
risk decision for the drug” (FDA, 1996)”. 
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2. Perspectives and future research 
PPARγ: 
Surely, for single gene disorders, molecular genetics have helped to determine cause, prognosis, and 
appropriate treatment, but for more common polygenic diseases such as T2D, the role of molecular 
genetics will more likely – at least in the short term - be to enhance understanding of disease 
pathogenesis and help formulate preventative and treatment strategies. While genetics undoubtedly 
play a role in the development of many metabolic and vascular conditions, the prevalence of obesity 
and T2D has increased too rapidly over the last two decades to be the result of alterations in the gene 
pool. The obesity epidemic is more likely to be explained by an interaction between genotype and 
acquired factors. Currently most evidence supports the notion that the sedentary lifestyle and high-
calorie diet common to Western societies is the major contributor to the obesity pandemic – a key 
risk factor for MS, T2D and CVD in genetically susceptible individuals.  
The current evidence suggests that the common variations within PPARγ have only a marginal effect 
on the risk of obesity and T2D. Therefore, as with many of the other so-called “common variant – 
modest effect” genetic variants, the study of PPARγ variants needs to be further examined using 
larger well-characterized and statistically powered study samples, preferably also assessing gene-
gene and gene-environment interaction effects. It would also be useful to do comparative analyses of 
genetic versus environmental (unhealthy diet, physical activity, socio-economic status) obesity-
contributing effects within the same study sample, in order to do direct comparisons of the 
importance of each of these variables. Furthermore, novel phenotypes could be investigated, such as 
the ratio between waist circumference/BMI as suggested by Bigaard et al. (Bigaard et al., 2003), 
different physiological “challenges” (e.g. meal test) or the impact on early-onset disease. Mouse 
models with increased expression of the PPARγ protein have not yet been reported, but such a model 
could maybe help to clarify if more subtle variations in PPARγ protein levels (i.e. mimicking the 
effects of PPARγ2 promotor variation) would have clinically relevant effects, which therefore could 
help to sort out the reasons for the discrepancies reported in the many human association studies. 
Only if such data is available and if most findings are corroborative, genetic testing could be used in 
the clinic for diagnostic and treatment purposes. However, currently the available data for the 
importance of single-gene effect on the molecular genetic pathogenesis of common obesity is not 
convincing. 
 
It may be argued that genetic influence may have minimal effects on the development of obesity, and 
that environmental changes may be the overall responsible for the obesity epidemic in urbanized 
civilizations. If that is the case, then it is argued that subtle effects from single gene variations would 
be unlikely or merely impossible to identify. However, with many novel genetic methods currently in 
development, including the availability of genome-wide SNP assays with the potential to look at the 
effect of thousands of different gene variants at a time, it may be that future efforts will be much 
more effective in identifying important genetic contributors of common obesity. These efforts will 
however, still rely on the premise that the contribution from genetic variation is quite large, and that 
it has an impact that is as a minimum as large, and preferably larger than the inherent inter-individual 
“noise” or variability from other non-measured genetic and non-genetic factors that may remain in 
the study sample. 
 
CLA: 
Is seems plausible that different types of fatty acids have different biological effects. We have solid 
evidence about the effects of the most common fatty acids, including fatty acids derived from dairy, 
meat, vegetable and fish oils, and we also have some knowledge about the effect of eating products 
high in - in most cases unspecified types of – trans fats. But the precise biological activity from each 
particular trans fatty acid is far less investigated. 
Hence, from various mechanism studies and intervention studies there is robust evidence that TFA 
induces adverse effects on cardiovascular risk factors (i.e. LDL and HDL), and from epidemiological 
studies we have evidence that TFA increases the risk of cardiovascular events and for the 
development of T2D. However, epidemiological studies cannot establish a cause-and-effect 
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relationship without support from other types of studies. Furthermore, the assessment of diet 
consumption is quite inaccurate, and may be very much affected by non-assessed factors which could 
introduce bias. Clearly there is a need to study further the effects of single isomers of fatty acids, and 
preferably to perform such studies as comparative dose-rising studies in order to evaluate if some 
effects are only apparent with low- or high concentrations. As listed in appendix C (which is 
certainly not exhaustive), there is a huge variation in the structural composition in the fatty acids that 
we consume in our diet, and each of which may have different metabolic effects. 
 
Regarding CLA, there are also some obvious highly controversial findings in the existing literature:  
For instance Vessby and colleagues have provided evidence that when given alone, the CLA isomer 
c9,t11 and the t10,c12 isomer increase insulin resistance, whereas there was no effect of a mixture of 
these isomers. This may apparently seem quite peculiar and if it proves to be true, it will be very 
interesting to look further into the mechanisms behind this observation. Such interactions will 
certainly also suggest that studies of single isomers cannot be used reliably to illustrate the effects on 
real life situations, where different fats are consumed together and in various amounts. 
 
Many fatty acids have a natural origin, but also many foods (and dietary supplements such as CLA) 
nowadays may contain a wide range of different fatty acids that cannot be found at all, or at least 
only in small amounts in natural foods. It can be argued that our body metabolism may not be 
genetically adapted to (or at least not optimally adapted) such “odd” fatty acids in excessive 
amounts, and that these fatty acids therefore may have deleterious effects in the body.  
It is plausible that such “odd” fatty acids not only have adverse effects in single tissues, but may have 
biological effects in all biological pathways, in a wide variety of tissues and organs where it 
competes with other more natural fatty acids. Despite the evidence that CLA may have 
characteristics of other trans fats, some of which have been associated with adverse biological 
effects, one should of course not fully ignore the possibility that CLA may have substantial anti-
obesity properties and/or that it has (other) beneficial effects that may override the subtle adverse 
effects that have been identified. Many (non-natural) drugs, including e.g. statins do have different 
degrees of adverse effects, but their beneficial effects clearly overrides their adverse effects – and so 
could CLA. 
 
In conclusion, the current evidence on the effects of CLA on obesity and associated risk factors are 
highly controversial. Therefore, before any recommendations should be put forward stating that 
CLA-supplementation can be taken without any safety concerns, further studies are needed, 
preferably including a large sample size and including accurate measures of changes in body 
composition and various risk markers associated with the development of MS, T2D and CVD. 
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3. List of abbreviations 
ADA   American Diabetes Association 
ADIGEN   ADIposity and GENetics 
AFABP   Adipocyte lipid-Binding Protein 
Apo(b)   Apoliprotein B 
BMI   Body Mass Index 
BNP   Brain Natriuretic Peptide 
CARLA   Co-Activator-dependent Receptor Ligand Assay 
CD/CV   Common Disease/Common Variant  
CLA   Conjugated Linoleic Acid 
CRP   C-Reactive Peptide 
CT   Computed Tomography 
CVD   Cardiovascular Disease 
DGAT-1   Diacylglycerol O-acyltransferase 1 protein 
DHA   DocosaHexenoic Acid 
dHPLC   Denaturing High-Performance Liquid Chromatography 
DXA   Dual X-ray Absorptiometry 
EGIR   European Group for the study of Insulin Resistance 
EPA   EicosaPentanenoic Acid 
FDA   Food and Drug Administration 
FFA   Free Fatty Acids 
HbA1c   Hemoglobin A1c 
HDL   High Density Lipoprotein cholesterol 
HIV   Human Immunodeficiency Virus 
HMGI-C   High Mobility Group protein 
HOMA   Homeostasis model 
HOMA-IR   Homeostasis Insulin Resistance model 
hsCRP   hypersensitive C-Reactive Peptide 
HSL   Hormone Sensitive Lipase 
ICAM   InterCellular Adhesion Molecule 
IL   InterLeukine 
IMCL   Intra-MyoCellular Lipid 
IMT   Intima-Media Thickness 
KO   Knock Out 
Lipin-1   Fatty liver dystrophy protein 
LDL   Low Density Lipoprotein cholesterol 
LP(a)   LipoProtein a 
LPL   LipoProtein Lipase 
MCP-1   Monocyte chemotactic protein 1 
MC4R   MelanoCortin-4 Receptor 
MMP   Matrix MetalloProteinase 
MR   Magnetic Resonance 
MS   Metabolic Syndrome 
NAFLD   Non-Alcoholic Fatty Liver Disease 
NASH   Non-Alcoholic SteatoHepatitis 
NCEP/ATPIII  National Cholesterol Education Program/Adult Treatment 
   Panel III 
NHANES   National Health and Nutrition Examination Survey 
NHR   Nuclear Hormone Receptor 
PAI-1   Plasminogen activator inhibitor type-1 
PEPCK   PhosphoEnolPyruvate CarboxyKinase protein 
POMC   Pro-OpioMelanoCortin 
PPARγ   Peroxisome Proliferator-Activated Receptor gamma 
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Pref-1   Preadipocyte factor-1 
P:S ratio   Ratio of dietary intake of polyunsaturated fat to saturated fat 
QTL   Quantitative Trait Loci 
RXR   Retinoic acid Receptors 
sCD40L   soluble CD40 Ligand    
SFA   Saturated Fatty Acids 
SGBS   Simpson-Golabi-Behmel Syndrome 
SNP   Single Nucleotide Polymorphism 
TFA   Trans Fatty Acids 
TG   Triglycerides 
TNFα   Tumor Necrosis Factor alfa 
TTA   Tetradecyl Thioacetic acid 
TZD   Thiazolidinedione 
T2D   Type-2 Diabetes 
VCAM   Vascular Cell Adhesion Molecule 
VEGF   Vascular Endothelial Growth Factor 
VLDL   Very Low Density Lipoprotein 
WAT   White Adipose Tissue 
WHO   World Health Organisation 
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ABSTRACT 1 
Background 2 
Conjugated linoleic acid (CLA) is marketed as a safe, simple and effective dietary supplement to 3 
promote body fat and body weight loss. However, most of the previous studies have been of short 4 
duration and inconclusive, and some recent studies have questioned the safety of long term 5 
supplementation with CLA. 6 
 7 
Objective 8 
To assess the effect of one year supplementation with CLA (3.4g/day) on body weight and body 9 
fat regain in moderately obese people. 10 
 11 
Design 12 
122 obese (BMI>28 kg/m2) healthy subjects underwent an 8-week dietary run-in with energy 13 
restriction (3300-4200 kJ/day). 101 subjects who lost >8% of initial body weight, were 14 
subsequently randomised to a 1 year double blinded CLA (3.4g/day, n=51) or placebo (olive oil, 15 
n=50) supplementation regime in combination with a modest hypocaloric diet of -1250 kJ/day. 16 
Treatment effects on body composition using Dual-energy X-ray Absorptiometry (DXA) and 17 
safety (blood samples, adverse events) were assessed. 18 
 19 
Results 20 
After 1 year no significant difference was observed between treatments. The CLA group (n=40) 21 
regained 3.1 ± 5.3 kg body weight and 2.1 ± 5.0 kg fat mass compared with 3.2 ± 5.2 kg and 2.7 ± 22 
4.9 kg, for body weight and fat mass respectively, in the placebo group (n=43). There were no 23 
differences in reported adverse effects or indices of insulin resistance, but a possible incremental 24 
effect on leucocytes was observed. 25 
3 
 
 26 
Conclusion 27 
One year 3.4 g daily CLA supplementation does not prevent weight or fat mass regain in a 28 
healthy obese population. 29 
 30 
Key words: Conjugated linoleic acid, dietary supplement, obesity, body fat, safety 31 
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Introduction 32 
The long-term effects of conventional weight-management programmes are unsatisfactory, and 33 
alternative therapies, including dietary supplements, are repeatedly called for by the obese and the 34 
society. Although the use of dietary supplements is widespread, their documentation on efficacy 35 
and safety is not convincing (1). Conjugated linoleic acid (CLA) is a mixture of linoleic acid 36 
isomers with conjugated double bonds which has been studied intensively(2). CLA is sold 37 
commercially as dietary supplements for weight and/or fat loss. The products often have a 40/40 38 
% content of cis9, trans11 (c9,t11), trans10,cis12 (t10,c12) fatty acids and the remaining 20% are 39 
usually other fatty acids; approx. 1-4 % other types of conjugated fatty acids and 15-19 % other 40 
non-conjugated fatty acids (3). The CLA isomer c9,t11 is a natural constituent in the human diet 41 
and the average daily intake of the c9,t11 isomer in western societies is between 150-200 42 
mg/day(4), whereas the intake of the t10,c12 isomer is negligible. 43 
In humans, a dose-response study with CLA (a mixture of c9,t11 and t10,c12) over 3 months 44 
reported a decrease in body fat, assessed by DXA-scanning, without additional effect at doses 45 
greater than 3.4 g/day (5). The only published long-term (>6 months) placebo controlled human 46 
study provided subjects with CLA (a mixture of c9,t11 and t10,c12 as either free fatty acids or 47 
triacylglycerol) for 12 months and induced significant losses of 2.0 kg body weight (CLA 48 
triacylglycerol group only) and 2.2 kg body fat mass (both CLA supplementation regimens) 49 
compared to placebo (6).  An open label 1-year extension of that study showed that the placebo 50 
group lost body fat mass when given CLA, but also that 2-year treatment did not add further loss 51 
of fat mass compared to 1 year treatment (7). 52 
To our knowledge, only two studies have investigated the effect of CLA during weight gain in 53 
humans, and both found no effect on body weight or body fat regain after 3 or ~6 months 54 
treatment with CLA (a mixture of c9,t11 and t10,c12) after an initial loss of body weight(8;9). 55 
However, the 3 months study found that CLA did increase the amount of lean body mass when 56 
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compared to placebo(8).  57 
In the present study, we investigated whether one year supplementation with CLA (3.4g/day of a 58 
mixture of c9,t11 and c10, t12 as triacylglycerols) could decrease body weight and body fat mass 59 
regain in moderately obese people after a Low Calorie Diet (LCD) induced weight loss. In 60 
addition we assessed treatment safety (monitoring adverse events, vital signs, ECG, and blood 61 
parameters including indices of insulin resistance) and the influence of CLA on hormones that 62 
may influence growth and/or body fat metabolism such as insulin-like growth factor-1 (IGF-1), 63 
growth hormone (GH), thyroid-stimulating hormone (TSH) and testosterone. 64 
 65 
Subjects and methods 66 
The study was initiated in January 2002, the first subject was included in February 2002, and the 67 
clinical part of the study was terminated in June 2003. Subjects were healthy participants of both 68 
genders between 18 and 65 years of age with BMI between 28 and 35 kg/m2. The subjects were 69 
recruited by 2 research centers (Department of Human Nutrition, RVA University, Copenhagen, 70 
Denmark & Department of Clinical Nutrition Hvidovre Hospital, Copenhagen, Denmark). All 71 
subjects gave written informed consent before inclusion in the study. Subjects were not included if 72 
they did not have a stable weight (± 3 kg in the last two months), were receiving drug therapy, 73 
consuming a special diet, or taking dietary supplements for weight loss. In addition, pregnant or 74 
lactating women were excluded. Subjects with renal, liver, pancreatic, or chronic inflammatory or 75 
infectious diseases, cardiac disease or malignant tumors were excluded. Diet treated diabetics as 76 
well as subjects with treated simple hypertension were allowed inclusion. Subjects who had active 77 
thyroid disease or who were receiving thyroid hormone treatment, and subjects taking adrenergic 78 
agonists, or with known or suspected drug or alcohol problems or with any clinical condition 79 
rendering them unfit to participate were excluded.  80 
The study was a randomised double-blinded, placebo controlled, parallel-group study with two 81 
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treatment arms. Initially, all subjects followed a LCD (Nutrilett®, Collett Pharma, Lysaker, 82 
Norway), with an energy content of 3300-4200 kJ/day for 8 weeks. All subjects attended 6 group 83 
meetings where experienced dieticians guided them through the weight loss regimen. Subjects that 84 
lost 8% or more of their initial weight during the LCD were randomised to CLA or placebo. The 85 
two treatment groups received either 6x750mg capsules of CLA (TONALIN®, Natural ASA, 86 
Hovdebygda, Norway) or 6 capsules of placebo (4.5 g olive oil) per day. The dose was selected 87 
based on previous studies(5;10). The CLA content of the capsules was approximately 80% of total 88 
lipid (~3.4g CLA/day); 39% c9,t11 CLA & 41% t10,c12 CLA as triacylglycerols and 20% others, 89 
as analysed by the manufacturer. The soft gel capsules were opaque and identical in taste and in 90 
appearance, and the energy content in both types of capsules was matched. The randomization 91 
sequence was generated by Scandinavian Clinical Research (Contract Research Organization) 92 
using a simple block randomization procedure without any stratifications. The allocation sequence 93 
was provided to each centers study personnel via an internet based interface. Both centers 94 
followed the study’s randomization procedure and did not break the code at any time during the 95 
study. The randomization list was kept confidential and was opened only after closure of the 96 
database. Assuming a difference of 1.7 kg of fat mass between treatment groups based on prior 97 
studies of 3.4 g CLA/day vs. placebo(5) and an estimated SD of 2.2 kg (based on prior experience 98 
of within-group detectable differences using DXA-methodology) an estimated number of 37 99 
subjects pr. group were required (using 90% statistical test power and 5 % significance level). To 100 
account for a high dropout rate, the required number of subjects needed for initial inclusion was 101 
estimated to be N=60 per group. After the 8-week LCD-period (Week 0), the 101 subjects who 102 
achieved the weight loss goal were randomised. For a total of 52 weeks, subjects were provided 103 
with CLA or placebo in combination with a modest hypocaloric diet of approx. -1250 kJ/day (1 104 
kcal = 4.18 kJ). The dietary instruction was given via 14 individual consultations (~1 per month) 105 
from dieticians throughout the treatment period and was based on the isocaloric interchangeable 106 
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and educational diet program "Eat for life"(11). The energy requirement during the 52 week 107 
hypocaloric period was estimated using appropriate equations, according to body weight, gender 108 
and age(12).  109 
Characteristics (including smoking and drinking habits) and demographic data were recorded 110 
when subjects entered the study. Body weight, adverse events and concomitant medication were 111 
recorded at each visit with the dietician, i.e. a total of 14 times during the 52 weeks treatment. 112 
Physical measurements, blood samples, urine samples, measurements of blood pressure, waist, 113 
hip, pulse, and ECG were taken and DXA scanning was performed 4 times in total, i.e. before the 114 
LCD-period (Week -8), after the LCD-period (Week 0) and after ~26 and 52 weeks of treatment. 115 
The dietary supplements were provided to (and returned from) the study participants at every 116 
bimonthly visit. Fasting blood samples (>10 hours fasting) were obtained at between 07.00-13.00 117 
hours, and the time point of sampling was repeated if possible. The samples were all (except 118 
insulin) analysed in an accredited laboratory (Capio Diagnostik, Copenhagen, Denmark). Insulin 119 
was analysed using a commercially available kit (DPC, IMMULITE 1000 Insulin). 120 
Blood was analysed for the following: Haemoglobin, erythrocytes, leukocytes (white blood cells), 121 
platelets, alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase, 122 
creatinine, IGF-1, GH, TSH, glucose, insulin and total testosterone. An index of insulin resistance 123 
(HOMA-R), was derived from fasting values of glucose and insulin according to the formula: 124 
Glucose*Insulin/22.5. Urine was obtained for analysis of blood, glucose and protein content and 125 
for pregnancy testing. All blood samples were taken, and DXA-scanning and clinical assessments 126 
(except body weight) were performed at the same center, i.e. the Royal Veterinary and 127 
Agricultural University, Copenhagen. Blood samples were obtained at all time points for a total of 128 
75 participants. Compliance was measured every 2 months by comparison of the number of 129 
unused capsules with the number of capsules that should have been used. A subject was 130 
considered compliant when he or she took ≥ 75% of the capsules provided. 131 
8 
 
DXA-scanning (Lunar Radiation Corp, Madison, WI) was used to determine body composition 132 
with LUNAR PRODIGY software (version 5; Lunar Radiation). All DXA-scans were performed 133 
by the same experienced technical assistant in the morning within +/- 1 hour for each subject. The 134 
results of the DXA-scan were divided into body fat mass (FM) and body fat free mass (FFM). Fat 135 
free mass was calculated as lean tissue mass + bone mineral content. Fat mass percentage is 136 
calculated as the ratio fat mass (DXA)/(fat mass (DXA) + fat free mass (DXA))*100. Waist and 137 
hip circumferences were measured immediately before DXA-scanning. Body weight was assessed 138 
at each visit on regularly calibrated electronic weight scales (SCALE). In addition body weight 139 
was also assessed as the sum of fat mass and fat free mass as assessed by DXA-scanning at 4 time 140 
points during the study. 141 
Diet records were completed 3 times: before entering the study (week -8) and after ~24 and 52 142 
weeks of treatment. Each participant recorded their diet for 3 consecutive days prior to the visit at 143 
the medical center according to a previously evaluated method (Astrup, 2002). The method 144 
provides information on quantity and type of all food consumed during the 3-day registration 145 
period. Each participant was given detailed instructions on how to fill out the questionnaire, and 146 
all returned questionnaires were monitored by the clinical dietician. Food intake was converted 147 
into energy intake.  148 
 149 
Ethics 150 
The study was approved by the regional Ethics Committee for the districts of Copenhagen & 151 
Frederiksberg, Denmark (journal no. KF 01-247/01). The study was performed according to the 152 
Declaration of Helsinki (Edinburgh Amendment 2000) and the current International Conference 153 
on Harmonization (ICH) guidelines. 154 
 155 
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Statistics  156 
All analyses were performed using the SPSS 12.0 software. Statistical tests were performed 157 
using 5% as the nominal level of significance and interval estimates were constructed using 95% 158 
as the level of confidence. We defined a modified Intention-To-Treat (ITT) population (Modified 159 
ITT = 77 patients who completed the 26 week treatment + 6 subjects who were withdrawn or lost 160 
during the last 26 week treatment, i.e. a total of 83 subjects) which were used for the analysis of 161 
changes from baseline to 1 year. Use of last-observation-carried-forward (LOCF) was used for 162 
this modified ITT population who completed the 26 weeks treatment, but did not complete the 1 163 
year period, for the analyses of changes in fat mass, fat free mass, fat percentage and body weight. 164 
Also LOCF was applied on missing values in the 8-week LCD period for body weight. No 165 
substitution of missing data was performed on other variables. No stratification was used. Fisher’s 166 
exact test was used for testing differences between treatment groups regarding gender distribution 167 
and drop out rate. Analysis of Covariance (ANCOVA) was used to compare the changes in fat 168 
mass, fat free mass, fat percentage and body weight in the CLA and placebo groups using the 169 
week 0 value and the body weight change (weight at week 0 minus weight before LCD) as 170 
covariate. Also treatment center and gender was inserted as covariates. We also performed 171 
repeated analyses of changes in fat mass, fat free mass, fat percentage and body weight. The 172 
values for each variable at the time points week 0, 25 and 52 was compared between treatment 173 
groups, using change in body weight at week 0 minus weight before LCD, center and gender as 174 
covariates. The changes from week 0 to week 52 within treatment groups were tested with the 175 
paired T-test. Between group analyses of changes in waist, hip, energy intake and all blood 176 
parameters were analyzed using an unpaired t-test. 177 
 178 
Results:  179 
135 subjects were screened for potential inclusion in the study and 122 subjects were enrolled in 180 
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the 8 week LCD-period. A total of 101 subjects were randomized to one of the two treatment 181 
groups after having completed the 8 week LCD and lost at least 8% of their initial body weight. 182 
The 83 subjects who completed the 26 weeks of treatment were included in the 1-year (modified) 183 
intention to treat analyses (ITT), i.e., 40 subjects in the CLA group and 43 subjects in the placebo 184 
group. 77 subjects completed the whole treatment period. [INSERT FIGURE 1] As assessed by 185 
the counting of returned capsules, the compliance was high: 95.7 + 8.7 % and 96.7 + 8.8 % for the 186 
CLA and placebo group respectively (NS). The drop out rate (CLA: 27.5% vs. placebo: 26.0 %) 187 
did not differ significantly between the treatment groups after 12 months.  188 
 189 
Baseline characteristics 190 
The subjects were all of Caucasian origin and the study groups were well matched with respect to 191 
gender, ethnic origin, smoking habits (n=83), habitual alcohol intake and body height (data not 192 
shown). There was no difference between groups at the start of the study with respect to vital 193 
signs (blood pressure and heart rate), medical conditions or concomitant medications. Significant 194 
differences between the groups (p<0.05) were observed for body weight, BMI, body fat mass and 195 
lean body mass at week –8 (before LCD) and week 0 (baseline). Subjects in the placebo group 196 
had higher body weight and BMI than subjects in the CLA group. Consequently, body fat mass 197 
and fat free mass were also higher in the placebo group than in the CLA group. However, the 198 
percentages of body fat mass were not different between the groups at week -8 and at week 0 199 
(baseline). Hip measurements were slightly higher in the placebo group at baseline, whereas waist 200 
and waist/hip measurements were not different between treatment groups [TABLE 1]. 201 
 202 
Changes in body weight, body composition & dietary registrations 203 
During the LCD period, both groups of subjects lost about 10 kg body weight of which ~70% was 204 
fat mass, group difference was not significant [TABLE 1]. According to the food records, energy 205 
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intake decreased from baseline to week 52 in both groups despite an average weight gain during 206 
the same period. No significant differences between groups were found; during the one-year 207 
supplementation period, both groups regained approximately 3 kg body weight when measured by 208 
DXA-scan (data not shown) and approximately 4 kg when assessed on a weight scale [FIGURE 209 
2]. Similarly, both groups gained equal amounts of fat mass; 2.1 + 5.0 kg vs. 2.7 + 4.9 kg and fat 210 
free mass 0.9 + 1.7 kg vs. 0.5 + 1.8 kg in the CLA and Placebo groups, respectively. Repeated 211 
analyses provided essentially the same results (p = 0.65 for changes in body fat mass). It should 212 
be noted that the LOTF analysis is rather conservative, making it less likely to detect a treatment 213 
effect (the drop outs are more likely to be the individuals who could not maintain the weight loss 214 
and therefore the reported mean weight gain data are probably too low). Changes in hip and waist 215 
measurements did not differ between groups at any time point. 216 
 217 
Adverse events (AEs) 218 
A total of 563 adverse events were reported, but with no significant difference between the two 219 
groups. Among these AEs, 35 were considered related to the treatment and 528 were not. 94.1% 220 
and 98.0% of subjects from CLA and placebo group respectively experienced AEs during the 221 
study (not significant between groups). 3 subjects from the CLA group and 2 from the placebo 222 
group withdrew from the study because of pregnancy of because of adverse events (soft stools, 223 
depression, air in stomach or stomach pain). 5 serious AEs were registered, 4 of them in the 224 
placebo group. None of them were considered related to the treatment. 225 
 226 
Laboratory analyses 227 
Several of the safety blood parameters changed during the LCD induced weight loss, but these 228 
parameters recovered during the subsequent weight regain period (week 0 until week 52), and to a 229 
similar extent in both groups (data not shown). Only the change in leukocyte concentration from 230 
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week 0 to week 52 was significantly different between groups with a higher increase in the CLA 231 
group (0.81 ± 1.21 109/L) than placebo (0.19 ± 1.14 109/L, p=0.033). This increase appeared only 232 
after more than 25 weeks of supplementation. Urine analyses, ECG registrations, systolic and 233 
diastolic blood pressure and heart rate did not reveal any other abnormal observations in any of 234 
the study groups (data not shown). CLA did not affect fasting values of plasma glucose and 235 
insulin, and insulin resistance was also not affected, as assessed by the HOMA-R index [TABLE 236 
2]. In addition to the safety parameters, we assessed a panel of hormones (Testosterone, GH, IGF1 237 
and TSH), but CLA treatment did not affect any of these measures [TABLE 2]. 238 
 239 
Discussion 240 
Numerous animal studies have shown that CLA causes repartitioning of the body composition i.e. 241 
decreased fat mass and increased lean body mass(13). In addition, CLA has been reported to be an 242 
effective inhibitor of atherogenesis in rabbits(14) and of insulin resistance in skeletal muscle in 243 
rats(15). Hence, CLA has been suggested to be useful in treating diabetes by controlling body fat 244 
and weight gain(16), but other recent studies in humans have indicated that CLA may actually 245 
have negative effects on insulin sensitivity(17). Though the animal studies have been very 246 
optimistic, and some human studies have also shown positive effects on body fat, most human 247 
studies (duration <6 months) have shown only marginal effect on body weight and body 248 
composition (18). The apparent discrepancies between animal and short-term human studies have 249 
been ascribed to a) lower doses pr kg body weight, b) shorter treatment duration in human studies, 250 
c) the view that CLA may only be effective during fat accumulation and d) the quality and 251 
reliability of methods of measurements. 252 
Our main objective was to investigate whether one year of CLA supplementation in obese adults 253 
would safely prevent regain of body fat mass and body weight after a major initial weight loss as 254 
compared to placebo. In this respect, we found no effect on either body weight, body fat mass or 255 
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fat free mass. The absence of a significant effect on fat mass and body weight corroborates the 256 
results of other studies recently reported. In a placebo controlled study, obese subjects were given 257 
6g CLA/d for 28 weeks, the first 12 weeks being in conjunction with a LCD(9). CLA neither 258 
affected body weight nor body fat content(9). Also, Kamphuis et al. performed a study with a 259 
CLA preparation similar to that used in our study and found that neither of 2 CLA doses (1.8g/day 260 
and 3.6g/day) were able to significantly lower fat mass and body weight when supplemented for 261 
13 weeks, after an initial ~6 kg weight loss(8). However, CLA did significantly decrease the 262 
regain of fat free mass by ~2.3 %. Our findings stand in contrast to the findings from Gaullier et 263 
al. which performed a 1 year study in a large sample of moderately obese subjects given 3.4 g 264 
CLA/day(6). Here CLA supplementation induced a significant weight and body fat loss of 2.0 and 265 
2.2 kg, respectively. The discrepancy between the studies is not easily explainable, but could be 266 
due to the different designs, i.e. our study was carried out in more obese persons and it was 267 
performed during weight gain, whereas the study by Gaullier et al. was not. Another explanation 268 
may be the absence of diet restrictions during the study by Gaullier et al. A third possible 269 
explanation is the significant baseline differences between the groups in the present study. 270 
However, by using the ANCOVA analysis this difference is not likely to have influenced the 271 
study to any major extent, but we also note that, given the finding of a numerical difference of 272 
approx. 0.6 kg fat mass between groups and a SD of ~5 kg, the present study may have been 273 
inadequately powered. 274 
The secondary endpoint in the current study was the safety issue. Generally, CLA supplements 275 
have been considered to be safe when studied in animals(19). However, some studies in mice have 276 
shown that particularly the t10,c12 isomer may induce lipoatrophy, hyperinsulinaemia and fatty 277 
liver (20) and that this may occur at dosing levels that are comparable to the doses used in human 278 
studies(21). However, due to species differences, it should be emphasized that one should always 279 
be cautious when comparing human and animal studies. In this respect, there are also human 280 
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studies that have questioned the safety of commercially available supplements of CLA, by 281 
reporting that  the t10,c12 isomer (and perhaps the cis9,trans11 isomer)  produce insulin 282 
resistance, even when taken for only 4 months(22;23). In contrast, a 1 year study showed that 283 
CLA does not seem to impair glucose metabolism or liver function, though it may increase HDL, 284 
LDL and apolipoprotein B in some circumstances(6). In the present study CLA did not affect 285 
fasting values of plasma glucose and insulin, and we did not find any effect on HOMA-R. This 286 
confirms previous studies by Riserus et al. where only supplements with purified trans-10, cis-12 287 
(22) or cis-9, trans-11 isomers (23) increased insulin resistance among subjects with the metabolic 288 
syndrome, whereas a 50/50 mixture like the one used in the present study apparently did not(22). 289 
In the present study, 21% of the reported AE´s were severe, with 7% and 5% related to CLA and 290 
placebo, respectively, NS. The majority of the AE´s were related to the gastrointestinal tract. The 291 
number of drop-outs was low for a one-year study with obese subjects (23.7%, without difference 292 
between groups). The compliance was very high (96%), indicating that 6 capsules/day for 1 year 293 
was no source of discomfort. Some minor changes in the laboratory safety data were observed in 294 
both groups in one direction during the LCD period, and in the opposite direction during the one-295 
year supplementation, but without any difference between CLA and placebo. Also, the urine tests 296 
and the ECG records were normal until the end of the study. Only leukocyte concentrations was 297 
increased by 1 year CLA treatment. Similar observations have been reported in previous long-298 
term studies(6;7;9). Although the actual increase in leucocytes is generally small, this increase 299 
may be of some concern as previous studies have indicated that leukocytes are an important 300 
indicator of inflammation and has also been identified as an predictor of CHD mortality(24). As 301 
the values are within reference values [3.0-10.0 109/L], and as CLA in most cases are used for a 302 
limited time period, the clinical relevance of this finding is still unclear. Also, a recent 12 week 303 
study in humans actually suggested that CLA may have beneficial effects on immune 304 
function(25). Further studies should be done to clarify this issue. We analysed whether CLA 305 
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might affect energy metabolism via effects on the hormones testosterone, GH, IGF1 or TSH. We 306 
found no changes, which seems to be in accordance with the apparent lack of effect on body 307 
weight and body composition.  308 
 309 
Conclusions 310 
Unfortunately we did not obtain a perfect group match for body weight at randomization. Despite 311 
the reservations that this issue may imply, we conclude that 1 year of supplementation with a 312 
mixture of 3.4 g/day CLA isomers has no clinically important effect on body weight and body fat 313 
regain after an 8 week LCD induced weight loss.  314 
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Table 1. Changes in body weight, body composition, waist, hip and energy intake. 326 
 327 
 
 Before LCD1,2 Week 0 (Baseline) Week 25 Week 52
3 
∆ 52-0 
∆ 52−0  p-
value 
within group4 
∆ 52−0  p-value 
between groups5 
CLA 94.5 + 11.7 82.6 + 9.56 84.6 + 11.3 86.7 + 13.2 4.0 + 5.6 p < 0.001  Weight (kg) 
 
Placebo 100.6 + 13.2 88.5 + 12.0 90.7 + 13.0 92.5 + 13.0 4.0 + 5.0 p < 0.001 
0.51 
CLA 34.6 + 6.9 26.9 + 7.27 26.6 + 7.5 29.0 + 8.5 + 2.13 + 4.99   p = 0.01 
FM (kg) 
Placebo 37.4 + 7.4 29.9 + 8.1 29.7 + 9.5 32.6 + 9.6 + 2.73 + 4.92   p < 0.001 
0.56 
CLA 59.3 + 11.5 56.4 + 11.1 57.9 + 11.5 57.4 + 11.7 + 0.94 + 1.74    p < 0.001 
FFM (kg) 
Placebo 62.3 + 12.8 59.7 + 12.2 60.7 + 12.3 60.2 + 12.3 + 0.51 + 1.77    p = 0.066 
0.33 
CLA 37.1 + 7.3 32.5 + 9.0 31.6 + 8.5 33.7 + 8.7 1.1 + 4.0       p = 0.086 FAT % 
[DXA]8 Placebo 37.9 + 7.5 33.7 + 8.7 33.0 + 9.5 35.2 + 9.2 1.4 + 3.9       p = 0.008 
0.47 
CLA 101.9 + 8.8 93.3 + 7.8 95.0 + 7.1 97.5 + 8.95 4.2 + 5.9 p < 0.001 
Waist (cm) 
Placebo 104.9 + 9.8 95.8 + 9.6 98.6 + 10.4 99.7 + 10.8 4.0 + 6.7 p < 0.001 
0.88 
CLA 108.3 + 7.8 101.9 + 6.59 104.2 + 6.3 106.7 + 7.3 4.9 + 6.3 p < 0.001 
Hip (cm) 
Placebo 109.6 + 7.5 104.7 + 6.5 108.3 + 8.1 110.7 + 7.9 6.1 + 5.9 p < 0.001 
0.37 
CLA 10102 + 3238 - 7167 + 199910 7807 + 2054 -2295 + 2690    p < 0.001 Energy 
intake 
(KJ/day) Placebo 9889 + 2378 - 7567 + 2461
10
 7328 + 1622 - 2561 + 1981   p < 0.001 
0.71 
1The number of subjects were CLA=40 and Placebo=43. 328 
2The gender distribution was male/female (CLA=17/23, Placebo=19/24) and the age was (mean+SD, CLA=43.4 + 8.4, Placebo=41.7 + 8.2 years), with no 329 
significant difference between groups. 330 
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3For body weight, fat mass, fat free mass and FAT%, Last-Observation-Carried-Forward analysis is applied for subjects who completed the 26 weeks 331 
treatment, but did not complete the 1 year period. 332 
4Paired t-test 333 
5For analyses of changes in weight, FM, FFM and FAT%, covariance analysis (ANCOVA) was performed using the week 0 value and the body weight 334 
change (week 0 minus week -8), treatment center and gender as covariates. Other changes was analysed using unpaired t-test. 335 
6Values are mean +/- SD 336 
7The change in body weight (kg or %) and the change in FM, FFM and FAT% during the 8 week LCD was not different between the groups. 337 
8Fat mass percentages are calculated as the ratio FM(dxa) / (FM(dxa)+FFM(dxa))*100.  338 
9Significantly different at baseline (p<0.05) 339 
10Assessed at week 24, the number of subjects reporting energy intake at all time points was CLA=28, Placebo=20. 340 
 341 
 342 
 343 
 344 
 345 
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Table 2. Blood parameters before LCD, at week 0, week 25 and week 52.  n(CLA)=36, n(placebo)=39.  346 
1 Unpaired t-test. 347 
2 Values are mean +/- SD 348 
3 HOMA-R=glucose*insulin/22.5349 
Blood parameter 
Absolute values  Before LCD 
Week 0 
(Baseline) Week 25 Week 52 ∆ 52-0 
∆ 52−0   
p value 
between groups1 
CLA 5.03 + 0.382 4.79 + 0.44 4.94 + 0.36 4.94 + 0.47 0.16 + 0.73 Glucose (mmol/l) 
Placebo 5.03 + 0.50 4.92 + 0.51 4.85 + 0.48 4.87 + 0.47 -0.4 + 0.61 
0.198 
CLA 60.2 + 19.1 40.6 + 16.0 44.1 + 20.3 53.5 + 21.8 12.9 + 18.9 Insulin (pmol/l) 
Placebo 58.4 + 23.0 44.2 + 23.4 42.9 + 20.8 50.9 + 24.4 6.66 + 24.2 
0.221 
CLA 0.60 + 0.76 1.20 + 2.40 1.15 + 2.34 0.50 + 0.69 -0.70 + 2.12 Growth horm. (µg/l) 
Placebo 0.50 + 0.72 1.59 + 3.18 0.98 + 1.61 0.87 + 1.54 -0.72 + 3.49 
0.982 
CLA 20.2 + 5.8 20.0 + 6.9 24.1 + 7.4 23.9 + 5.4 3.71 + 6.84 IGF-1 (nmol/l) 
Placebo 22.5 + 6.9 19.6 + 6.6 24.5 + 6.5 24.5 + 6.9 4.75 + 4.86 
0.465 
CLA 6.91 + 6.50 8.60 + 7.91 9.20 + 8.19 6.52 + 6.74 -2.09 + 2.77 Testosterone (nmol/l) 
Placebo 6.78 + 6.16 8.25 + 7.05 9.65 + 8.51 7.14 + 7.53 -1.10 + 3.05 
0.151 
CLA 1.33 + 0.49 1.20 + 0.58 1.41 + 0.59 1.07 + 0.36 -0.13 + 0.44 TSH (mIU/l) 
Placebo 1.33 + 0.63 1.24 + 0.64 1.44 + 0.90 1.12 + 0.63 -0.11 + 0.45 
0.867 
CLA 13.7 + 4.7 8.8 + 4.0 9.9 + 5.1 11.8 + 4.7 3.01 + 4.63 HOMA-R3 
Placebo 13.2 + 5.7 9.9 + 5.9 9.3 + 4.6 11.0 + 5.2 1.10 + 5.72 
0.119 
CLA 6.21 1.43 5.56 1.69 6.03 1.39 6.36 1.66 0.81 + 1.21 Leukocytes (109/L) 
Placebo 5.85 1.53 5.32 1.53 5.89 1.54 5.51 1.30 0.19 + 1.14 
0.026 
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Figure legends and footnotes 350 
 351 
 352 
Figure 1: Study participant & randomization scheme 353 
 354 
Footnotes: LCD indicates the initial 8 week low calorie diet period 355 
ITT indicates the study population for which Intention-To-Treat analyses are performed 356 
for changes in body weight, body fat, fat free mass and body fat percentage from baseline 357 
to 1 year treatment (n=83 in total). The dropout rate was not significantly different 358 
between groups (χ2 test). 359 
AE = Withdrawn due to Adverse Event 360 
 361 
 362 
 363 
Figure 2: Body weight during the study.  364 
 365 
Footnotes:  366 
Number of subjects are CLA=40, Placebo=43. 367 
Where relevant, Last-Observation-Carried-Forward has been used to insert body weight 368 
for week 26 (or later) to be inserted at week 52. 369 
There was no significant difference between groups in body weight change throughout the 370 
study (both p > 0.5 using ANCOVA or repeated measures analysis). 371 
 372 
Error bars indicate SEM 373 
 374 
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Nov 3, 2004 
To Associate Editor 
Lee M. Kaplan, MD, PhD, 
Obesity Research 
 
 
 
Re: Revised version of MS# 04-113 
Identification of novel variants in the putative PPARγ2  
promoter and relationships with obesity in Danish men 
 
 
Dear Dr. Kaplan, 
We are most grateful for the constructive comments from You and the reviewers, and we have done our 
best to comply with them within the space limits of this type of reports. 
 
 
Editor corrections/manuscript formatting 
 
The present manuscript has been corrected according to the “Brief Genetic Analysis” format, i.e.  
A) No headings for Introduction, Results, or Discussion. 
B) Methods section follows main text. 
C) Accordingly, we have changed the order of the tables 1, 2 and 3. 
 
 
 
Ekstra notes 
 
The reference number 1 has been changed:  
From: Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The heritability of 
body mass index among an international sample of monozygotic twins reared apart. Int.J.Obes.Relat 
Metab Disord. 1996;20:501-6)  
To: Sorensen TIA. The genetics of obesity. Metabolism 1995;44:4-6.)
  2
 
Point to point reply to reviewers. 
 
Reviewer 1 
 
We are most grateful for the helpful and constructive criticism offered by the reviewer. 
 
Q1 (p7, para3): This appears to be a retrospective cohort identified from military records. To do the 
genotyping a blood sample must have been obtained recently. State briefly what the participation rate 
was of the originally chosen subjects in the follow-up and blood sampling. A statement about informed 
consent or ethics committee approval should be made. 
 
Reply: The study is a retrospective study, and the blood samples have been obtained recently 
(year 1998-2000). We have now made it clear how the current study group relates to the original 
epidemiological study population of draftees, page 10 line164. In the paper, we now also provide 
the informed consent statement and the ethics committee approval as required by the reviewer, 
page 10 line 177. Also the participation rate is provided, page10 line 174 
 
Q2 (p8, para3):  
Exact tests are appropriately used for categorical variables. It appears for the data on genotype vs BMI 
(p.10) that ANCOVA was used on highly skewed data from the very small numbers (e.g. n=3 for the -
882 T/C variant, with SD´s of 0.4 and 3.4 between the groups). This is a recipe for outliers to have 
undue influence. A non-parametric test i.e. Wilcoxon rank sum would be more appropriate for the 
calculation of P values for continuous variables.  
 
Reply: As pointed out by the reviewer, the use of an ANCOVA model can be misleading when the 
data are skewed. Hence, we have performed non-parametric tests (2 independent samples, Mann-
Whitney Test / Wilcoxon rank sum, age=covariate) for the analyses on the -882T/C variant, and 
with these tests the difference turned out to be non-significant (p=0.059). 
The same statistical procedure performed on the Pro12Ala and 2604T>C variants (non-
parametric test, K independent samples, Kruskal-Wallis Test, age & BMI=covariates) also gave 
non-significant outcomes, p=0.100 and p=0.215 respectively. 
However, one of the problems using non-parametric tests is that any effect of possible covariates 
(i.e. age and BMI) cannot easily be adjusted for, hence significant effects (which may be true) are 
likely to disappear when using the non-parametric tests. 
However, we agree that the non-parametric test may be the appropriate choice also in our sample 
when data are skewed, and we have thus removed these non-significant findings from the 
“Results section”, page 7 line 100. 
 
Q3 (p9):  
It is a little confusing why the -1881 was not studied further due to tight linkage with -1505, then it 
turned out that the -816 and -2604 were also in complete linkage with -1505 but they were still 
genotyped in everyone. Why was this not apparent from the initial scanning as it was for the -1881? 
There is nothing wrong with genotyping these variants in the larger set it is just not apparent why this 
was done for some but not all of these linked variants. 
 
Reply: We found that the variants -816C>T, -1505G>A, -1881C>T and -2604T>C, respectively, 
were in complete linkage disequilibrium (LD). However, only the -2604T>C variant was studied 
further. Hence, the correct description should have been: 
 “Also, the initial analyses showed that the variant -1881C>T was tightly coupled to the -
2604T>C  (NOT -1505G>A) variant and was thus also not studied further (Table 1). [Insert 
Table 1]”. The manuscript is revised accordingly, page 6 line 89. 
 
  3
 
 
Q4 (Table):  
Presumably all the numbers in the Table are n´s. Label them as such, and include the % in each row for 
each genotype to enable easy comparison of the genotype distributions.  
 
Reply: The numbers in the table are n´s. In the revised manuscript they are labelled as such, and 
we have included the % in each row for each genotype as suggested by the reviewer. 
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Reviewer 2 
 
We thank the reviewer for the most valuable comments which have helped us to improve and clarify 
our manuscript. 
 
Q1. It was found that the -882T>C polymorphism was associated with BMI in the obese but not in the 
lean cohort (top of page 10). It seems reasonable to find the association only within the obese group 
(top of page 10). However, the number of heterozygotes for this polymorphism is very small, making it 
inadequate for association studies. The -792 and Pro12Ala would have been a better indicator. 
 
Reply: We agree that the sample size for the test of -882T>C variant with respect to phenotypic 
variable is quite small. Hence, in our discussion and final conclusion we have deliberately not 
made any final conclusions on these findings. However, due to the comments raised by reviewer 
1, we have re-analyzed the data using non-parametric tests, which may be a more correct 
statistical method for this purpose. As these analyses actually turned out with non-significant p-
values, we have revised the manuscript accordingly, i.e. concluding that all genotype-phenotype 
analyses did not suggest any genotype effects of either variant. Please see page 7 line 102. 
 
Q2. Table 2. It appears that the sample size was not sufficient to detect linkage desequillibrium 
between a number of marker pairs. One would conclude that the -882, -2604 and the Pro12Ala are in 
very strong disequllibrium. Therefore, the Pro12Ala should also have been associated with obesity in 
the obese subgroup.  
 
Reply: We report that the -882T>C variant is not in linkage disequilibrium with any of the other 
identified variants. However, the Pro12Ala variant is in strong linkage disequilibrium with the -
2604T>C variant (R2=0.93). In our initial ANCOVA analyses, this is also in accordance with our 
reporting that both the Pro12Ala variant and the -2604T>C variant are associated with lean 
tissue mass. However, as described in Q1, after using the non-parametric tests these associations 
were not statistically significant. 
 
Q3. A previous study (Meirhaeghe, A et al. (1999) Int. J. Obesity 24:195-199) found an association of 
the Pro12Ala polymorphism with obesity in a much larger French cohort. Perhaps discrepancies 
between studies are due primarily to sample size differences. The results in this paper should be 
discussed. In addition, there are a number of publications on this topic that have not been mentioned in 
this manuscript. I would suggest putting all the positive and negative findings on associations of the 
Pro12Ala polymorphism with obesity in a table with the number of subjects, gender and age of the 
subjects. 
 
Reply: Most interestingly, the study by Meirhaeghe A et al. found a significant association 
between obesity and the Pro12Ala polymorphism in a larger French cohort (n= 839) and in a 
recent meta-analysis by Masud S et al. J Med Genet 2003;40:773-780 it was also concluded that 
Ala12 homozygotes had significantly higher BMI than heterozygotes and Pro12homozygotes. 
Both studies are relevant to consider in the context of the present study, and both studies are 
included in this manuscript. As suggested by the reviewer, the discrepancies between our findings 
and the study by Meirhaeghe and the meta-analysis could be due to sample size. However, it 
should be noted that the 2 largest studies to date (n=1600, Memisoglu A et al. Pharmacogenetics 
2002;12:597-603 & n=2245, Frederiksen L et al. J.Clin.Endocrinol.Metab 2002;87:3989-92) did 
not report any evidence that the Pro12Ala variant was associated with obesity, but also that the 
literature on this issue is generally inconsistent. With this in mind, the aim of the present study 
was to determine if the inconsistent results of previous studies could be explained by other gene 
variants in the PPARgamma promoter region, whether these variants were in linkage 
disequilibrium with the Pro12Ala variant or not. 
  5
Finally, including a list of all findings on Pro12Ala and obesity (and type 2 diabetes) within the 
manuscript limitations for publication in “Brief Genetic Analyses” section of Obesity Research 
would not be feasible or acceptable according to the Journal policy. However, such lists can be 
found in the meta-analysis by Masud et al., although more studies on the topic have been 
published since that analysis was reported. 
 
 
Q4. Perhaps it would be good to determine the frequency of haplotypes generated by -792 promotor 
variants, the Pro12Ala and the +1431 polymorphisms and perform associations with haplotypes instead 
of single polymorphisms.  
 
Reply: Haplotype analyses of haplotypes generated by the variants -792A>G, Pro12Ala and 
+1431C>T may be substantiated due to their relative frequency and/or theoretical speculations 
on their individual and combined influence on PPARgamma transcriptional activity. However, 
due to the limited sample size this may not be appropriate. Combinations of these 3 gene variants 
can theoretically give rise to a total of 3*3*3=27 different haplotypes. However in our sample, the 
actual number is 15 different haplotypes, of which n=1 for three of the haplotypes. Thus, though 
the idea is very tempting, it is not likely to be successful to perform such analyses with the 
available sample size.  
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Feb 25, 2005 
To Associate Editor 
Lee M. Kaplan, MD, PhD, 
Obesity Research 
 
 
 
Re: Revised version of MS# 04-113 
Identification of novel variants in the putative PPARγ2  
promoter and relationships with obesity in Danish men 
 
 
Dear Dr. Kaplan, 
We are most grateful for the opportunity to provide you with a revised version of the manuscript. 
Below, we have addressed the remaining points raised by reviewer 2, and changes in the manuscript are 
marked with bold type. 
We hope that our reply appropriately addresses the points raised, and that the manuscript will be 
acceptable for publication. Due to the previously very long reviewer processing time we sincerely 
thank you that you will expedite and conclude the editorial handling of our paper. 
 
 
Points raised by reviewer 2 
I still have problems with linkage disequilibrium between markers. It appears to me that all the 
promoter polymorphisms should be in LD with each other and with the Pro12Ala and that all of these 
lie within a single LD block. The observed lack of LD is most likely due to low power of detecting LD, 
particularly if they are in negative LD. The conclusion from this work is that the promoter 
polymorphisms do not explain the reported discrepancies in the association of the Pro12Ala 
polymorphism with obesity and type 2 diabetes. This should be clearly stated in the abstract and 
discussion. I believe that the most likely reasons for such discrepancies are sample size, ethnicity and 
population stratification. 
 
Reply: 
We have detected LD between pairs of variants using R2 and have found complete LD between 4 
novel variants and the Pro12Ala variant, which all had an allele frequency of around 15 %. We 
agree with the reviewer that we have limited power to detect LD due to our sample size, but the 
other determined variants in the promoter all have different allele frequencies and might 
therefore not be in any significant LD with each other. However, this does not rule out that these 
variants together form haplotypes with limited variance in the linkage block surrounding the 
PPARG locus. 
 
We acknowledge that the discrepancies between the present study and previous findings may be 
due to differences in sample size, ethnicity and population stratification. This is now stated in the 
discussion (page 8, line 124) part of the manuscript. 
 
Finally, we agree that our findings infer that the overall conclusion is that “the identified novel 
variants in the PPARγ2 promoter region do not explain the reported discrepancies in the 
association of previous identified variants with obesity and type 2 diabetes”. Hence, this has been 
inserted into both the abstract (page 3, line 20) and into the conclusion part (page 8, line 136) of 
the manuscript. 
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June 26, 2005 
Point to point reply: 
 
EDITORIAL COMMENTS: 
The file formats submitted were appropriate for review purposes, but cannot be used for publication purposes.  Before 
resubmitting your manuscript online, please either transfer each figure into a separate PowerPoint file or save each figure as 
a separate TIFF file.  The title page, body, references, and tables can be submitted in either Microsoft Word or Word Perfect 
format.  Please contact Sharon or Zann at the Editorial Office if you need help with this. 
 
Answer: Figure 1 is provided as a PowerPoint file, and the title page, body, references, and tables are submitted as a 
Microsoft Word file. 
 
We have not received a signed Authors Agreement form for your paper.  Please download one at 
http://www.ajcn.org/misc/agree.pdf, have all authors sign it, and return it by fax to 1-530-752-8371.   
Manuscripts can not be accepted for publication in the AJCN without this form signed by all authors. 
All manuscripts submitted to the AJCN must have line numbers in the margin throughout the abstract and text.  Our office 
staff added line numbers to the first version of your manuscript.  The revised manuscript must be submitted with line 
numbers. 
 
Answer: A signed Authors Agreement form will be provided by fax within the next days. 
The current revised manuscript has been provided line numbers throughout the abstract and text. 
 
 
INTRODUCTORY NOTES: 
The authors have just recently been informed that the dietary supplement used in the study was CLA given as 
triacylglycerol (CLA-TG) and not as free fatty acids (CLA-FFA).  
We apologize sincerely for this, and we have now incorporated this new information to the manuscript where 
appropriate, i.e. in the introduction and methods section. 
 
 
 
REVIEWER 3: 
 
1. Trade names should not be used within the text; generic descriptors should be used instead.  Such items should be 
identified once in the paper, in the Methods section in parenthesis.  The name and location of the manufacturer should also 
appear within the parenthesis. 
 
Reply: We agree, hence as suggested by the reviewer, the trade name is deleted from the text and identified in the 
Methods section instead, as well as the name and location of the manufacturer. 
 
2. The abstract should be written in complete sentences and limited to 250 words. The Introduction should be limited to 1.5 
pages (~450 words) and the Discussion to 4 pages (~1200 words). 
 
Answer: The current manuscript is revised, so that it fulfils these requirements. In this regard, please note that parts 
of the introduction has been moved from the introduction part to the discussion part of the manuscript. 
 
3. Please use US spelling. Center, randomization, tumor etc 
 
Answer: We have revised the manuscript using US spelling. 
 
4. Line 87.  Please replace "female subjects" with "women".  
 
Answer: We have replaced "female subjects" with "women". 
 
5. Line 161-162 should be moved to the beginning of the Methods section.  
 
Answer: We agree, and have moved line 161-162 to the beginning of the Methods section. 
 
6. Line 170.  The rationale for using the last-observation-carried-forward protocol is that this will make it MORE difficult to 
find a significant effect.  When dealing with weight loss/weight regain data it will make it LESS difficult to find a 
significant effect. (the drop outs are more likely to be the individuals who could not maintain the weight loss and therefore 
the mean weight gain data are probably too low).  Therefore this analysis should either be deleted from the paper or this 
perspective should be clearly stated when the results are reported.  
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Answer: The motivation of ITT is not to make findings more difficult, but is preferred as a method of analysis 
because a study should have the robustness to resemble real life. We admit that our use of ITT & last-observation-
carried-forward analyses are not well described, and that it actually differs slightly from standard use (usually all 
subjects who sign the informed consent and engages in the study). 
In our study we define our ITT population and we perform our last-observation-carried-forward analyses on the 
subjects who has completed 26 week treatment (i.e. body weight and DXA-data are available at week 26). Therefore, 
the number of subjects used for the analyses of 1 year treatment effects are 83 (The sum of the 77 subjects who 
completed the 1 year study + 6 subjects who were withdrawn or lost during the last 26 weeks treatment). In this 
respect, we note that the distribution of drop outs during the last 26 weeks treatment seems not heavily influenced by 
treatment (CLA=2, Placebo=4). 
We have described this more clearly in the revised manuscript, and the figure 1 has been revised accordingly. 
 
7. Page 8, line 173.  It is not obvious in figure 1 why you only had an ITT population of 83 rather than 101. (Also lines 185-
187).  
 
Answer: As described to point 6 above, the use of LOCF and ITT analyses have been described more clearly, and the 
figure 1 has been revised accordingly, also explaining how the ITT population consists of 83 persons. 
 
8. The statistical methods used in this paper tell us that two means are not significantly different, not that they are similar.  
There is an important, but subtle difference.  Additional tests are needed to determine that two means are the same.  Please 
use phrases such as "not different" rather than "similar", "same", "comparable" etc.   
 
Answer: We agree that this is a subtle, but important difference, and we have revised the manuscript accordingly. 
 
9. Line 201.  The word baseline is used twice in this sentence.  Once is enough.  
 
Answer: Is revised. 
 
10. Line 207.  Please don't use the abbreviation NS in the text. Spell it out.  
 
Answer: Is revised. 
 
11. Line 223.  A pregnancy might be an adverse event as far as the researchers are concerned, but hopefully it was not an 
adverse event for the woman.  Could this sentence be modified slightly? 
 
Answer: We agree, and have revised accordingly. 
 
12. Leukocyte concentrations should be included in the table.  
 
Answer: We agree, and the data for the Leukocytes have been inserted in the table.  
 
13. Figures 2 and 3 are not called out in the paper. Data should be presented only once in the paper, not in both tables and 
figures, and therefore they should be deleted. 
 
Answer: We believe that the presentation of the body weight change throughout the study is important to the reader, 
and thus we would like to keep it in. Figure 2 is now called out in the results section. 
We agree, that figure 3 is not necessary as the data are also presented in table 1, and figure 3 is thus deleted.  
 
14. Table 1.  Footnote 1 should be modified to read: P value from unpaired t test except for gender where Fisher's exact test 
was used.  The footnote should then be placed on each of the two column headings "P-value between groups".  Footnote 3 
should be deleted and the other footnote numbers changed.  
 
Answer: As the table 3 has been deleted, and most of the table 2 has been deleted/inserted into table 1, the foodnotes 
to table 1 has been changed accordingly. 
 
15. Much of the after LCD data are reported in both tables 1 and 2.  This should be avoided.   
 
Answer: The most relevant LCD data from table 2 are inserted into table 1, and thus table 2 has been deleted. 
 
16. Table 2 should have been analyzed with a 2- factor repeated measures ANOVA with interaction which includes the 25 
week data.  Because there were significant differences at 0 week, it would be appropriate to also control for the 0 week data 
in the analysis.   
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Answer: For analyses of changes (∆ 52−0) in body weight, FM, FFM and FAT%, covariance analysis (ANCOVA) 
was performed using the week 0 value and the body weight change (week 0 minus week -8), treatment center and 
gender as covariates.  
All though a repeated analysis could be used, we believe that this would give essentially the same results.  
One other concern is the fact that the statistics described in the protocol, and which was submitted for review and 
approved by the local ethical committee, only included ANCOVA analyses and not repeated measures ANOVA. 
It is recommended by the medical authorities (including the Danish Medicines Agency) that all measures are taken 
to ensure transparency in the execution of medicinal clinical trials, including statistical analyses and reporting – and 
therefore they recommend that the results are reported in the same way as initially described in the approved 
protocol.    
All though we realize, that CLA is not considered a medical drug (but could be considered so in the future?), and all 
though we agree that the statistical descriptions given in the protocol should not prevent the use of other statistical 
analyses, if arguments are in favour of this, overall we believe that a repeated analysis would not give any substantial 
extra value to the manuscript. 
Other changes (waist, hip & energy intake) was analysed using unpaired t-test. 
 
17. Table 3 should be deleted.  The first three columns should be summarized in footnote form to table 1 and the right hand 
3 columns should be deleted.  
 
Answer: The table 3 has been deleted, and the most important information from the first three columns are 
summarized in a footnote to table 1. 
 
18. Figure legends should include both the title of the figure and any explanatory information – number of subjects, 
identification of error bars, results of statistical analysis etc. 
 
Answer: The figure legends and explanatory information has been revised, so that it includes both title, number of 
subjects, identification of error bars, results of statistical analysis etc. 
 
  
REVIEWER 1: 
Comments: 
This study evaluated the effects of 3.4 g/d of mixed CLA (40% each of cis-9,trans-11 and trans-10,cis-12 as FFA) on body 
weight and body composition after major weight loss in obese men and women.  The study design involved a 10-wk weight 
loss diet followed by randomization and 12 months of monitoring while taking either CLA or placebo.  Despite the double 
blind randomization procedure and similar drop-out rates, the two study groups upon completion of the protocol were found 
to have been mismatched for initial body weight and BMI.   Correcting for this inequality at baseline, however, there was no 
effect of the 12-month CLA supplementation of the rate of weight regain compared to placebo.  Given similar frequencies 
of reported adverse events between the two groups and no significant effects on glucose and a panel of hormonal variables, 
the authors conclude that this formulation of CLA is as safe as placebo (olive oil). 
 
This study appears to have been well designed and carefully performed.  The weight disparity between groups is an 
unfortunate consequence of blinded randomization without stratification for weight, but even this procedure cannot prevent 
disparities due to differential weights of dropouts.  The authors are to be complemented for retaining 77 of 101 randomized 
subjects thru a 12 month protocol. 
 
The lack of a significant effect of this CLA formulation of body weight and body composition is an important observation.  
The lack of an overt treatment effect on insulin resistance is also a significant observation.   
 
This reviewer’s primary concern with the manuscript is the dismissal of the change in leukocyte concentration with CLA as 
inconsequential (lines 282-3).  The significant increase in total leukocytes across the 12 months of CLA supplementation 
was 0.77 vs 0.19 x10ninth for placebo (P=0.03).  Since the reports of Friedman (NEJM 290:1275-8, 1974) and Kannell et al 
(JAMA 267:1253-56, 1992), multiple additional studies have corroborated total WBC as a robust predictor of coronary risk 
within the “normal range” (see also Brown DW et al, J Clin Epidemiol 54:316-22, 2001).  This net increase in total WBC of 
0.6 in the present study predicts an increase in coronary risk on the order of 20%, and is thus should not be dismissed 
“minor”.  In discussing the importance of this observation, it would be very helpful if the authors could include the results 
of serum hs-CRP across the 12 month supplementation period in these subjects as well.  Particularly if there was an 
elevation in CRP with CLA in this protocol, the authors should consider revising their assessment of the safety of CLA as 
equivalent to that of olive oil. 
 
Answer: We agree that this information could be given more emphasis. Note that the numbers have been 
recalculated (now CLA group (0.81 ± 1.21 109/L) than placebo (0.19 ± 1.14 109/L), p=0.033) which is essentially 
unchanged. 
Accordingly, we have changed this sentence into: 
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“Only leukocyte concentrations seemed increased by 1 year CLA treatment. Similar observations have been 
reported in previous long-term studies(7;10;18). All though the actual increase in leucocytes is generally small, this 
increase may be of some concern as previous studies have indicated that leukocytes are an important indicator of 
inflammation and has also been identified as an predictor of CHD mortality(19). However, as the values are within 
reference values [3.0-10.0 109/L], and as CLA in most cases are used for a limited time period, the clinical relevance 
of this finding is still unclear. Also, a recent 12 week study in humans actually suggested that CLA may have 
beneficial effects on immune function(25).” 
Also, we have changed the abstract and conclusion slightly to mention this observation. 
We note that the changes in platelets (thrombocytes) did not change significantly different between groups (p~0.6). 
We agree that data on hs-CRP could add important information to this issue, but unfortunately we don´t have any 
data on hs-CRP. 
 
  
REVIEWER 2: 
Comments: 
There are now several published studies that have reported the effects of CLA on body weight and body fat in humans.  
Only one research group in Norway has reported in various publications that CLA may reduce body weight and fat, but the 
effects were relatively small and not always significant and consistent.  All the other studies published by other research 
groups did not find any significant effect.  The present study confirms this observation. The present manuscripts provides 
interesting information.  However, there are several issues that need attention. 
 
1. Line 39: Reviews.  Only one review is quoted. 
 
Answer: We have changed accordingly, now only one review is quoted. 
 
2. Line 44 and line 102 : Other fatty acid isomers and others.  Commercial CLA preparations are made by isomerisation of 
linoleic acid and contain usually 40% of the 9,11 and 40% of the 10, 12 CLA isomer.  The remaining 20% are usually other 
fatty acids and and only a small amount of other CLA isomers.  The expression “fatty acids isomers” and “others” is not 
very clear and specific. E.g. “others” could mean other fatty acids or other CLA isomers. 
 
Answer: We agree, and the description has been changed accordingly into “the remaining 20% are usually other 
fatty acids; approx. 1-4 % other types of conjugated fatty acids and 15-19% other non-conjugated fatty acids”. 
 
3. Line 47:  A reference should be given that describes the CLA intake. 
 
Answer: We agree and a reference has been given. 
 
4. Line 52: CLA may be useful in treating diabetes.  A large number of studies in mice have clearly shown that CLA 
induces diabetes and a similar trend has been found in pigs (Stangl et al.), and hamsters (Bouthegard et al.).  Also in a 
previous publication (JLR), the authors have described that CLA has severe side effects like diabetes and hyperinsulinemia.  
Only in diabetic rats, CLA has been shown to improve diabetes (Henriksen et al, and some other publications in obese and 
diabetic rats).  In addition. CLA induces in mice a fatty and enlarged liver and similar results have been reported in hamster 
studies (Dedeckere et al).  Further, various studies by the group of Vessby et al. suggest that CLA may lower insulin 
sensitivity.  Only one study in humans have reported an improved insulin sensitivity  (Eyjolfson et al. Med. Sci. Sports 
Exercise 36: 814, 2004)  Thus, most of these studies suggests that CLA rather induces diabetes than that CLA improves 
diabetes.  
 
Answer: In the JLR review, we have not specifically provided evidence that CLA is able to induce clinical diabetes in 
humans! However, we agree that CLA´s effect on insulin sensitivity & type-2 diabetes is highly controversial and we 
have adjusted the description in the present manuscript accordingly, into: “Hence, CLA has been suggested to be 
useful in treating diabetes by controlling body fat and weight gain(7), but other recent studies in humans have 
indicated that CLA may actually have negative effects on insulin sensitivity(8)”. 
 
5. Line 67:  The only two publications:  A third study has now been published in J. Nutr. April issue, and one of the authors 
of the present manuscript is also author of this publication.  In this manuscript, CLA appears to be able to prevent weight 
gain and the results of this publication should be discussed.  The discrepancy between between the present study and the 
publication in J. Nutr. shows again that the results found in the Norwegian studies could not be reproduced by other research 
groups.  The reason for that is not clear. 
 
Answer: The current study design is novel, in that it studies the efficacy of CLA to decrease weight gain (i.e. AFTER 
an initial weight loss). We are only aware of 2 previous studies (Kamphuis et al, 2004 & Whigham LD et al. 2004) 
using a similar design. The mentioned study (Gaullier J-M, 2005, J.Nutr) is not a weight regain study, Therefore the 
design is not directly comparable. However, we have now made a reference to this study in the discussion section. 
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6. Fig 1. and the number of subjects.  Figure 1 does not appear to be clear.  In the Tables, the CLA group comprises 40 
subjects and the control group comprises 43 subjects.  None of these numbers can be found in Fig. 1.  However, scrutinizing 
the text learns that the 40 subjects in the CLA and the 43 subjects in the control group completed the 25 week period, 
whereas only 38 subjects in the CLA group and 39 subjects in the control group completed the whole 52 week period.  This 
should be clearly stated in Fig. 1.  Figure 1 could also be simplified.  For example: 
 
135 subjects 
? 
122 involved in Low Calorie Diet 
? 
101 subjects randomized 
? 
51 in CLA                 50 in placebo 
?                                    ? 
40 in CLA        43 in placebo  (completed 25 weeks) 
?                               ? 
38 in CLA       39 in placebo  (completed 52 weeks) 
 
Also the sizes of the corresponding boxes should be the same.  Also the abbreviation AE should be clarifed in a foot note to 
this figure.   
 
Answer: Reviewer 3 did also find the figure 1 unclear, and we agree that it is not very well described.  
We have revised the figure 1 including the abbreviations and footnotes. 
 
7. Line 170:  Last observation carried forward.  Does this mean that the 25 week values of the subjects that did only 
complete the 25 week period were also used for the 52 week period?  This should be more clearly mentioned for the reader 
who is not familiar with this concept.  This should also be mentioned in the footnotes of the Tables. 
 
Answer: Yes, the 25 week values of the subjects that did only complete the 25 week period were also used for the 52 
week period! We have described this more clearly in the methods as “Also LOCF was used for the subjects who 
completed the 26 weeks treatment, but did not complete the 1 year period, for DXA and weight variables”, 
This has also been added as a footnote to table 1.  
 
8. Line 14, Line 115, Table 2.  The authors use sometimes kJ and sometimes calories.  This is very confusing and either 
calories or kJ should be used.  kJ could be used (metric system) and within brackets calories and indicate that 1 kcal = 4.18 
kJ. 
 
Answer: We agree, and have revised accordingly, so that kJ are used throughout the manuscript. 
 
9. Line 109:  Power analysis to estimate the number of subjects needed.   
This is usually difficult, since the expected standard deviation has to be known, although a standard deviation can be 
estimated from other, similar studies.   
a) In the present study, it is calculated that if there is a difference in body weight regain of 2.2 kg between the groups, 
how many subjects are needed to pick up this effect.   
b) What is the reason for using 2.2 kg as a criterium (because of the results of the studies of Gaullier)?   
c) What was the estimated SD that has been used for these calculations?   
d) Table 2 shows that the SD of the difference in body weight between week 0 and week 52 is 4.99.  If one wants to 
pick up a difference of 2.2 kg and the SD of these differences is 4.99, then the number of subjects needed is 132 
per group (p value <0.05 and power of 90%, unpaired t-test of the differences between week 0 and week 52, can be 
calculated with statistics computer programs or with power analysis programs found on the internet).  
e) Since the calculations of the number of subjects needed is difficult because of the unknown SD, I would suggest to 
leave out this issue in the manuscript, unless the procedure is being more clarified.   
f) Further, what means (line 110) “efficiency size estimated”?  Where does the number 1.7 come from?  This is not 
clear to the reviewer. 
 
Answer:  
a) We agree that accurate and meaningful power analyses are very difficult to perform, particularly when using 
novel study designs. However, many journals now encourage that descriptions of power analyses are reported in the 
manuscript, all though they may not always be meaningful. In the present study, the power analysis was based on 
changes in fat mass regain (not body weight regain). 
b+c) The 1.7 effect size was based on a previous study of Blankson et al. J.Nutr. 2000, where a 3.4 g CLA/day over 
(only) 12 weeks induced a fat loss of 1.7 ± 1.9 kg (mean ± SD). The SD at 2.2 kg was assumed to be detectable 
differences in fat mass using DXA-methodology, based on prior experience on studies performed at RVAU. I.e. we 
had prior experience of within-group SD~2.2 kg fat mass using DXA. 
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d) Retrospectively, we agree that the estimate of SD of 2.2 kg was lower than the observed ~5.0 kg. 
e) As we would like to inform the reader about the reasoning about the sample size (and to comply with most journal 
guidelines), we have revised the description of the sample size calculation, and hope that this current description is 
clear to the reader: “Assuming a difference of 1.7 kg of fat mass between treatment groups based on prior studies 
using 3.4 g CLA/day vs. placebo(9) and an estimated SD of 2.2 kg (based on prior experience of within-group 
detectable differences using DXA-methodology) an estimated number of 37 subjects pr. group [please note the 
change from 28 to 37 per group] were required (using 90% statistical test power and 5 % significance level)”. 
Calculations performed via http://hedwig.mgh.harvard.edu/sample_size/quan_measur/para_quant.html
Also, in the discussion we now mention that “given the finding of a numerical difference of 0.6 kg fat mass between 
groups and a SD of ~5 kg, the study may have been inadequately powered”.  
f) See point b+c above. 
 
10. Line 115:  Why were the subjects fed a modest hypocaloric diet during the study?  What was the rationale for that? 
 
Answer: The study was performed in overweight and obese (28<BMI<35), who after an >8% weight loss should be 
given CLA or placebo. Of ethical reasons (the obese participants should have obvious benefits from participation) 
and in order to motivate the subjects to maintain the weight loss, they were instructed to follow a hypocaloric diet. 
 
11. Line 161 and 162:  This does not appear to belong to the ethics section. 
 
Answer: We agree, and it is moved to the methods section. 
 
12. Line 177:  ITT  The abbreviation is explained on the next page, but should be explained here, where it is being used for 
the first time.  Maybe, such abbreviations should not be used at all, these are not very common abbreviations and these 
expression are only used once or twice in the text.  The same is true for abbreviations such as AE. 
 
Answer: The ITT has been changed to Intention-To-Treat, and the AE is now given a separate explanatory note in 
the figure 1. 
 
13. Fig. 2 and 3.  These figures are not mentioned in the text at all.  Figure 3 can be deleted, since all these data are already 
given in the Tables. 
 
Answer: Figure 3 is deleted (see comment to reviewer 3, point 13). We believe that figure 2 provides some important 
information and we want to keep it, but we have also now mentioned the figure 2 in the text. 
 
14. Table 1, 2, and 3:  There is a large overlap between these tables.  For example, data that are given in Table 1, are given 
in Table 2 again.  I believe that the tables 1 and 2 should be merged into one Table.  The data in Table 3 do not seem to give 
any additional information.  Table 2 indicates that there are no effects at all between the CLA and the Control group, thus 
the additional information that the percentage changes are also not different appears to be a kind of redundant.   
 
Further, all the tables should have the same format and layout.  This makes it easier for the reader to grasp quickly the 
results.  For example, in Table 2, the CLA and Placebo groups are given in columns, but in Tables 1 and 3 in rows.  The 
following layout could be used. 
 
 Before LCD Week 0 Week 25 Week 52 
     
Weight     
   CLA     
   Placebo     
     
Fat Mass     
   CLA     
   Placebo     
 
This way, the results in each group can be easily followed in the time and the two groups can be compared easily at each 
time point.  The same format should be used for all the Tables.  Statistical differences between the CLA and the Placebo 
group could be indicated with superscripts. 
 
Answer: We agree with the reviewer, and we have deleted table 3, and have merged table 2 into table 1. Likewise, the 
table 1 and table 2 (the previous table 4) has now been changed to the same format and layout. 
 
15. Table 2.  The DXA weight can be left out.  The scale weight indicates that the regain is exactly the same in the two 
groups, and the DXA weight does not give any additional information.  Further, the results in Table indicate that the regain 
is almost identical in the two groups and I believe that giving p values in the range of 0.5 – 0.7 is kind of redundant.  
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Further, for every parameter, the number of subjects is repeatedly given.  The number of subjects could be given in a 
footnote and then also the age and the number of male and females could be given in this footnote.  Why is the number of 
subjects for the energy intake data different from the other numbers?  This should be clarified.  The energy intake at week 0: 
Is this the intake that has been calculated, because at week 0, the subjects just finished the low calorie diet.  It is not clear 
what this represents. 
 
Answer: We agree, and have deleted the DXA weight data and the table 1 have been revised according to the 
suggestions; the number of subjects are given in a footnote, as well as the age and gender ratio. 
The numbers of subjects for the energy intake reflects that not all subjects did report energy intake at all ime points. 
This is now clarified in the table 1.  
By mistake, the baseline energy intake was described at week 0, which is incorrect. That has been changed into 
“Baseline”, and thus there is no calculation of energy intake at week 0, where they have just finalized the LCD-
period. 
 
16. Statistics:  Repeated measurements are done on the same subjects.  It appears that the results of week 25 are not used for 
statistical analyses.  Would it not be appropiate to do repeated measures analysis?  This will, however, not affect the results, 
since it is very clear that there is no effect of CLA.   
 
Answer: 
All though we agree that a repeated analysis could be used, we believe that this would give essentially give the same 
results. Hence we have estimated that a repeated analysis would not give any substantial extra value to the 
manuscript. 
 
17. Footnote 8 to Table 2:  Why is an ANOVA test used?  There are only two groups and an unpaired t-test could have been 
used.  Reviewer statistically re-analyzed the data and the given p-value is actually the result of a simple t-test.   
 
Answer: We agree, an unpaired t-test would be more appropriate. This is changed accordingly. 
 
18. Footnote 1 to Table 3.  Only two groups are compared, and an unpaired t-test could have been used. 
 
Answer: We agree, however table 3 is now deleted. 
 
19. Footnote 1 to Table 1.  p-values between groups.  In this case of gender, what is actually being tested?   
 
Answer: The ratio distribution is being tested. 
 
20. Footnote 1 to Table 3.  Univariate analysis (ANOVA).  Does this mean that a one way ANOVA is used?  Why is here 
just an ANOVA used, whereas in Table 2 an ANCOVA is used? 
 
Answer: We agree, that this seems inconsistent – and ANCOVA should have been indicated here for the analyses. 
However, the table 3 is now deleted. 
 
21. Footnote 2 to Table 2.  ANCOVA:  In the text or in the footnotes, it should be mentioned that gender and week 0 value 
did not have any effects on the results.  This is only mentioned in the Discussion section (Line 257).  If the reviewer 
understands properly, the ANCOVA is being used to test whether gender, week 0 values, treatment center, and the effect of 
the low calorie diet has any effect on the results.  The results of this test should be mentioned in the result section. 
 
Answer: The reviewer is correct in that the ANCOVA is used to analyze the difference between treatment groups 
taking into account the week 0 values, the effect of the low calorie diet (change in body weight during LCD) as well 
as gender and treatment center.  
For changes in body weight from baseline to week 52, the results indicated that both value 0 (p=0.046) and change in 
body weight during LCD (p=0.010) did influence change in body weight, whereas gender and center did not turn out 
statistically significant. 
For changes in body fat mass from baseline to week 52, the results indicated that change in body weight during LCD 
(p=0.014) did influence change in body fat mass, whereas gender, center and initial body fat mass was not significant 
predictors of change. 
However, for both analyses – as well as for analysis of FFM and FAT%, all parameters (i.e. initial body weight/fat 
mass/fat free mass/FAT%, and LCD-induced change in body weight, gender and center were kept in the ANCOVA 
analysis all though they did not necessarily affect the results directly.) 
 
22. In general, the statistics are not always clear and should be described and executed carefully.  This should be more 
clearly explained and kept as simple as possible.  It should be explained why particular tests are being used and what the 
results of these test were.   
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Answer: We agree, that this has not been presented clearly, but we have now carefully revised the statistical 
descriptions throughout the paper. 
 
23. Page 25:  These are not Legends but Footnotes.  The figure title and the number of subjects should be included in the 
legends. 
 
Answer: That has been revised accordingly. 
 
24. Line 260:  Few mice studies.  There are however, numerous studies in mice that show the deleterious effects of CLA, 
even when very small doses of 0.5% CLA (on weight basis) are given (See CLA website of the Wisconson University).  
These doses are comparable to the doses given to humans when expressed per kg metabolic weight or expressed as gram per 
1000 kJ energy intake.   
 
Answer: We agree, that there are indications that even quite small doses of the t10,c12 isomer has shown deleterious 
effects in some animal studies, and we have changed the description accordingly into: “However, some studies in 
mice have shown that particularly the t10,c12 isomer may induce lipoatrophy, hyperinsulinaemia and fatty liver (19). 
This may occur at dosing levels that are comparable to the doses used in human studies(20). However, due to species 
differences, it should be emphasized that one should always be cautious when comparing human and animal studies. 
” 
 
25. Line 292:  We conclude that.  The present study does not show any side effects, but other studies indicate that in some 
cases these side effects that are seen in animal studies may also show up in humans.  Thus, one has to be cautious, and it 
seems to still be questionable whether the use of CLA can be considered as safe.  
 
Answer: We agree, and have modified the abstract and conclusion accordingly, emphasizing the observation of 
increased leukocyte number and with the subtle change that “…CLA dietary supplement may be as safe as olive oil”. 
 
26. Inspection of Table 2 and Figure 2 and 3 shows that during the first 25 weeks, only an increase in FFM has taken place 
and no increase in body fat.  During the second 25 weeks (week 25 – 52), there was only an increase in body fat, and no 
increase (rather a small decrease) in FFM.   
 
Answer: The likely explanation for this observation is that subjects are – at least to some extent – depleted for water 
after finishing the LCD-period (i.e. loss of water bound to glycogen depots etc.). The change in FFM from baseline to 
week 25 can therefore – to some extent – be explained by repletion of water in the glycogen depots as well as the 
slight weight gain (which usually also includes gain of FFM as well as FM).  
In contrast, the changes in FFM from week 25 to week 52 will only be caused by weight gain (and not by glycogen 
water repletion).  
Another reason could be time-dependent changes in physical activity, i.e. the subjects may be more physically active 
during the first 25 weeks (i.e. gaining more FFM), and they may be less likely to engage in the same amount of 
physical activity during the last ~26 weeks (i.e. losing FFM). This could also give an explanation for the observed 
results. 
 
27. It would be nice that the reader would have an overview of all the human studies done this far.  Besides authors previous 
review (JLR), some other reviews (such as Kelley, Lipids 38:377, 2003, Terpstra, AJCN 79:352, 2004) could also be given 
and also the latest studies that are not mentioned in these reviews, for example the studies of Malpuech et al. (Int J 
Obes12:591, 2004, Gaullier et al (J. Nutr. 135:778, 2005), Tricon et al. (AJCN 80:614,2004)  Petrodou et al. (Lipids 38:805 
2003) should also be cited.  Also the Wisconsin University website should be cited.  This is a very useful website and gives 
an oveview of all the CLA studies. 
 
Answer: We believe that the review by Larsen et al. (JLR, 2003) covers most relevant studies in humans, and with 
the addition of the 1-year and 2-year studies of Gaullier et al. published in 2004 & 2005, the most important studies 
are now mentioned. The review by Kelley et al does not add important imformation, and the studies by Petridou, 
Malpuech & Trican are only short term (6-8 week supplementation) studies which are not directly comparable to the 
results obtained in the present study.  
However, for the interested reader, the Wisconsin Website could be useful, and is therefore added into the 
manuscript in the introduction and the more recent review by Terpstra, AJCN 2004 is now also mentioned. 
 
 
In conclusion, the manuscripts provides interesting information and confirms the results of most of the other CLA studies, 
that CLA has no or minimal effects on body weight and body fat.  However, the results should be described and presented in 
a more clear fashion.  Further, careful attention should be paid to the statistics. 
 
 
26 September 2005 
 
Point to point reply:
 
GENERAL COMMENTS: 
 
The lines 91-93: “The randomization sequence was generated by Scandinavian Clinical Research (monitor firm) 
using a simple block randomization code without stratification”  
 
have been changed into: 
 
“The randomization sequence was generated by Scandinavian Clinical Research (Contract Research Organization) 
using a simple block randomization procedure without any stratifications”. 
 
 
REVIEWER 3: 
 
Q1: Please start the Introduction on a new page.  
A1: The Introduction is now started on a new page (page 3) 
 
Q2: Trade names should not be used within the text; generic descriptors should be used instead.  Such items should 
be identified once in the paper, in the Methods section in parenthesis.  The name and location of the manufacturer 
should also appear within the parenthesis. (lines 83 and 87 for example)  
A2: The trade name “Clarinol®” has been deleted from line ~252.  
The name and location of the Nutrilett LCD product is provided at line ~83 (Collett Pharma, Lysaker, 
Norway). 
 
Q3: Line 89.  Please write as …39% c9,t11 CLA and 41% t10,c12 CLA. (add CLA).  
A3: Lines 85-90 have been revised to increase clarification. 
 
Q4: The authors state in their reply that they believe that a repeated analysis would give essentially the same 
results.  This should be tested and the results of the repeated analysis included in the paper. If the interaction is 
significant, subgroup analysis should be done using the Tukey test across time within group, not paired t tests.  
A4: We have performed repeated analyses of changes in fat mass, fat free mass, fat percentage and body 
weight. The values for each variable at the time points (week 0, 25 and 52) have been compared between 
treatment groups, using change in body weight from week 0 minus weight before LCD, center and gender as 
covariates. We did not identify any significant treatment effects (i.e. time*treatment effect) on any of these 
variables (fat mass, p=0.651; body weight, p=0.840; fat%, p=0.657 and fat free mass, p=0.323). 
 
The statistical methods of the repeated analyses are inserted in the manuscript (line 170-173) and the results 
are stated in line 210 as: “Repeated analyses provided essentially the same results (p = 0.65 for changes in 
body fat mass)”. 
 
Q5. Generally:  Each table and figure should stand alone without reference to the text.  Each table and figure 
should include an indication of the variability of the data (SEM, SD etc.), the results of the statistical analysis, and 
the n.  Please identify in table footnotes and figure legends the statistical test used to analyze the data 
A5: The figure legends and footnotes have been changed accordingly (line 353-373). 
 
Q6. Figure 2.  The results of the statistical analysis should be reported in the figure legend.  
A6: The results of the statistical analyses are reported in the figure legend. 
  
 
REVIEWER 1: 
Comments: 
This manuscript has been significantly revised in response to the prior reviews.  Unfortunately the authors have not 
added serum CRP data to further examine the issue of inflammation and safety raised in review.  In addition, the 
authors’ comments concerning the significant increase in total WBC seen in this study are worded in such a way as 
to minimize concern for this observation. 
     
The potential effects of CLA on CRP aside, the repeated observation in a number of independent human studies of 
increased WBC with CLA administration makes this an important point, and one which should not be minimized.  
Given that increased WBC count within the reference range is a robust predictor of chronic coronary risk 
independent of dyslipidemia, the fact that it was not associated with serious adverse events within this one-year 
scope study can not be interpreted as implying safety in the longer term.  The argument that changes in 
inflammatory markers have not yet been linked to coronary outcome has been addressed by the study by Ridker et 
al (NEJM 352:20-28, 2005), in which it was shown that CRP reductions by statin therapy reduce coronary events 
independent of the lipid-lowering effects of this drug class.  Thus, within this context, it is incorrect to equate the 
safety of CLA to that of olive oil. 
 
Specific comments: 
 
Line 24.  Remove the word “possible”.  Given the P-value of 0.026 (i.e., less than 0.05), there was a significant 
increase in the leukocyte count attributed to CLA administration. 
Reply: We agree, and the word possible is now deleted. 
 
Lines 28 and 310.  “may be as safe as olive oil” represents speculation unsupported by the data.  Olive oil has not 
been shown to increase WBC or CRP in multiple independent human studies, and increased WBC within the 
reference range has been repeatedly demonstrated to be associated with cardiovascular disease risk. 
Reply: We agree, and have changed accordingly – into: “One year 3.4 g daily CLA supplementation does not 
prevent weight or fat mass regain in a healthy obese population.” 
 
Line 293.  delete “seemed”.  Leukocyte concentrations were significantly increased.   
Reply: “seemed” is changed into “was”. 
 
Line 294.  Replace “All though’ with “Although”. 
Reply: All though is replaced with although. 
 
Lines 297-298.  The sentence beginning with “However…” is gratuitous, and should be deleted.   The rise in the 
leukocyte count within the reference range is associated with increased cardiovascular disease risk, and there are no 
data on how long the leukocyte count remains increased after CLA administration. 
Reply: “However” is deleted. 
 Appendices: 
 
Appendices A-G: Background information 
 
Appendix A: Map of 20 kb region of the PPARγ locus harbouring the Pro12Ala variant 
 
Appendix B: Map of PPARγ region illustrating variant linkage disequilibrium within the 
proximal 20 kb region of the Pro12Ala variant (*rs1801282*) / position 12.368.125 on 
chromosome 3. 
 
Appendix C: Table with nomenclature of the most common fatty acids 
 
Appendix D: Natural origin of rumenic acid (c9,t11 CLA): rumenal synthesis from linoleic acid, 
and endogenous occurrence from delta-9 desaturation of trans-vaccenic acid. 
 
Appendix E: Cellular metabolism and bioavailability of the 2 main CLA isomers c9,t11 and 
t10,c12 
 
Appendix F: Industrially and naturally generated 18:1 trans fats 
 
 
 
Appendices G-L: Paper 1 to 4 and point-to-point replies for paper 1 and 2 
 
Appendix G: Paper 1: Larsen, T. M., L. H. Larsen, S. K. Torekov, J. Ek, E. Black, S. Toubro, A. 
Astrup, T. I. Sorensen, T. Hansen, and O. Pedersen, 2005, "Novel Variants in the Putative 
Peroxisome Proliferator-activated Receptor γ Promoter and Relationships with Obesity in Men," 
Obes. Res. 13, 953-958”. 
 
Appendix H: Point-to-point replies for paper 1. 
 
Appendix I: Paper 2: Larsen TM, Toubro A, Gudmundsen O, and Astrup A, 2005, "One year 
conjugated linoleic acid supplementation does not prevent weight or body fat regain.," Am J Clin 
Nutr. Submitted. 
Appendix J: Point-to-point replies for paper 2. 
Appendix K: Paper 3: Larsen, T. M., S. Toubro, and A. Astrup, 2003, "PPARgamma agonists in 
the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?," Int. 
J. Obes. Relat Metab Disord. 27, 147-161. 
Appendix L: Paper 4: Larsen, T. M., S. Toubro, and A. Astrup, 2003, "Efficacy and safety of 
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 Appendix A: 
Map of 20 kb region of the PPARγ locus harbouring the Pro12Ala variant (marked with red S). 
 
Adapted from http://www.ensembl.org/Homo_sapiens/ldview?snp=rs1801282&w=20000&pop=898 
The map is based on 24 samples from the Coriell Cell Repository, primarily of European American descent. 
 
Additional notes: 
a) The PPARG gene can be found in the Ensembl Gene Report for ENSG00000132170 
http://www.ensembl.org/Homo_sapiens/geneview?gene=ENSG00000132170;db=core 
 
b) The PPARG protein can be found in the UniProtKB/Swiss-Prot accession number P37231  
http://www.ebi.uniprot.org/entry/P37231 
 Appendix B:  
 
Map of PPARγ region illustrating variant linkage disequilibrium within the proximal 20 kb region of the Pro12Ala variant 
(*rs1801282*) / position 12.368.125 on chromosome 3. 
 
Adapted from 
http://www.ensembl.org/Homo_sapiens/ldtableview?_format=HTML&dump=ashtml&panel_image=on&w=20000&format_pdf=off&image_width=700&format_svg=off&format_posts
cript=off&snp=rs1801282&context=10000&pop=898&panel_options=on&submit=Dump
 Appendix C:  
 
Table with nomenclature of the most common fatty acids 
 
Adapted from (Shields et al., 1999) 
 Appendix D:  
Natural origin of rumenic acid (c9,t11 CLA): rumenal synthesis from linoleic acid, and endogenous 
occurrence from delta-9 desaturation of trans-vaccenic acid. 
 
Adapted from (Martin and Valeille, 2002) 
 
 
Appendix E:  
Cellular metabolism and bioavailability of the 2 main CLA isomers c9,t11 and t10,c12 
 
Adapted from (Martin and Valeille, 2002)
 Appendix F:  
 
Industrially and naturally generated 18:1 trans fats 
 
Upper graph: The composition of industrially generated 18:1 trans fats is highly heterogenic.  
The trans fats differ substantially regarding the position of the double bond (x-axis).  
The relative contribution from each of these fatty acids also differ substantially (y-axis). 
 
Lower graph: The composition of 18:1 trans fats from ruminant fats. The trans fats from ruminant  
fats consists primarily of rumenic acid (c9,t11 CLA).  
 
Adapted from (Steen Stender and Jørn Dyerberg, 2003) 
